WO2006111858A2 - Bis-(coumarin) compounds with anti-inflammatory activity - Google Patents

Bis-(coumarin) compounds with anti-inflammatory activity Download PDF

Info

Publication number
WO2006111858A2
WO2006111858A2 PCT/IB2006/001259 IB2006001259W WO2006111858A2 WO 2006111858 A2 WO2006111858 A2 WO 2006111858A2 IB 2006001259 W IB2006001259 W IB 2006001259W WO 2006111858 A2 WO2006111858 A2 WO 2006111858A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
compound
hydroxy
phenyl
Prior art date
Application number
PCT/IB2006/001259
Other languages
French (fr)
Other versions
WO2006111858A3 (en
Inventor
Mladen Mercep
Ivica Malnar
Boska Hrvacic
Stribor Markovic
Anita Filipovic Sucic
Berislav Bosnjak
Andreja Cempuh Klonkay
Renata Rupcic
Antun Hutinec
Ivaylo Jivkov Elenkov
Milan Mesic
Original Assignee
Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. filed Critical Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.
Priority to JP2007550880A priority Critical patent/JP2008526951A/en
Priority to EP06765427A priority patent/EP1846387A2/en
Priority to US11/813,885 priority patent/US20080153872A1/en
Publication of WO2006111858A2 publication Critical patent/WO2006111858A2/en
Publication of WO2006111858A3 publication Critical patent/WO2006111858A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Definitions

  • the present invention relates to certain bis-(coumarin) compounds as well as the products of their intramolecular cyclization including pharmaceutically acceptable salts, solvates (including hydrates), clathrates, prodrugs, tautomers and stereoisomers thereof.
  • the invention further relates to processes and intermediates for the preparation of certain bis- (coumarin) compounds, as well as to the use of these compounds as therapeutically active agents in the prophylaxis and treatment of asthma and other inflammatory diseases and conditions in mammals, especially humans.
  • the present invention is responsive to the technical problem of providing novel antiinflammatory agents that have pronounced activity against inflammatory conditions or disorders, that are more effective against specific types of inflammation disorders than steroids or NSAIDs and/or that have an improved side effect profile compared to heretofore known PDE4 inhibitors, or leukotriene inhibitors.
  • Asthma is a chronic inflammatory disease of the respiratory airways in mammals. Clinically, in hypersensitive persons the inflammation causes periodic coughing attacks, troubled breathing, wheezing, tightness in the chest and chest pain. The inflammation makes respiratory airways more susceptible to irritations by allergens, chemical irritants, tobacco smoke, cold air and strain. Exposed to these irritants, respiratory airways become edematous, contracted, filled with mucus and hypersensitive.
  • the pathogenesis of asthma is complex and includes the interaction of inflammatory cells, mediators as well as of the tissue and cells of respiratoy airways. In the asthmatic process an early phase and a late phase of a response are distinguished. Allergic diseases as well as allergen-induced asthma are characterised by the synthesis of a specific type of IgE antibodies. Immediately after the inhalation of allergens, complexes of allergens and allergen specific IgE's are bound to high affinity IgE receptor (Fc ⁇ receptor type I) present on basophils, mastocytes and eosinophils. By the binding to the receptor the activation of signal transfer cascade occurs, which results in:
  • proinflammatory genes e.g. interleukin-4 and interleukin-5
  • the granules contain inflammatory mediators such as histamine, serotonin, leukotrienes C4, D4 and E4, and proteins such as major basic protein and mieloperoxidase. These inflammatory mediators co-operate in the processes of vasodilation, bronchoconstriction, triggering and control of the inflammatory process and activation of the cells and damage to the inflamed tissue. These processes form the early asthmatic response.
  • the inhibition of degranulation may prevent the symptoms and stop the inflammation progress, which has been proven by the clinical use of degranulation inhibitors (sodium cromoglycate, nedocromil sodium and ketotifen).
  • the late asthmatic response includes a permanent obstruction of air passages, a hyperreactivity of the bronchi and a development of inflammation changes including the accumulation of neutrophils, eosinophils, lymphocytes and monocytes/macrophages in the respiratory system.
  • the accumulation of inflammatory cells results from harmonized interaction of lymphokines (TNF- ⁇ , IL-4, IL-5), adhesion molecules on the surface of leukocytes (integrins) and endothelial cells (selectins), and chemokins (eotaxin, RANTES).
  • T-lymphocytes The role and significance of T-lymphocytes in asthma were confirmed by the existence of an increased number of activated CD4+ T-cells in bronchoalveolar lavage and bronchial biopsies of patients suffering from asthma.
  • Two subpopulations of CD4+ cells differ with regard to the profile of cytokines they secrete.
  • Th 1 cells secrete IL-2, IL-3, GM-CSF, INF- ⁇ .
  • Activation of Th 1 cells is important in the defense of the host against intracellular organisms, viruses and neoplasms. Investigations have demonstrated that, in asthma, Th 2 cell response prevails with an increased expression of IL-5 that is important in the formation of eosinophilic infiltration typical of allergic inflammation.
  • Morphologic changes occurring in asthma include an infiltration of the bronchi by inflammation cells (mastocytes, T-lymphocytes and eosinophils are the key executive cells), a clogging of respiratory airways by a secrete, interstition oedema and increased microcirculation permeability.
  • eosinophilic infiltration is specific and differentiates asthma from other types of inflammation.
  • the symptomatic medicaments include short-acting bronchodilators such as ⁇ 2- agonists, anticholinergics, theophylline, which rapidly relax the contracted respiratory airways and alleviate the acute symptoms.
  • the basic medicaments include antiinflammatory drugs and long-acting bronchodilators. Antiinflammatory drugs alleviate and prevent the inflammation reaction and they include inhalable corticosteroids, systemic corticosteroids and inhalable cromones, such as cromolyn and nedocromil.
  • Steroid antiinflammatory compounds are still considered to be the most effective medicaments in the treatment of inflammatory diseases and conditions such as asthma.
  • the good potency and efficacy of this type of medicament are, however, accompanied by numerous undesired side effects, such as disturbances of carbohydrate metabolism, of calcium resorption, of the secretion of endogenic corticosteroids and of physiological functions of the hypophysis, of the suprarenal gland core and of the thymus, hi the literature (WO 94/13690, WO 94/14834, WO 92/13872 and WO 92/13873) so-called "soft" steroids or hydrolysable corticosteroids with local action are described.
  • Their systemic, undesired effect is reduced due to the instability of "soft" steroids in serum, where the active steroid is rapidly hydrolyzed to an inactive form.
  • a steroid without negative side effects in long-term use has yet to be found.
  • New medications concentrate on reducing inflammatory response as a method for alleviating or eliminating symptoms (Barnes, P. J. Nature Reviews Drug Discovery, 2004, 3, 831-844; BaIs, R. Curr. Med. Chem. - Anti-Inflammatory & Anti-Allergy Agents, 2004, 3, 39-52; Coruzzi, G. Current Drug Targets - Inflammation & Allergy, 2004, 3, 43-61; Prescott, S. L. Med. Chem. Reviews — Online, 2004, I, 163-177).
  • the leukotriene inhibitors are the newest addition to the asthma therapy. Leukotrienes are produced by 5 -lipoxygenase enzyme pathway, and inhibitors are divided into several groups according to their mode of action.
  • Cysteinyl leukotriene antagonists have proven efficacy in short and long-term studies: improvements in baseline lung function in asthmatics and improvement of a variety of symptoms as well as decreased use of ⁇ 2-agonists and a reduction in asthma exacerbations have been reported (Barreiro, E. J. Curr. Med. Chem. - Anti-Inflammatory & Anti-Allergy Agents, 2004, 3, 9-18).
  • the 5 -lipoxygenase inhibitor, zileuton is as effective as the cysteinyl leukotriene antagonists, and its therapeutic effects are indistinguishable from those of the cysteinyl leukotriene antagonists.
  • LTB4 antagonists are currently under investigation aimed at different indications (Balazy, M. Current Drug Targets - Inflammation & Allergy, 2004, 3, 19-33).
  • Leukotriene inhibitors represent an advance over current anti-asthma products in terms of faster onset of action, oral formulation and favorable side effect profile.
  • PDEs The phosphodiesterases
  • cAMP and cGMP cyclic adenosine and guanosine monophosphate
  • Type 4 phosphodiesterase (PDE4) is a cAMP-specific enzyme localized in airway smooth muscle cells as well as in immune and inflammatory cells.
  • the PDE4 activity is associated with a wide variety of diseases some of which have been related to an inflammatory state, e.g. asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), while others have recently been connected to autoimmune pathology. Therefore, an intense effort towards the development of PDE4 inhibitors has been generated for the last decade (Giembycz, M. A.
  • Some compounds of the coumarm class are known to inhibit the immunological release of chemical mediators such as SRS-A (the slow reacting substance of anaphylaxis) and histamine from mast cells (US 4,731,375).
  • SRS-A the slow reacting substance of anaphylaxis
  • Other compounds of the coumarm class are known to not only protect against the release of SRS-A and other mediators of the allergic response but to also inhibit the action of SRS-A (US 4,200,577).
  • Still other compounds of the coumarin class are known to not only inhibit the release of mediator substances but to also antagonize the effects of histamine released after the antibody-antigen combinations (US 4,263,299).
  • the present invention relates to bis-(coumarin) compounds with valuable properties, in particular pharmacological properties for treating inflammatory diseases and conditions such as asthma, and which can also be used to produce pharmaceuticals.
  • the present invention relates to bis-(coumarin) compounds of Formula I,
  • R 1 , R 2 , R 3 and R 4 are each independently hydrogen, fluoro, chloro, bromo, C 1 -C 4 -alkyl, C 2 - C 4 -alkenyl, C 2 -C 4 -alkynyl, halo-CrQ-alkyl, hydroxy, C 1 -C 4 -alkoxy, trifluoromethoxy, C 1 - C 4 -alkanoyl, amino, amino-C 1 -C 4 -alkyl, iV-(C 1 -C 4 -alkyl)amino, N,iV-di(CrC 4 -alkyl)amino, mercapto, C 1 -C 4 -alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C 1 -C 4 -alkylsulfino, carboxy, C 1 -C 4 -alkoxycarbonyl
  • n is, independently, an integer which is 0 or 1;
  • R- 5 is an hydroxy, alkoxy, amino, alkylamino, aryl or arylamino group
  • R 6 is hydrogen or CH 3 ;
  • D is CH, CH 2 , CCH 3 , CHCH 3 , CHCH 2 OH, or carbonyl
  • ⁇ is a single or a double bond
  • R 1 , R 2 , R 3 and R 4 are not all hydrogen;
  • X is not phenyl, 3-bromophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,
  • X is not phenyl, 2-chlorophenyl, 4-hidroxyphenyl, 2,4-dichlorophenyl, 3- methoxyphenyl, 4-methoxyphenyl 4-hydroxy-3-methoxyphenyl, 3-nitrorophenyl, 2- nitrorophenyl, 2-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-(N,N-dimethylamino)phenyl, 2-pyridinyl, 3- pyridinyl, 4-pyridinyl, 2-quinolinyl; and
  • X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 3-nitrophenyl, 4-hydroxy-3- methoxyphenyl, 2-pyridinyl, 3- pyridinyl, 4-pyridinyl, 2-(6-methyl)pyridinyl, 2- quinolinyl,
  • X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2-(6-methyl)pyridinyl, 3- pyridinyl, 4- pyridinyl, 2-quinolinyl; and
  • X is not phenyl, 4-methoxyphenyl, 2-hydroxyphenyl, 3-hydoxyphenyl, 4-hydroxy-3- methoxyphenyl, 4-hydroxy-3-ethoxyphenyl, 5-benzo[l,3]dioxolyl; and
  • R 15 R 2 , R 3 and R 4 are not all hydrogen
  • Bis-(coumarin) compounds with unsubstituted and variously substituted benzene rings which are represented by Formula I, compounds of Formula II with various R 1 , R 2 , R 3 , and R 4 groups, and compounds of Formula III, wherein the benzene rings are substituted with various Ri and/or R 2 and/or R 3 and/or R 4 groups sucli as alkyl and alkoxy groups and halogen atoms, as well as their pharmaceutically acceptable salts and pharmaceutical preparations including such compounds, have not hitherto been described.
  • the compounds of the present invention have not hitherto been described as substances with a strong antiinflammatory action or as effective agents in the treatment of asthma and other inflammatory diseases and conditions.
  • the compounds of the present invetion are represented by the compounds of Formula I or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof,
  • R 1 , R 2 , R 3 and R 4 is each independently hydrogen, fluoro, chloro, bromo , C 1 -C 3 - alkyl, hydroxy, or nitro;
  • A is carbonyl or CH-X
  • X is not phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methoxyphenyl, 4-methoxyphenyl, or 4-methylthiophenyl; and
  • X is not phenyl, 2-chlorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2- methoxyphenyl, 3,4,5-trimethoxyphenyl, 2-pyridinyl, 4-pyridinyl, or 2-quinolinyl; and
  • X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2-pyridinyl, 4-pyridinyl, or 2-quinolinyl;
  • X is not phenyl, 3-hydroxyphenyl, 4-methylphenyl, 2-pyridinyl, or 5- benzo[l,3]dioxolyl;
  • X is not phenyl, or 4-methoxyphenyl
  • X is not phenyl, 4-methoxyphenyl, 3-hydoxyphenyl, or 5-benzo[l,3]dioxolyl;
  • R 1 , R 2 , R 3 and R 4 are each independently C 1 -C 4 -alkyl, chloro, brom
  • R 1 , R 2 , R 3 and R 4 are each independently, fluoro, chloro, bromo, Q-Q-al
  • R 1 , R 2 , R 3 and R 4 are each independently Q-Gralkyl, fluoro, chloro or bromo.
  • a further particular class of compounds are those of Formula II wherein X is carboxy, acetyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups and at least one of the R 1 , R 2 , R 3 and R 4 are each independently, C 1 -C 4 -alkyl, fluoro, chloro or bromo.
  • a further particular class of compounds are those of Formula III wherein D is CHCH 3 , CHCH 2 OH or carbonyl and — is a single bond; or D is CCH 3 and ⁇ is a double bond; and at least one of the R 1 , R 2 , R 3 and R 4 are each independently, fluoro, chloro, bromo, C 1 - C 4 -alkyl, hydroxy, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl, halo-Ci-Q-alkyl, C 1 -C 4 -alkoxy, trifluoromethoxy, Ci-C 4 -alkanoyL amino, amino-C 1 -C 4 -alkyl, N-(C 1 -C 4 -alkyl)amino, NN- di(C 1 -C 4 -alkyl)amino, mercapto, Q-Q-alkylthio, sulfo, C 1 -C
  • a further particular class of compounds are those of Formula III wherein D is CH or CH 2 ; and at least one of the R 1 , R 2 , R 3 and R 4 are each independently, fluoro, chloro, bromo, C 1 - C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl, halo-C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, trifluoromethoxy, CrG ⁇ -alkanoyl, amino, amino-C 1 -C 4 -alkyl, N-(C 1 -C 4 -alkyl)amino, NN ⁇ i(C 1 -C 4 - alkyl)amino, mercapto, C 1 -C 4 -alkylthio, sulfo, CrC 4 -alkylsulfo, sulfino, C 1 -C 4 -alkylsulf
  • halogen relates to a halogen atom, which may be: fluorine, chlorine, bromine or iodine.
  • alkyl relates to alkyl groups derived from alkanes, which may be straight, branched or cyclic or a combination of straight and cyclic chains or of branched and cyclic chains.
  • the preferred straight or branched alkyls are e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-bvAyl. Methyl is most preferred.
  • the preferred cyclic alkyls are e.g. cyclopentyl or cyclohexyl.
  • Alkyl groups may be substituted with one up to five substituents including halogen (preferably fluorine or chlorine), hydroxy, alkoxy (preferably methoxy or ethoxy), acyl, acylamino cyano, amino, N-(Ci-C 4 )alkylamino (preferably N-methylamino or N-ethylamino), N,N-di(C 1 -C 4 -alkyl)amino (preferably dimethylamino or diethylamino), aryl (preferably phenyl) or heteroaryl, thiocarbonylamino, acyloxy, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylarnino, aminothiocarbonylamino, aminocarbonyloxy, aryl, heteroaryl, aryloxy, aryloxyaryl, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carb
  • C 1 -C 4 -alkyl represents an alkyl group with 1 to 4 carbon atoms.
  • Q-Cr-alkyl represents an alkyl group with 1 to 7 carbon atoms. Similar terminology is used herein to represent the number of carbon atoms within a specified group.
  • alkyl carries over to other groups having an alkyl moiety such as alkoxy.
  • Alkenyl means a linear or branched monovalent hydrocarbon radical of two to ten, preferably two to six, carbon atoms which has at least one carbon-carbon double bond. Alkenyl groups may be substituted with the same groups as alkyl and such optionally substituted alkenyl groups are encompassed within the term "alkenyl.” Ethenyl, propenyl, butenyl and cyclohexenyl are preferred.
  • Alkynyl means a linear or branched monovalent hydrocarbon radical, having a straight-chain or a branched-chain of two to ten, preferably two to six, carbon atoms and containing at least one and preferably no more than three carbon-carbon triple bonds.
  • Alkynyl groups can be substituted with the same groups as alkyl, and the substituted groups are within the present definition of alkynyl. Ethynyl, propynyl and butynyl groups are preferred.
  • Cycloalkyl means a cyclic group having 3-8 carbon atoms having a single ring optionally fused to an aryl or heteroaryl group.
  • the cycloalkyl groups can be substituted as specified for "aryl” below, and the substituted cycloalkyl groups are within the present definition of "cycloalkyl”.
  • Preferred cycloalkyls are cyclopentyl and cyclohexyl.
  • Aryl means an unsaturated aromatic carbocyclic group having 6-14 carbon atoms having a single ring such as phenyl or multiple fused rings such as naphthyl.
  • Aryl may optionally be further rased to an aliphatic or aryl group or can be substituted with one or more substituents such as halogen (fluorine, chlorine and/or bromine), hydroxy, Ci-C 7 alkyl, Ci-C 7 alkoxy or aryloxy, Ci-C 7 alkylthio or arylthio, alkylsulfonyl, cyano or primary or nonprimary amino.
  • substituents such as halogen (fluorine, chlorine and/or bromine), hydroxy, Ci-C 7 alkyl, Ci-C 7 alkoxy or aryloxy, Ci-C 7 alkylthio or arylthio, alkylsulfonyl, cyano or primary or nonprimary amino.
  • Heteroaryl means a monocyclic or a bicyclic aromatic hydrocarbon ring having from 2 to 10 carbon atoms and from 1 to 4 heteroatoms, such as O, S or N.
  • the heteroaryl ring may optionally be fused to another heteroaryl, aryl or aliphatic cyclic group. Examples of this type are furan, thiophene, pyrrole, imidazole, indole, pyridine, oxazole, thiazole, pyrrole, pyrazole, tetrazole, pyrimidine, pyrazine and triazine, with furan, pyrrole, pyridine and indole being preferred.
  • the term includes groups that are substituted with the same substituents as specified for aryl above.
  • Heterocyclic means a saturated or unsaturated group having a single or multiple rings and from 1 to 10 carbon atoms and from 1-4 heteroatoms selected from nitrogen, sulphur or oxygen, wherein in a fused ring system the other ring or rings can be aryl or heteroaryl. Heterocyclic groups can be substituted as specified for alkyl groups and the thus substituted heterocyclic groups are within the present definition.
  • alkoxy relates to straight or branched chains containing an alkoxy group. Examples of such groups are methoxy, propoxy, pro ⁇ -2-oxy, butoxy, but-2-oxy or methylprop-2-oxy.
  • alkanoyl relates to straight chains containing an acyl group such as formyl, acetyl or propanoyl.
  • aroyl group relates to aromatic acyl groups such as benzoyl.
  • Compounds of Formulae I and III possess at least one acidic hydroxy group on a coumarin nucleus, as well as the compounds of formula II wherein X denotes a carboxy group. Thus, these compounds may form corresponding salts with pharmaceutically acceptable bases.
  • the present invention encompasses such salts.
  • salts formed on a hydroxy substituent are e.g. aluminum salts, corresponding salts of alkali metals such as sodium or potassium, salts of alkaline earth metals such as calcium or magnesium, pharmaceutically acceptable salts of transient metals such as zinc and copper, salts with ammonia or salts with lower organic amines such as cyclic amines, mono-, di- or W
  • lower hydroxyalkylamines such as lower mono-, di- or trihydroxyalkylamines, lower (hydroxyalkyl)alkylamines or lower polyhydroxyalkylainines and salts with amino acids, e.g., methylglutamine, alanine or serine.
  • Suitable pharmaceutically acceptable cyclic amines include, e.g., morpholine, thiomorpholine, piperidine or pyrrolidine.
  • Suitable lower monoalkylamines include, e.g., ethylamine and tert- butylamine
  • suitable dialkylamines include, e.g., diethylamine and diisopropylamine
  • suitable lower trialkylamines include, e.g., trimethylamine and triethylamine.
  • Corresponding lower hydroxyalkylamines include, e.g., mono-, di- or triethanolamine
  • lower (hydroxyalkyl)alkylamines include, e.g., ⁇ iV-dimethylaminoethanol and N,N- diethylaminoethanol.
  • Suitable amino acids include, e.g., lysine, arginine, methylglutamine, alanine or serine.
  • Any substituent having basic properties may also form pharmaceutically suitable salts with inorganic acids (e.g. hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric or sulfuric acid) or organic acids (e.g. tartaric, acetic, methane-sulfonic, trifluoroacetic, citric, maleic, lactic, fumaric, benzoic, succinic, methanesulfonic, oxalic and p-toluenesulfonic acids).
  • inorganic acids e.g. hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric or sulfuric acid
  • organic acids e.g. tartaric, acetic, methane-sulfonic, trifluoroacetic, citric, maleic, lactic, fumaric, benzoic, succinic, methanesulfonic, oxalic and p-toluenesulfonic acids.
  • salts may be prepared in situ during the final isolation and purification of the compounds of the present invention or separately in a reaction with a suitable inorganic or organic base in a manner known to one skilled in the art, for example in a suitable solvent or solvent mixture, e.g., in ethers (diethylether) or alcohols (ethanol, n-propanol, 2-propanol or fert-butanol), or by mixing equivalent amounts of corresponding reactants and the subsequent lyophilization and purification of the reaction mixture.
  • a suitable solvent or solvent mixture e.g., in ethers (diethylether) or alcohols (ethanol, n-propanol, 2-propanol or fert-butanol)
  • Lower alkyl is, for example, ⁇ -propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl or n-heptyl, preferably ethyl or methyl.
  • the free forms of the compounds of the present invention and their pharmaceutically acceptable salts are identical forms and in the corresponding context it is suitable to consider the free forms of the compounds of the present invention and their corresponding pharmaceutically acceptable salts as synonymous.
  • the present invention also encompasses prodrugs of compounds of Formulae I, II and III, i.e. compounds which release an active drug according to Formulae I, II or III in vivo when administered to a mammalian subject.
  • Prodrugs of a compound of Formulae I, II and III are prepared by modifying functional groups present in the compound of Formulae I, II and III in such a way that the modifications may be cleaved in vivo to release the parent compound.
  • Prodrugs include compounds of Formulae I, II and III wherein a hydroxy, amino, or carboxy group of a compound of Formulae I, II and III is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino or carboxy group, respectively.
  • prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives) of compounds of Formulae I, II and III or any other derivative which upon being brought to the physiological pH or through enzyme action is converted to the active parent drug.
  • esters e.g., acetate, formate, and benzoate derivatives
  • the present invention also relates to solvates (preferably hydrates) that can be formed by the compounds of Formulae I, II and HI or their salts.
  • the present invention also relates to clathrates that can be formed by the compounds of Formulae I, II and III or their salts.
  • the compounds represented by Formulae I, II and III, and their salts may exist in more than one physical form (e.g. in different crystal forms) and the present invention relates to all physical forms (e.g. to all crystal forms) of the compounds represented by Formulae I, II and III, and to their mixtures.
  • the compounds of Formulae I, II and III may exist in numerous forms of structural isomers that may be formed as a result of tautomerism, and may exist in different ratios at equilibrium. Due to dynamic equilibrium such isomers (tautomers) are rapidly interconvertible from one isomeric form to another.
  • the most common isomerism is keto- enol tautomerism, but equilibrium between open chain and cyclic forms is also known. It is to be understood that whenever in the present invention reference is made to the compounds of Formulae I, II and III it is intended to include tautomeric forms thereof, keto-enol tautomeric, open chain-cyclic, isolated as separate isomers or existing in any other mixture of different ratios at equilibrium.
  • the isomeric forms predominant for a particular compound of Formulae I, II and III are dependent on the nature of the substituent, whether the compound exists in the free form or in the form of any of its salts, type of the salt, solvent in which the compound is dissolved, as well as pH value of the solution.
  • Compounds of the present invention may further exist as different geometric isomers or as different stereoisomers. Isomers that differ only with regard to the arrangement of the atoms in the space around the asymmetric (stereogenic, chiral) center are called "stereoisomers”. Stereoisomers that are not mirror images of each other are called diastereomers, while stereoisomers that have a mirror-image relationship, i.e.
  • stereoisomer that are mirror images of each other are called enantiomers.
  • Each stereoisomer may be characterized by determining the absolute configuration of the stereogenic center by the use of Cahn-Ingold- Prelog priority rules and hence characterized as R- or ⁇ -isomer.
  • Another way of identification of stereoisomers is the measurement of the rotation of the plane of polarized light that passes through the molecule, and designating chiral molecules to be right-rotating (+) or left-rotating (-) isomers.
  • Chiral molecules may exist in a form of single enantiomer or in a mixture of enantiomers. A mixture consisting of equal parts (+) and (-) enantiomers of a chiral substance is called a racemic mixture.
  • the present invention relates to each stereoisomer that may be shown by Formulae I, II and III either isolated as separate enantiomers, diastereomers or existing in racemic or any other mixture thereof. Methods for determination of stereochemical configuration, resolution and separation of stereoisomers are well known in the literature.
  • the enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereomeric salts which may be separated, for example, by crystallization; formation of diastereomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent.
  • the diastereomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above.
  • the present invention also encompasses stereoisomers of the syn-anti type, and mixtures thereof encountered when an oxime or similar group is present.
  • the group of highest Cahn- Ingold-Prelog priority attached to one of the terminal doubly bonded atoms of the oxime, is compared with the hydroxy group of the oxime.
  • a further aspect of the present invention involves to the processes for the preparation of the compounds of Formulae I, II and III, and salts thereof and/or, optionally, converting the resulting free compounds represented by Formulae I, II and IH, having salt-forming properties into corresponding salts, and/or, optionally, converting the resulting salts into free compounds or into other salts.
  • the present invention also relates to reactive intermediates obtained during the preparation of the compounds of the present invention and of their pharmaceutically acceptable salts. Such intermediates can be isolated and defined or used without isolation in the next step of chemical synthesis.
  • acyl groups such as alkanoyl, alkoxycarbonyl and aroyl groups
  • solvolysis e.g., by hydrolysis under acidic or basic conditions.
  • Arylmethoxycarbonyl groups e.g., benzyloxycarbonyl
  • a catalyst such as palladium-on-charcoal.
  • a corresponding aliphatic aldehyde such as glyoxylic acid, pyruvic aldehyde, glycolaldehyde or glyceraldehyde.
  • a corresponding aliphatic aldehyde such as glyoxylic acid, pyruvic aldehyde, glycolaldehyde or glyceraldehyde.
  • the reaction is carried out in an aqueous medium such as water or aqueous buffer, or aqueous-organic medium inert to the utilized chemical reagents.
  • Suitable organic solvents include, but are not limited to. tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, methanol, ethanol, 2- propanol and tert-butaxiol.
  • Preferable organic solvents include, but are not limited to, acetonitrile, methanol, ethanol and 2- ⁇ ropanol.
  • reaction may be performed in a pH range from 2 to 12, preferably in a pH range from 6 to 9.
  • aqueous aldehyde solution may be employed in the reaction, which may be used in substantial excess in respect to hydroxycoumarin, preferably in the ratio 2:1.
  • Reaction may be carried out at a temperature in the range of 0 0 C to the boiling point of the solvent employed.
  • Compounds mentioned in this section can be prepared using standard reducing reagents known to those skilled in the art, for example complex metal hydrides such as sodium cyanoborohydride.
  • Compounds mentioned in this section can be prepared using standard reducing reagents known to those skilled in the art, for example complex metal hydrides such as sodium cyanoborohydride.
  • Compounds of Formula I wherein A represents a CH-X group, wherein X represents a -C( N-R.
  • O-methylhydroxylamine O-methylhydroxylamine
  • hydrazine alkylhydrazine (e.g. methylhydrazine), aryl amine (e.g. aniline), and arylhydrazine (e.g. phenylhydrazine), respectively, using standard procedures for the preparation of oximes, imines, and hydrazones well known to those skilled in the art (See, e.g., Hadjipavlou-Litina, D. J. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 611-614).
  • phenylhydrazine respectively, using standard procedures for the preparation of oximes, imines, and hydrazones well known to those skilled in the art (See, e.g., Hadjipavlou-Litina, D. J. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 611-614).
  • the reaction may be carried out at a temperature in the range of about 0 0 C to the boiling point of the employed solvent. In some cases it would be desirable to remove one or more acetyl groups after dehydration process by procedures well known to those skilled in the art, for example by acidic or alkaline hydrolysis.
  • Compounds of Formula II wherein X represents a formyl group may optionally be prepared from corresponding intramolecular hemiacetals of Formula III wherein D represents CHOH and — denotes a single bond (See, e.g., WO 2005/010006), by the process described in the immediately preceding section.
  • a dehydrating agent for example thionyl chloride, alkyl monocarboxylic acid such as acetic acid, acetic anhydride-acetic acid or thionyl chloride-acetic acid mixtures. Reactions may be carried out at a temperature in the range of about 0 0 C to the about boiling point of the employed solvent.
  • the reaction is carried out in acetic anhydride or in acetic acid in the presence of dehydrating agent such as sulfuric acid.
  • a dehydrating agent for example thionyl chloride
  • Compounds of Formula III wherein D represents a CH 2 group and ⁇ represents a single bond may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of formula IV with 2-chloroacetaldehyde, its acetal, glycolaldehyde or its acetal (Fucik, K. et al. Bull. Soc. Chim. Fr. 1949, 16, 626-628).
  • the reaction is carried out in water, alkyl monocarboxylic acid such as acetic acid or trifluoroacetic acid or mixtures thereof followed by usual purification procedures well known to those skilled in the art, for example recrystallization or trituration.
  • Compounds of Formula III wherein D represents a CH group and - represents a double bond may be prepared by a process which comprises aromatization of the corresponding compound of formula III wherein D represents CH 2 group and ⁇ represents a single bond, and which is the object of the present invention.
  • the aromatization process may be performed by halogenation, most preferably bromination with reagent such as N- bromosuccinimide, in the presence of a radical source such as benzoyl peroxide (Furniss, B. S. et al., Eds., Vogel's Textbook of Practical Organic Chemistry: Longman, London, 1989), followed by in situ dehydrohalogenation.
  • reaction is carried out in an organic solvent inert to utilized chemical reagents such as tetrachloromethane.
  • Reaction may be carried out at a temperature in the range of 0 0 C to the boiling point, preferably at the boiling point of the employed solvent.
  • Compounds of Formula III wherein D represents CHCH 2 OH and — represents a single bond may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of formula IV with glyceraldehyde ⁇ See, e.g., Eckstein, M. et al. Roczniki Chem. 1964, 38, 1115-1120).
  • the reaction is carried out in water, alkyl monocarboxylic acid such as acetic acid or trifluoroacetic acid or mixtures thereof followed by usual purification procedures well known to those skilled in the art, for example recrystallization or trituration.
  • the above-mentioned compounds may be prepared from the compounds of Formula I wherein A represents a CH-X group, wherein X
  • CH 2 OH is a — CH-OH group, in an alkyl monocarboxylic acid such as acetic acid. Reaction may be carried out at a temperature in the range of O 0 C to the boiling point of the employed solvent. In some cases it would be desirable to remove one or more acetyl groups after dehydration process by procedures well known to those skilled in the art, for example by hydrolysis, most preferably by addition of water without isolation of intermediates.
  • Compounds of Formula IH wherein D represents CHCH 3 and — represents a single bond may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of formula IV with acrolein or 2-bromo-pro ⁇ ionaldehyde (See, e.g., Eckstein, M. et al. Acta Pol. Pharm. 1988, 45, 8-13).
  • the reaction is carried out in ethanol followed by usual purification procedures well known to those skilled in the art, for example recrystallization or trituration. Reaction may be carried out preferably at the boiling point of the employed solvent.
  • the above-mentioned compounds may be prepared from the compounds of Formula I wherein A represents CH-X group, wherein X is
  • n O, in a dehydrating agent such as trifluoroacetic acid.
  • hydroxycoumarin compounds of Formula IV may be prepared from the corresponding enamines of Formula V:
  • Enamines of Formula V may be prepared in a manner well described in the literature, e.g. by condensation of commercially available phenols with either cyanoacetic acid (See, e.g., Sonn, A. Ber.
  • the present invention relates to the use of the compounds of Formulae I, II and III, and their pharmaceutically acceptable salts, solvates (including hydrates), clathrates, tautomers and stereoisomers in the treatment and prophylaxis of diseases, states, disorders and/or conditions which may occur as a result of disturbance of the immunological system, particularly inflammatory diseases, states, disorders and conditions, especially asthma in mammals (especially humans), in therapeutically effective amounts.
  • the present invention further relates to the use of the compounds of Formula VI,
  • R 1 , R 2 , R 3 and R 4 are each independently hydrogen, halogen, C 2 -C 4 -alkenyl, C 2 - C 4 -alkynyl, halo-Ci-C 4 -alkyl, hydroxy, C 1 -C 4 -alkoxy, trifluoromethoxy, Ci-C 4 -alkanoyl, amino, amino-Ci-Q-alkyl, ⁇ -(CrQ-alky ⁇ amino, iV,N-di(C 1 -C 4 -alkyl)amino, mercapto, C 1 - C 4 -alkylthio, sulfo, Ci-C 4 -alkylsulfo, sulfino, C 1 -C 4 -alkylsulfino, carboxy, C 1 -C 4 -alkoxycarbonyl, cyano, or nitro;
  • n is, independently, an integer which is O or 1;
  • R 5 is an hydroxy, alkoxy, amino, alkylamino, aryl or arylamino group
  • R 6 is hydrogen or CH 3 ;
  • D is CH, CH 2 , CCH 3 , CHCH 3 , CHCH 2 OH, or carbonyl
  • a “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, state, disorder or condition, is sufficient to effect such treatment.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the mammal to be treated.
  • Treating” or “treatment” of a disease, state, disorder or condition includes:
  • the benefit to a subject to be treated is either statistically significant or at least perceptible to the patient or to the physician.
  • Symptoms and signs of inflammation associated with specific conditions include: rheumatoid arthritis- pain, swelling, warmth and tenderness of the involved joints; generalized and morning stiffness; insulin-dependent diabetes mellitus- insulitis; this condition can lead to a variety of complications with an inflammatory component, including: retinopathy, neuropathy, nephropathy; coronary artery disease, peripheral vascular disease, and cerebrovascular disease; autoimmune thyroiditis- weakness, constipation, shortness of breath, puffiness of the face, hands and feet, peripheral edema, bradycardia; multiple sclerosis- spasticity, blurry vision, vertigo, limb weakness, paresthesias; uveoretinitis- decreased night vision, loss of peripheral vision; lupus erythematosus- joint pain, rash, photosensitivity, fever, muscle pain, puffmess of the hands and feet, abnormal
  • Type II diabetes- end organ complications including cardiovascular, ocular, renal, and peripheral vascular disease lung fibrosis- hyperventilation, shortness of breath, decreased oxygenation; vascular disease, such as atherosclerosis and restenosis- pain, loss of sensation, diminished pulses, loss of function; and alloimmunity leading to transplant rejection- pain, tenderness, fever.
  • Subclinical symptoms include without limitation diagnostic markers for inflammation the appearance of which may precede the manifestation of clinical symptoms.
  • One class of subclinical symptoms is immunological symptoms including, but not limited to, the invasion or accumulation in an organ or tissue of proinflammatory lymphoid cells or the presence locally or peripherally of activated pro-inflammatory lymphoid cells recognizing a pathogen or an antigen specific to the organ or tissue. Activation of lymphoid cells can be measured by techniques known in the art. Other classes of immunological symptoms are discussed infra in connection with the Examples under the Section "Pharmacological Properties".
  • Delivery a therapeutically effective amount of an active ingredient to a particular location within a host means causing a therapeutically effective blood concentration of the active ingredient at the particular location. This can be accomplished , e.g., by local or by systemic administration of the active ingredient to the host.
  • the present invention also includes pharmaceutical compositions containing a therapeutically effective amount of one or more of the compounds of Formula I, II, III, VI, VII, or VIII or a pharmaceutically acceptable salt, solvate, clathrate, tautomer or stereoisomer thereof with a pharmaceutically acceptable diluent or carrier.
  • the pharmaceutical compositions of the invention are formulated in such a manner to achieve an optimal bioavailability of the active compounds.
  • active compound denotes the compounds of Formula I, II, III, VI, VII, or VIII or a pharmaceutically acceptable salt, solvate, clathrate, tautomer or stereoisomer thereof.
  • the active compound may be administered orally, buccally, rectally, parenterally, or topically, such as nasally or by inhalation when preferred administration is local application in the respiratory tract.
  • the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral or topical administration.
  • Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy.
  • the compositions of the invention may contain 0.1-99% by weight of active compound.
  • the compositions of the invention are generally prepared in unit dosage form. Preferably, the unit dosage of active ingredient is 1-500 mg.
  • the effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, tautomer or stereoisomer thereof is from about 0.004 to about 4000 ⁇ mol/kg body weight/day; preferrably from about 0.04 to about 400 ⁇ mol/kg body weight/day; more preferrably from about 4 to about 400 ⁇ mol/kg body weight/day; most preferrably from about 12 to about 120 ⁇ mol/kg body weight/day.
  • excipients used in the preparation of these compositions include, but are not limited to the excipients readily known in the pharmacist's art.
  • a “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
  • a “pharmaceutically acceptable excipient” as used in the present application includes both one and more than one such excipient.
  • compositions for oral administration are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oil suspensions.
  • the excipients used in the preparation of these compositions include, but are not limited to the excipients readily known in the pharmacist's art.
  • Tablets may be prepared by mixing the active compound with an inert diluent such as calcium phosphate in the presence of disintegrating agents, for example maize starch, and lubricating agents, for example magnesium stearate, and tableting the mixture by known methods.
  • the tablets may be formulated in a manner known to those skilled in the art so as to B2006/001259
  • Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.
  • capsules for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner.
  • the tablets and capsules may conveniently each contain 1 to 500 mg of the active compound.
  • compositions for oral administration include, but are not limited to, aqueous suspensions containing the active compound in an aqueous medium in the presence of a nontoxic suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
  • a nontoxic suspending agent such as sodium carboxymethylcellulose
  • oily suspensions containing a compound of the present invention in a suitable vegetable oil for example arachis oil.
  • the active compound may be formulated into granules with or without additional excipients.
  • the granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion.
  • the granules may contain disintegrants (for example a pharmaceutically acceptable effervescent couple formed from an acid and a carbonate or bicarbonate salt) to facilitate dispersion in the liquid medium.
  • compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
  • compositions may also be administered parenterally (for example subcutaneously, intramuscularly, intradermally and/or intravenously [such as by injection and/or infusion]) in the known pharmaceutical dosage forms for parenteral administration (for example sterile suspensions in aqueous and/or oily media and/or sterile solutions in suitable solvents, preferably isotonic with the blood of the intended patient).
  • parenteral dosage forms may be sterilized (for example by micro-filtration and/or using suitable sterilising agents [such as ethylene oxide]).
  • suitable sterilising agents such as ethylene oxide
  • one or more of the following pharmaceutically acceptable adjuvants suitable for parenteral administration may be added to parenteral dosage forms: local anaesthetics, preservatives, buffering agents and/or mixtures thereof.
  • Parenteral dosage forms may be stored in suitable sterile sealed containers (for example ampoules and/or vials) until use. To enhance stability during storage the parenteral dosage form may be frozen after filling the container and fluid (for example water) may be removed under reduced pressure.
  • fluid for example water
  • Especially important pharmaceutical compositions are those that may be administered nasally or by inhalation in known pharmaceutical forms for such administrations (for example sprays, aerosols, nebulised solutions and/or dry powders). Metered close systems known to those skilled in the art (for example aerosols and/or inhalers) may be used.
  • the compounds of Formula I, II, III, VI, VII, or VIII or their salts being previously homogenized in lactose, glucose, higher fatty acids, sodium salt of dioctylsulfosuccinic acid, or most preferably in carboxymethylcellulose, in such a way that most of the particles are 5 ⁇ m in size.
  • the compounds of the present invention in the form of particles of very small size may be obtained, for example by fluid energy milling.
  • the aerosol can be mixed with a propellant intended for the spraying of the active substance.
  • compositions may be administered to the buccal cavity (for example sub- lingually) in known pharmaceutical forms for such administration (for example slow dissolving tablets, chewing gums, gums, troches, lozenges, pastilles, gels, pastes, mouthwashes, rinses and/or powders).
  • compositions for topical administration may comprise a matrix in which the pharmacologically active compound of the present invention is dispersed so that the compound is held in contact with the skin in order to administer the compound transdermally.
  • a suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or wax, for example paraffin wax or beeswax, together with 'a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol.
  • a topical vehicle such as a mineral oil, petrolatum and/or wax, for example paraffin wax or beeswax
  • the active compound may be dispersed in a pharmaceutically acceptable ointment, cream, gel or lotion.
  • Ointments, creams and gels may be formulated with a water base or an oil base under the addition of a suitable emulsifler or gelling agent when gel is formulated
  • the amount of the active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
  • the compounds of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body.
  • Internal sources include implanted reservoirs W
  • containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as a suspension or solution in a pharmaceutically acceptable oil of the compound to be infused for example in the form of s very sparingly water-soluble derivative or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused.
  • the support may be a single body containing the entire compound or a series of several bodies each containing part of the compound to be delivered.
  • the amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
  • the active compound may be used individually or, if desired, may be associated with other compatible pharmacologically active ingredients.
  • a further aspect of the present invention relates to the use of one or more' of the compounds of Formula I, II, III, VI, VII, or VIII, or pharmaceutically acceptable salts, solvates (including hydrates), clathrates, prodrugs, tautomers or stereoisomers thereof or pharmaceutical compositions containing a therapeutically effective amount thereof in the prophylaxis and therapeutic treatment of inflammatory diseases, pathological allergy disorders and/or conditions.
  • Such conditions and diseases are, without limitation, asthma; chronic obstructive pulmonary disease; bronchitis; adult respiratory distress syndrome; nasal inflammatory diseases such as allergic rhinitis, nasal polyps; mflarnmatatory skin disorders such as eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis; rheumatoid arthritis; inflammatory bowel diseases such as Crohn's disease, colitis and ulcerative colitis; further insulin-dependent diabetes, autoimmune thyroiditis, lupus erythematosus, multiple sclerosis, Raynaud's disease, and other arthritic conditions having an inflammatory component such as rheumatoid spondylitis, septic arthritis, polyarthritis, retinitis, inflammatory brain disorders such as meningitis and encephalitis; conditions associated with acute trauma such as cerebral injury, heart tissue injury and lung injury; inflammation accompanying infections such as sep
  • HPLC high-performance liquid chromatography
  • HPLC-MS high-performance liquid chromatography connected to a mass spectrometer
  • ESI electrospray ionisation
  • NMR nuclear magnetic resonance
  • hydroxylamine (2 equiv.) was added (or O-alkylhydroxylamine, e.g. 0-methylhydroxylamine, hydrazine, alkylhydrazine, e.g. methylhydrazine, aryl amine, e.g. aniline, or arylhydrazine, e.g. phenylhydrazine) resulting in a clear solution.
  • Assays that can be used to determine the anti-inflammatory effects of the compounds and hense, their use for the treatment of diseases characterized by pathologic inflammation are represented by Examples 285 to 287, 289 and 375 to 377.
  • the cytokines assayed in these examples when expressed at elevated amounts, are markers for inflammation and, in the case of other immune events assayed such as cell proliferation, granulocyte degranulation and lung netrophilia, the behaviors of these immune cells are also markers for their activation and, therefore, inflammation. Consequently, reduction of pro-inflammatory cytokine expression or secretion and reduction in cell proliferation, mast cell degranulation or neutrophil accumulation is a measure of a compound's anti-inflammatory activity.
  • Lung neutrophilia specifically serves as a model for COPD and lung eosinophilia as a model for asthma.
  • Phosphodiesterases are involved in various inflammatory states such as asthma* (PDE4), COPD (PDE4) and pulmonary hypertension (PDE3).
  • Prostaglandins and leukotrienes are also potent inflammation mediators, the former being produced in the cyclooxygenase (COX) pathway and the latter in the lipooxygenase pathway.
  • Thromboxanes are also potent inflammation mediators produced in the COX pathway.
  • a compound analyzed using the biological assays as defined herein is considered to be fully “active” if inhibition is significant (i.e. 50% or higher) in at least one inhibitory function (e.g., inhibition of TNF- ⁇ or IL-6) after stimulation with at least one stimulant (e.g., OVA, PMA or LPS), as described for each particular in vitro assay, or if activity in at least one of in vivo testings (e.g. in suppression of ear oedema) is statistically significantly different in comparison to a positive control group, as calculated by the statistical methods known in the art (e.g. ANOVA).
  • at least one inhibitory function e.g., inhibition of TNF- ⁇ or IL-6
  • at least one stimulant e.g., OVA, PMA or LPS
  • Mast cell degranulation is indicated as invoked in immediate or delayed type hypersensitivity reaction, allergy, anaphylaxis, inflammation, asthma and urticaria (hives).
  • RBL-2H3 cell line of rat basophilic leukaemia was used for the investigation of inhibition of degranulation induced by the activation of Fc ⁇ receptor type I or calcium ionophors.
  • RBL-2H3 cell line was cultivated in DMEM medium (Invitrogen Cat. No. 31966- 021) with 10 % of phoetal calf serum (Invitrogen Corporation) at 37 °C, 5 % CO 2 , 90 % relative humidity. Cells were seeded in the same medium into 24- well plates, 50000 per well, and left to reach 80-90 % of confluence.
  • Dilutions of compounds were prepared in DMEM medium without phenol red (Invitrogen Corporation) in concentrations from 200 ⁇ M to 1 ⁇ M. The medium was removed from the cells and the diluted of compounds were added to the wells with the exception of the positive and the negative control where pure DMEM medium was added. Subsequently,
  • the supernatant (50 ⁇ L) was transferred in duplicate to a 96-well plate. Thereto 100 ⁇ L of 50 mM sodium citrate buffer with 1 mg/mL para-nitrophenyl-N-acetyl- ⁇ -D- glucosaminide (Calbiochem) were added and it was incubated for 1 hour at 37 °C. The reaction was stopped with 100 ⁇ L of a saturated sodium carbonate solution. The absorbance was measured at 405 nm. The percentage of inhibition was expressed by the formula:
  • % inhibition (l-(OD 4 Q 5 sample-OD 405 negative control)/(OD 405 positive control- OD 4 o 5 negative control)) x 100.
  • Ketotifen used as a standard, significantly inhibits degranulation in concentrations from 200-50 ⁇ M.
  • Leukotrienes are important mediators in host defense mechanisms and in inflammatory disease states due, for example, to their effects on cell migration, muscle contraction, vascular permeability, and the release of lysozomal enzymes. Leukotriene production depends on the enzyme activity of 5-lipoxygenase. RBL-2H3 cells have a potent 5-lipoxygenase activity and thus serve as a cell model for production of leukotrienes.
  • RBL-2H3 cell line (ATCC 2256) is grown in DMEM medium (Invitrogen) supplemented with 10% FBS (Invitrogen) in the atmosphere of 5% CO2, 90% humidity, 37 C. Cells are trypsinazed, washed with fresh DMEM medium and adjusted to 1x10 5 cells per mililiter. 500 ⁇ L/well of cell suspension is transferred into 24 well plate (Falcon) and grown overnight in culturing condition described herein.
  • %inhibition (l- LTB4 sample concentration/LTB4 positive control concentration) x 100.
  • 5 -lipoxygenase is involved in number of immune diseases like asthma and inflammatory bowel disease.
  • 5-LO 5 -lipoxygenase
  • AU compounds were dissolved in dimethyl sulfoxide (DMSO). Final concentration of the DMSO in all tests was 1% (v/v). Inhibition in all tests is considered preferred if it exceeds 50% at 10 ⁇ M concentration (or less).
  • DMSO dimethyl sulfoxide
  • 5-lipoxygenase is involved in number of immune diseases like asthma and inflammatory bowel disease.
  • HBSS Hanks Balanced Salt Solution
  • Substrate arachidonic acid
  • LTB4 as a final product of arachidonic acid metabolism was measured using competitive enzyme immunoassay ⁇ See, e.g., Safayhi, H. et al. Planta Medica 2000, 66, 110-113) and percentage of inhibition was calculated from the levels of LTB4 in cell supernatant.
  • CysLTl receptor is involved in immune diseases such as asthma, and has clinical significance as a point of intervention in asthma therapy. CysLTl receptor is expressed in CHO-Kl cells (Chinese hamster ovary cells Kl clone). This is a competitive radioligand binding assay where substances compete with [ 3 H]-labeled Leukotirene D4 (LTD4). Radioactive substance is measured with scintillation counting. Percentage of inhibition is calculated from the total radioactivity of the sample.
  • Phosphodiesterases are involved in many cellular processes of signal transduction and have implication in cell growth and division, inflammation, pulmonary hypertension and asthma. Inhibitors of PDE4 have been developed for asthma treatment. The PDE3 inhibitor cilostazol has been approved in certain countries for treatment of arterial occlusive diseases and stroke.
  • PDE3 assay Isolated human platelets are pre-incubated at 25 0 C in Tris-HCl buffer containing magnesium ions for 15 minutes. 1.01 ⁇ M tritium labeled cyclic adenosine monophosphate (cAMP) is added as substrate, followed by incubation at 25 °C for 20 minutes. Percentage of inhibition is calculated by comparing the adenosine levels in supernatant which is formed from cAMP in treated versus control cells.
  • cAMP tritium labeled cyclic adenosine monophosphate
  • PDE4 assay PDE is implicated in diseases such as chronic obstructive pulmonary disease and neutrophilia.
  • Human monocytic leukemia cell line U937 is pre-incubated at 25 0 C in Tris-HCl buffer containing magnesium ions for 15 minutes. 1.01 ⁇ M tritium labeled cyclic adenosine monophosphate (cAMP) is added as substrate, followed by incubation at 25 0 C for 20 minutes. Percentage of inhibition is calculated by comparing the adenosine levels in supernatant which is formed from cAMP in treated versus control cells.
  • cAMP tritium labeled cyclic adenosine monophosphate
  • Human prostanoid receptor is expressed in Chinese hamster ovary cell line, clone Kl (CHO-Kl). Substances and radioactive competitor (tritium labelled Prostaglandin D2 in 1.7 nM concentration) are incubated with cells in HEPES buffer for 2 hours at 25 0 C in the presence of manganese ions. Level of the bound PGD2 is measured by scintillation counting, and competition is calculated from comparing the total amount of the bound PGD2 in treated versus control cells. Prostanoids are involved in many physiological and pathological processes, from inflammation to pain.
  • TxA2 receptor is expressed in HEK-293 cell line. Compounds and radiolabeled competitor SQ-29548 are incubated for 30 minutes at 25 °C. Level of bound SQ-29548 is measured by scintillation counting, and competition is calculated from the total amount of the bound SQ-29548.
  • TxA2 receptor is an unstable lipid mediator involved in blood clotting, and immune processes.
  • Human ERKl is expressed in Escherichia coli and purified. Compounds are pre- incubated in MOPS/EGTA buffer with pervanadate, DTT and ⁇ -[ 32 P]-ATP with recombinant enzyme for 15 minutes at 37 °C. Substrate (purified myelin basic protein, MBP) is added, followed by incubation at 37 0 C for 30 minutes. Enzyme activity is measured by quantitation of [ 32 P]-MBP and inhibition is calculated from specific radioactivity.
  • ERKl is a serine/threonine kinase activated in MAPK (mitogen activated kinase) pathway. ERKl is implicated in a high proportion of human cancers, including Hodgkin disease. ERKl is involved in processes of cell growth, division and inflammation.
  • LcIc Human recombinant LcIc is expressed in insect Sf21 expression system and purified. Substances are pre-incubated for 15 minutes at 25 0 C in HEPES buffer containing ATP 5 pervanadate and magnesium. Substrate (poly Glu-Tyr) is added and incubated for 60 minutes at 25 °C. Activity of the enzyme is measured using phosphotyrosine (p-Tyr) specific enzyme immunoassay and inhibition is calculated from the determination of the concentration of p- Tyr.
  • Protein tyrosine kinase, Lck is a protein tyrosine kinase which is abundantly expressed in T-lymphocytes and is essential for T-cell receptor signal transduction and thus activation of T-lymphocytes. Lck activation stimulates recruitment and activation of ZAP-70, which is essential for T-cell activation. Inhibitors of Lck act as immunoregulatory agents in various models. Lck is implicated in T-cell leukemias and
  • Compound represented by Example 19 significantly inhibited human Lck activity at a concentration of 10 ⁇ M.
  • Tachykinin NK2 receptor is expressed in Chinese hamster ovary cell line, clone Kl (CHO-Kl). Substances and radioactive competitor (tritium labelled SR-48968) are incubated with cells in HEPES/NaOH buffer for 90 minutes at 25 °C in the presence of manganese ions. Levels of the bound SR-48968 is measured by scintillation counting, and competition is calculated from the total amount of the bound SR-48968 in treated and control samples. Tachykinin receptors are involved in physiological and pathological processes of inflammation and pain. Tachykinin NK2 has been identified as a target for intervention in asthma, GI disease, irritable bowel syndrome and pancreatitis.
  • Example 375 Inhibition of cytokine production
  • White blood cells were obtained from venous blood of healthy volunteers by sedimentation on 2% dextran T-500 (Amersham Biosciences) and subsequent centrifugations of leukocyte rich plasma. Cells were seeded in a 48-well plate at a concentration of 3 -5x10 6 cells per well and preincubated with the tested compounds for 2h at 37 0 C. Afterwards, stimuli (Sigma) were added to the final concentration of 2 ⁇ g/mL lipopolysaccharide (LPS), l ⁇ g/mL phorbol-12-myristate acetate (PMA) or 120 ⁇ g/mL zymosan (ZYM). Samples were incubated overnight at 37°C.
  • LPS lipopolysaccharide
  • PMA l ⁇ g/mL phorbol-12-myristate acetate
  • ZYM 120 ⁇ g/mL zymosan
  • % Inhibition (1 - cytokine concentration of sample/cytokine concentration of positive control) x 100.
  • Compounds are considered active if the percent of inhibition is 50% or greater in concentration of 25 ⁇ M or lower.
  • LPS lipopolysaccharide
  • hPBMCs human peripheral blood mononuclear cells
  • Blood was taken from healthy volunteer donor, diluted with the same volume of saline and was separated by gradient density centrifugation on FicollPaqueTM Plus on 40Og for 30 minutes. PBMCs were collected, washed in RPMI, counted and number per mL was adjusted.
  • PBMCs Collected PBMCs were cultured into 96 well tissue culture plate, flat bottom as 35.000 cells/well/200uL in RPMI supplemented with 10 % fetal bovine serum, prior inactivated on 56°C for 30 minutes.
  • Cells were stimulated on IL- l ⁇ production by adding LPS (serotype 0111:B4, Sigma, cat# L-2630), at final concentration lng/mL. Unstimulated cells were cultured in medium alone.
  • Stock solution was prepared out of testing compounds as 1OmM in DMSO. Final concentrations made in cell culture medium were tested when they had been added together with LPS. The final DMSO volume ratio in all assays did not exceed 0.1%.
  • Negative and positive control samples were prepared in sextaplicates and samples with tested compound concentrations in triplicates. After overnight incubation in humidified atmosphere containing 5% CO 2 , supernatants were collected.
  • % Inhibition (1 - cytokine concentration of sample/cytokine concentration of positive control) x 100. Compounds are considered active if the percent of inhibition is 50% or greater in concentration of 25 ⁇ M or lower.
  • Compound 244 significantly inhibited IL- l ⁇ production in concentration of 25 ⁇ M.
  • Spleen cell suspension was obtained from BALB/c mice and lymphocytes separated by gradient density centrifugation on Histopaque 1.083 on 40Og for 30 minutes. They were washed once in medium, counted and their number adjusted as 3xl0 5 /200 ⁇ L/well in 96 flat bottomed culture plate in RPMI supplemented with 10 % fetal bovine serum. Cells were stimulated on cytokine production by adding concanavalinA (ConA) at 5 ⁇ g/mL final concentration. Unstimulated cells were cultured in medium alone. Stock solution was prepared out of testing compounds as 1OmM in DMSO. Final concentrations made in cell culture medium were tested when they had been added together with ConA.
  • ConA concanavalinA
  • IL-4, IL-5, IL-10 and IFN ⁇ were detected and quantified using enzyme linked immunosorbent assay (ELISA) specific for pointed cytokines (R&D Systems).
  • % Inhibition (1 - cytokine concentration of sample/cytokine concentration of positive control) x 100.
  • Compounds are considered active if the percent of inhibition is 50% or greater in concentration of 25 ⁇ M or lower.
  • Compound 244 significantly inhibited IL-4, IL-5, IL-IO, as well as IFN ⁇ production in concentration of 25 ⁇ M.
  • Compound 30 significantly inhibited IL-5 and IL-IO production in concentration of 25 ⁇ M.
  • Example 376 Pkorbol 12-myristate 13-acetate, PMA, induced ear oedema in CDl mice
  • PMA phorbol 12-myristate 13-acetate
  • Test compounds were administered at a single dose of 250 or 100 ⁇ g/15 ⁇ L/ear and dexamethasone at a single dose of 50 ⁇ g/15 ⁇ L/ear. Thirty minutes later, 0.01 % PMA solution in acetone was applied topically to the same area of each animal in a volume of 12 ⁇ L/ear. During the treatment and challenge, animals were anaesthetized by using inhalation anaesthesia. Six hours after the challenge, animals were euthanized by asphyxiation in 100% CO2 atmosphere. For assessing the auricular oedema, 8 mm discs were cut out of left and right auricular pinna and weighed. The degree of oedema was calculated by subtracting the weight of 8 mm disc of the untreated ear from that of the treated contralateral ear.
  • the compound at appropriate dose is considered active if the supression of ear oedema in compound treated group is statistically significantly different in comparison to positive control group, as calculated by the statistical methods known from the art (e.g. ANOVA).
  • Example 289 Model of ovalbumin induced pulmonary eosinophilia in mice
  • mice with a body weight of 20-25 g are randomly divided into groups, and sensitized by an i.p. injection of ovalbumin (OVA, Sigma) on day zero and day fourteen.
  • OVA ovalbumin
  • PBS negative control
  • the compounds are administered daily i.n., Lp. or per os in different doses starting 2 days before the challenge and up to the completion of the test.
  • Compounds are administered as suspension either in PBS, methyl cellulose or carboxymethyl cellulose with addition od DMSO (up to 5% of the total volume). 48 hours after Ln.
  • bronchoalveolar lavage fluid BALF
  • BALF bronchoalveolar lavage fluid
  • BAL Bronchoalveolar lavage
  • BAL is performed by infusing ImL of PBS divided into 3 separate volumes (0.4, 0.3 and 0.3ml) through trachea into the lungs. The fluid is immediately withdrawn and the cell suspension stored into previously prepared l,5mL Eppendorf tube. Bronchoalveolar lavage fluid (BALF) is then centrifuged at O 5 Ig for 5min (4°C).
  • cytospins 320 ⁇ L of suspension is centrifuged at 250rpm for lOmin (Cytospin-3, Shandon Instruments). Cells are stained with Dif-Quik (Dade Behring) to determine percentage of eosinophils by counting of at least 100 cells. The remaining resuspended cells are used for total cell count in BALF analysis (Sysmex SF 3000). Finally, lungs are sampled and stored into 10% formalin for pathohistological evaluation of eosinophil and mononuclear infiltrate. Accumulation of eosinophils and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and in alveolar spaces is monitored.
  • PB peribronchial
  • PV perivascular
  • Results can be expressed as (I) decrease of absolute cell number per mL in BALF, (II) decrease of number of eosinophils per mL in BALF, (III) reduction of relative number (percentage) of eosinophils in BALF, (IV) reduction of cytokine concentrations in BALF, as well as (V) suppression of accumulation of eosinophils and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and in alveolar spaces by pathohistological scoring of treated animals compared to positive control (OVA stimulated, but untreated animals).
  • PB peribronchial
  • PV perivascular
  • results have to be statistically significantly different when compared to positive control group, as calculated by the statistical methods known in the art (e.g. ANOVA).
  • Fluticasone and beclomethasone are used as standard anti-inflammatory substances, and compared for ability to inhibit eosinophilia to the negative and positive controls.
  • Compounds represented by Examples 19, 30, 50 and 363 exhibited statistically significant reduction of percentage of eosinophils and/or their total number in BALF and/or by histological scoring.
  • Example 377 Model of LPS induced pulmonary neutrophilia in mice
  • Test compounds Male Balb/cJ mice (Iffa Credo, France) weighing ⁇ 25 g are randomly grouped into a negative control group, positive control group and groups treated with compounds to be assayed).
  • Test compounds as well as vehicle (DMSO + 0,5% methyl-cellulose) (all from Sigma), are administered in., i.p. or per os two hours prior to administration of lipopolysaccharide (LPS) (E. coli, serotype 0111:B4, Sigma) or two hours prior and two hours after administration of LPS.
  • LPS lipopolysaccharide
  • Test compounds are administered at a single dose (two hours prior the challenge) or divided into two doses (two hours prior and two hours after the challenge).
  • LPS solution in phosphate buffered saline (PBS) (Sigma) is administered intranasally in volume of 60 ⁇ L at concentration of 33,33 ⁇ g/mL, to all experimental groups except the negative control group, which received the same volume (60 ⁇ L) of vehicle PBS.
  • PBS phosphate buffered saline
  • animals were anaesthetized by using intraperitoneal anaesthesia. Animals are euthanized by i.p. anesthesia overdose approximately 24 hours after application of LPS to obtain bronchoalveolar lavage fluid (BALF), which is used to determine total protein concentration as well as concentrations of cytokines, such as IL- l ⁇ and TNF- ⁇ , absolute number of cells, and percentage of neutrophils in BALF.
  • BALF bronchoalveolar lavage fluid
  • Bronchoalveolar lavage (BAL) is performed by infusing ImL of PBS divided into 3 separate volumes (0.4, 0.3 and 0.3ml) through trachea into the lungs. The fluid is immediately withdrawn and the cell suspension stored into previously prepared l,5mL Eppendorf tube. Bronchoalveolar lavage fluid (BALF) is then centrifuged at 0,Ig for 5min (4°C). Cells are resuspended in 700 ⁇ L of PBS. To prepare cytospins, 320 ⁇ L of suspension is centrifuged at 250rpm for lOmin (Cytospin-3, Shandon Instruments).
  • BALF Bronchoalveolar lavage fluid
  • Dif-Quik Dade Behring
  • the remaining resuspended cells are used for total cell count in BALF analysis (Sysmex SF 3000).
  • lungs are sampled and stored into 10% formalin for pathohistological evaluation of granulocyte and mononuclear infiltrate. Accumulation of granulocytes and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and alveolar spaces is monitored.
  • PB peribronchial
  • PV perivascular
  • Results can be expressed as (I) decrease of absolute cell number per mL in BALF, (II) decrease of number of neutrophils per mL in BALF, (III) reduction of relative number (percentage) of neutrophils in BALF, (IV) reduction of cytokine concentrations in BALF, as well as (V) suppression of accumulation of granulocytes and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and in alveolar spaces by pathohistological scoring of treated animals compared to positive control (LPS stimulated, but untreated animals).
  • PB peribronchial
  • PV perivascular
  • results have to be statistically significantly different when compared to positive control group, as calculated by the statistical methods known in the art (e.g. ANOVA).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Certain bis-(coumarin) compounds of formula (VI) as well as the products of thei intramolecular cyclization including pharmaceutically acceptable salts, hydrates, solvates, clathrates, prodrugs, tautomers and stereoisomers thereof are disclosed. Certain processes and intermediates for the preparation of certain bis-(coumarin) compounds, as well as for the use of these compounds as therapeutically active agents in the prophylaxis and treatment of asthma and other inflammatory diseases and conditions in mammals, especially humans are also disclosed.

Description

BIS-(COUMARIN) COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY
Field of the Invention
The present invention relates to certain bis-(coumarin) compounds as well as the products of their intramolecular cyclization including pharmaceutically acceptable salts, solvates (including hydrates), clathrates, prodrugs, tautomers and stereoisomers thereof. The invention further relates to processes and intermediates for the preparation of certain bis- (coumarin) compounds, as well as to the use of these compounds as therapeutically active agents in the prophylaxis and treatment of asthma and other inflammatory diseases and conditions in mammals, especially humans.
Technical Problem
The present invention is responsive to the technical problem of providing novel antiinflammatory agents that have pronounced activity against inflammatory conditions or disorders, that are more effective against specific types of inflammation disorders than steroids or NSAIDs and/or that have an improved side effect profile compared to heretofore known PDE4 inhibitors, or leukotriene inhibitors.
Background of the Invention
Asthma is a chronic inflammatory disease of the respiratory airways in mammals. Clinically, in hypersensitive persons the inflammation causes periodic coughing attacks, troubled breathing, wheezing, tightness in the chest and chest pain. The inflammation makes respiratory airways more susceptible to irritations by allergens, chemical irritants, tobacco smoke, cold air and strain. Exposed to these irritants, respiratory airways become edematous, contracted, filled with mucus and hypersensitive.
The pathogenesis of asthma is complex and includes the interaction of inflammatory cells, mediators as well as of the tissue and cells of respiratoy airways. In the asthmatic process an early phase and a late phase of a response are distinguished. Allergic diseases as well as allergen-induced asthma are characterised by the synthesis of a specific type of IgE antibodies. Immediately after the inhalation of allergens, complexes of allergens and allergen specific IgE's are bound to high affinity IgE receptor (Fcε receptor type I) present on basophils, mastocytes and eosinophils. By the binding to the receptor the activation of signal transfer cascade occurs, which results in:
1. de novo synthesis of proinflammatory genes (e.g. interleukin-4 and interleukin-5),
2. exocytosis of the content of cytoplasmatic granules - degranulation.
The granules contain inflammatory mediators such as histamine, serotonin, leukotrienes C4, D4 and E4, and proteins such as major basic protein and mieloperoxidase. These inflammatory mediators co-operate in the processes of vasodilation, bronchoconstriction, triggering and control of the inflammatory process and activation of the cells and damage to the inflamed tissue. These processes form the early asthmatic response. The inhibition of degranulation may prevent the symptoms and stop the inflammation progress, which has been proven by the clinical use of degranulation inhibitors (sodium cromoglycate, nedocromil sodium and ketotifen).
The late asthmatic response includes a permanent obstruction of air passages, a hyperreactivity of the bronchi and a development of inflammation changes including the accumulation of neutrophils, eosinophils, lymphocytes and monocytes/macrophages in the respiratory system. The accumulation of inflammatory cells results from harmonized interaction of lymphokines (TNF-α, IL-4, IL-5), adhesion molecules on the surface of leukocytes (integrins) and endothelial cells (selectins), and chemokins (eotaxin, RANTES). The role and significance of T-lymphocytes in asthma were confirmed by the existence of an increased number of activated CD4+ T-cells in bronchoalveolar lavage and bronchial biopsies of patients suffering from asthma. Two subpopulations of CD4+ cells differ with regard to the profile of cytokines they secrete. Th 1 cells secrete IL-2, IL-3, GM-CSF, INF-γ. Activation of Th 1 cells is important in the defense of the host against intracellular organisms, viruses and neoplasms. Investigations have demonstrated that, in asthma, Th 2 cell response prevails with an increased expression of IL-5 that is important in the formation of eosinophilic infiltration typical of allergic inflammation.
Morphologic changes occurring in asthma include an infiltration of the bronchi by inflammation cells (mastocytes, T-lymphocytes and eosinophils are the key executive cells), a clogging of respiratory airways by a secrete, interstition oedema and increased microcirculation permeability. On the basis of pathohistological findings it has been established that eosinophilic infiltration is specific and differentiates asthma from other types of inflammation.
In the control of asthma two types of medicaments exists, symptomatic ones and basic ones. The symptomatic medicaments include short-acting bronchodilators such as β2- agonists, anticholinergics, theophylline, which rapidly relax the contracted respiratory airways and alleviate the acute symptoms. The basic medicaments include antiinflammatory drugs and long-acting bronchodilators. Antiinflammatory drugs alleviate and prevent the inflammation reaction and they include inhalable corticosteroids, systemic corticosteroids and inhalable cromones, such as cromolyn and nedocromil.
Steroid antiinflammatory compounds are still considered to be the most effective medicaments in the treatment of inflammatory diseases and conditions such as asthma. The good potency and efficacy of this type of medicament are, however, accompanied by numerous undesired side effects, such as disturbances of carbohydrate metabolism, of calcium resorption, of the secretion of endogenic corticosteroids and of physiological functions of the hypophysis, of the suprarenal gland core and of the thymus, hi the literature (WO 94/13690, WO 94/14834, WO 92/13872 and WO 92/13873) so-called "soft" steroids or hydrolysable corticosteroids with local action are described. Their systemic, undesired effect is reduced due to the instability of "soft" steroids in serum, where the active steroid is rapidly hydrolyzed to an inactive form. However, a steroid without negative side effects in long-term use has yet to be found.
New medications concentrate on reducing inflammatory response as a method for alleviating or eliminating symptoms (Barnes, P. J. Nature Reviews Drug Discovery, 2004, 3, 831-844; BaIs, R. Curr. Med. Chem. - Anti-Inflammatory & Anti-Allergy Agents, 2004, 3, 39-52; Coruzzi, G. Current Drug Targets - Inflammation & Allergy, 2004, 3, 43-61; Prescott, S. L. Med. Chem. Reviews — Online, 2004, I, 163-177). The leukotriene inhibitors are the newest addition to the asthma therapy. Leukotrienes are produced by 5 -lipoxygenase enzyme pathway, and inhibitors are divided into several groups according to their mode of action. Cysteinyl leukotriene antagonists have proven efficacy in short and long-term studies: improvements in baseline lung function in asthmatics and improvement of a variety of symptoms as well as decreased use of β2-agonists and a reduction in asthma exacerbations have been reported (Barreiro, E. J. Curr. Med. Chem. - Anti-Inflammatory & Anti-Allergy Agents, 2004, 3, 9-18). Therapeutically, the 5 -lipoxygenase inhibitor, zileuton, is as effective as the cysteinyl leukotriene antagonists, and its therapeutic effects are indistinguishable from those of the cysteinyl leukotriene antagonists. Several LTB4 antagonists are currently under investigation aimed at different indications (Balazy, M. Current Drug Targets - Inflammation & Allergy, 2004, 3, 19-33). Leukotriene inhibitors represent an advance over current anti-asthma products in terms of faster onset of action, oral formulation and favorable side effect profile.
The phosphodiesterases (PDEs) are responsible for the hydrolysis of intracellular cyclic adenosine and guanosine monophosphate (cAMP and cGMP, respectively). Type 4 phosphodiesterase (PDE4) is a cAMP-specific enzyme localized in airway smooth muscle cells as well as in immune and inflammatory cells. The PDE4 activity is associated with a wide variety of diseases some of which have been related to an inflammatory state, e.g. asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), while others have recently been connected to autoimmune pathology. Therefore, an intense effort towards the development of PDE4 inhibitors has been generated for the last decade (Giembycz, M. A. Drugs, 2000, 59, 193-212; Lipworth, B. Lancet, 2005, 365, 167-175). Unfortunately, the effects of prototype PDE4 inhibitors have been compromised by side effects such as nausea and emesis and the clinical use of those compounds is still limited.
Some compounds of the coumarm class are known to inhibit the immunological release of chemical mediators such as SRS-A (the slow reacting substance of anaphylaxis) and histamine from mast cells (US 4,731,375). Other compounds of the coumarm class are known to not only protect against the release of SRS-A and other mediators of the allergic response but to also inhibit the action of SRS-A (US 4,200,577). Still other compounds of the coumarin class are known to not only inhibit the release of mediator substances but to also antagonize the effects of histamine released after the antibody-antigen combinations (US 4,263,299). Similarly, others inhibit the effects of certain types of antigen-antibody reactions (US 4,059,704), have NMDA (N-methy-D-aspartate) antagonistic action (US 5,428,038), inhibit leukotriene biosynthesis (US 5,576,338), modulate the histamine-3 receptors (US 2002/0183309), and inhibit phosphodiesterase VII (US 2004/0138279). Therefore, the coumarin compounds described are useful in the prophylaxis and treatment of various diseases associated with allergic or immunological reactions such as allergic asthma, allergic dermatitis, allergic rhinitis or enteritis, allergic conjunctivitis or allergic eczema. There remains a need to develop compounds of the coumarin class for the treatment of inflammatory disorders with greater efficacy and potency while avoiding the side effects of current therapies.
Summary of the Invention
The present invention relates to bis-(coumarin) compounds with valuable properties, in particular pharmacological properties for treating inflammatory diseases and conditions such as asthma, and which can also be used to produce pharmaceuticals.
The present invention relates to bis-(coumarin) compounds of Formula I,
Figure imgf000006_0001
as well as the products of their intramolecular cyclization having Formulas II and III,
Figure imgf000006_0002
and pharmaceutically acceptable salts, solvates (including hydrates), clathrates, prodrugs and tautomers and stereoisomers thereof wherein:
R1, R2, R3 and R4, are each independently hydrogen, fluoro, chloro, bromo, C1-C4-alkyl, C2- C4-alkenyl, C2-C4-alkynyl, halo-CrQ-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1- C4-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, N,iV-di(CrC4-alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C1-C4-alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; A is carbonyl, CH-X or C=N-R5;
Each occurrence of n is, independently, an integer which is 0 or 1;
R-5 is an hydroxy, alkoxy, amino, alkylamino, aryl or arylamino group;
X is hydroxy, carboxy, acetyl, alkylcarbonyl, arylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, N-alkylcarbamoyl or -C(=N-R5)R6;
R6 is hydrogen or CH3;
D is CH, CH2, CCH3, CHCH3, CHCH2OH, or carbonyl; and
~ is a single or a double bond;
provided that i.) when A is carbonyl or C=N-R5 then n = 1; ii.) in compounds of Formula I, when n = O and X is aryl, heteroaryl, formyl, carboxy, acetyl, alkyloxycarbonyl,
CH2OH arylcarbonyl, N-alkylcarbamoyl, -CH2OH, or a — CH-OH group, then R1, R2, R3 and R4 are not all hydrogen; and
when n = O, R1=R2=R4=H5 and R3=OH or when n = O, R2=R4=H, and R1=R3=OH or when n = O, R1=R4=H, and R2=R3=OH or when n = O, R1=R2=H, and R3=R4=OH , then X is not a formyl or 2-formylphenyl; and
when n = O, R1=R2=R4=H, and R3=OH or when n = O, R2=R4=H, and R1=R3=OH, then X is not 4-carboxyphenyl group; and when n = O5 R1=R2=R4=H5 and R3=OH5 then X is not carboxy, phenyl, 4-styrylphenyl, 4-(N,N-dimethylamino)phenyl, 2- pyridinyl, 3- pyridinyl, 2-naphtalenyl; and
when n = 0, R1=R2=R3=H, and R4=Me then X is not phenyl, 3-bromophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,
2,4-dichloroρhenyl, 2-me1hoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4- nitrorophenyl, 4-hydroxy-3-methoxyphenyl, 4-(N,N-dimethylamino)phenyl5 4- methylthiophenyl;
when n = O5 R1=R3=R4=H5 and R2=Me then X is not phenyl, 2-chlorophenyl, 4-hidroxyphenyl, 2,4-dichlorophenyl, 3- methoxyphenyl, 4-methoxyphenyl 4-hydroxy-3-methoxyphenyl, 3-nitrorophenyl, 2- nitrorophenyl, 2-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-(N,N-dimethylamino)phenyl, 2-pyridinyl, 3- pyridinyl, 4-pyridinyl, 2-quinolinyl; and
when n = O5 R1=R3=R4=H5 and R2=F or when n = 0, R1=R2=R4=H, and R3=F then X is not carboxy, ethyloxycarbonyl,
when n = 0, R1=R2=R3=H5 and R4=Cl then X is not phenyl,
when n = 0, R1=R3=R4=H, and R2=Cl then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 3-nitrophenyl, 4-hydroxy-3- methoxyphenyl, 2-pyridinyl, 3- pyridinyl, 4-pyridinyl, 2-(6-methyl)pyridinyl, 2- quinolinyl,
when n = O5 Ri=R3=R4=H, and R2=Br then X is not phenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-methylphenyl, 4-hydroxy-3- methoxyphenyl, 4-hydroxy-3-ethoxyphenyl, 2-pyridinyl5 4-(N5N-dimethylamino)phenyl5 5-benzo[l,3]dioxolyl ; and when n = 0, R1=R2=R4=H5 and R3=Me or when n = O3 R2= R3=H and R1 =R4=Me, then X is not phenyl, 4-hydroxyphenyl, 4-nitrophenyl; and
when n = 0, R2= R4=H and R1 =R3=Me, then X is not phenyl; and
when n = 0, R1= R4=H and R2 =C1 and R3=Me, then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2-(6-methyl)pyridinyl, 3- pyridinyl, 4- pyridinyl, 2-quinolinyl; and
when n = 0, R1= R4=H and R2 = R3=Me, then X is not phenyl, 4-methoxyphenyl; and
when n = 0, R1= R3=H and R2= R4=Cl, then X is not phenyl
when n = 0, R1= R2=H and R3 = OH and R4=Me3 then X is not phenyl, 4-methoxyphenyl, 2-hydroxyphenyl, 3-hydoxyphenyl, 4-hydroxy-3- methoxyphenyl, 4-hydroxy-3-ethoxyphenyl, 5-benzo[l,3]dioxolyl; and
when n = 1 and X is carboxy, ethyloxycarbonyl then R15R2, R3 and R4 are not all hydrogen; and
when n = 1 and R1= R3= R4=H and R2 =Br, then X is not phenyl;
iii.) in compounds of Formula II,
CH2OH when X is aryl, heteroaryl, carboxy, acetyl, alkyloxycarbonyl, -CH2OH, or a — CH-OH group, then R1, R2, R3 and R4 are not all hydrogen; and when R1= R3= R4=H and R2 = Me, then X is not 3-(4-hydroxy-6-methyl-2-oxo-2H-l-benzopyranyl);
iv.) in compounds of Formula III, when D represents CH2, CHCH3, CHCH2OH, or carbonyl and -- represents a single bond, or when D represents CH or CCH3 group and ~ represents a double bond, then R1, R2, R3 and R4 are simultaneously not hydrogen atom; and
when R1=R2=R4=H and R3=OH, or when R2=R4=H and R1=R3=OH5 or when R1=R4=H and R2=R3=OH, or when R1=R2=H, R3=R4=OH, then D is not a CH or CH2 group.
Some compounds of Formulas I, II and III with unsubstituted benzene rings (R1=R2=R3=R4=H) are known in the literature (Fucik, K. et al. Nature 1950, 166, 830-831; Collect. Czech. Chem. Commun. 1951, 16, 304-318; ibid., 1951, 16, 319-326; Bull. Soc. CHm. Fr. 1949, 16, 99-103; ibid., 1949, 16, 609-610, ibid., 1949, 16, 626-628, by Eckstein, M. et al. Roczniki Chem. 1964, 38, 1115-1120; Acta Pol. Pharm. 1988, 45, 8-13, or by Sullivan, W. R. et. al. J. Am. Chem. Soc. 1943, 65, 2288-2291), several of which compounds are reported to have anticoagulant properties. Some compounds of Formulae I and III with unsubstituted benzene rings (R1=R2=R3=R4=H) and hydroxy substiruents on benzene rings (R1=R2=R4=H, R3=OH; R2=R4=H, R1=R3=OH; R1=R4=H, R2=R3=OH; R1=R2=H, R3=R4=OH) are also known from the patent literature (Ivezic, Z. et. al. WO 03/029237), and are reported to possess antiviral activity.
There are also known more complex dimeric and tetrameric derivatives of hydroxycoumarin asymmetrically bound by a central alkyl or aryl linker, which demonstrate anti-HrV action (Zhao, H. et al. J. Med. Chem. 1997, 40, 242-249). Similar anti-HIV action is also shown by several products of condensation of hydroxycoumarins possessing more than one hydroxy group per coumarin unit with aromatic or aliphatic mono- or dialdehydes (US patent 6,100,409 and WO 03/029237).
Bis-(coumarin) compounds with unsubstituted and variously substituted benzene rings which are represented by Formula I, compounds of Formula II with various R1, R2, R3, and R4 groups, and compounds of Formula III, wherein the benzene rings are substituted with various Ri and/or R2 and/or R3 and/or R4 groups sucli as alkyl and alkoxy groups and halogen atoms, as well as their pharmaceutically acceptable salts and pharmaceutical preparations including such compounds, have not hitherto been described. Likewise, the compounds of the present invention have not hitherto been described as substances with a strong antiinflammatory action or as effective agents in the treatment of asthma and other inflammatory diseases and conditions.
The applied in vitro and in vivo models quite successfully demonstrate pathophysiological occurrences present in asthma and it may be expected that the compounds tested in these models will also be effective in the therapy of human diseases.
Detailed Description of the Invention
Compounds of the Invention
One particular class of compounds of Formula I are those wherein n = 1 and A represents a carbonyl group.
hi some embodiments, the compounds of the present invetion are represented by the compounds of Formula I or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof,
wherein:
R1, R2, R3 and R4 is each independently hydrogen, fluoro, chloro, bromo , C1-C3- alkyl, hydroxy, or nitro;
A is carbonyl or CH-X,
Each occurrence of n is, independently, an integer which is 0 or 1; and X is carboxy, -C(O)O(C1-4alkyl), -CH(OH)CH2OH5 -CH2OH, C(O)OCH2CH2OH, C(O)NHdecyl, C(O)NH(CH2)3OH, C(O)NHC(CH3)2CH2OH, C(O)NHC(CH2OH)3, 1- hydroxyethyl, -C(=N)-0H, imidazolyl, phenyl, 2-methoxyphenyl, 4-quinolinyl, 2- quinolinyl, 2-nitroplienyl, 3-chlorophenyl, 2,4-dimethoxyphenyl, 4-(l-butyl)- imidazolyl, naphthyl, 2-hydroxy-4-nitrophenyl, 6-(2,3-dihydrobenzodioxanyl), 2-(4- chlorophenylthio)-phenyl, 2-pyridinyl, 3-bromo-4-fluorophenyl, 3-bromo-4- methoxyphenyl, 3-chloro-4-fluorophenyl, 3-ethoxyphenyl, 3-hydroxyphenyl, 3- phenoxyphenyl, 3-methoxy-4-benzyloxyphenyl, 4-thiomethylphenyl, 2-(4- bromothiophenyl), 4-chlorophenyl, 4-cyanophenyl, 4-isopropoxyphenyl, 4- methylphenyl, 4-phenoxyphenyl, 2-(5-methyl)-furanyl, 3,4,5-trimethoxyρhenyl, 4- fhiorophenyl, 4-pyridyl, 2-chlorophenyl, 1 -imidazolyl, 3,4-methylenedioxyphenyl, 4- methoxyphenyl, 3-quinolinyl, 2-quinolinyl, 4-hydroxyphenyl, 5-(2,3-dihydro)- benzofuranyl, 2-methoxyphenyl, 2-furanyl, 4-trifluoromethylphenyl, 2-[5-(3- trifluoromethylphenyl)]-furanyl, l-(5-hydroxymethyl)-furanyl; and
provided that i.) when A is carbonyl then n = 1 ; and ii.) when n = O and X is carboxy, -C(O)O(d-4alkyl), -CH(OH)CH2OH, -CH2OH, C(O)OCH2CH2OH, C(O)NHdecyl, C(O)NH(CH2)3OH, C(O)NHC(CH3)2CH2OH, C(O)NHC(CH2OH)3, imidazolyl, phenyl, 2-methoxyphenyl, 4-quinolinyl, 2- quinolinyl, 2-nitrophenyl, 3-chlorophenyl, 2,4-dimethoxyphenyl, 4-(l-butyl)- imidazolyl, naphthyl, 2-hydroxy-4-nitrophenyl, 6-(2,3-dihydrobenzodioxanyl), 2-(4- chloroρhenylthio)-phenyl, 2-pyridinyl, 3-bromo-4-fluorophenyl, 3-bromo-4- methoxyphenyl, 3-chloro-4-fluorophenyl, 3-ethoxyphenyl, 3-hydroxyphenyl, 3- phenoxyphenyl, 3-methoxy-4-benzyloxyphenyl, 4-thiomethylphenyl, 2-(4- bromothiophenyl), 4-chlorophenyl, 4-cyanophenyl, 4-isopropoxyphenyl, 4- methylphenyl, 4-phenoxyphenyl, 2-(5-methyl)-furanyl, 3,4,5-trimethoxyphenyl, 4- fluorophenyl, 4-pyridyl, 2-chlorophenyl, 1 -imidazolyl, 3,4-methylenedioxyphenyl, 4- methoxyphenyl, 3-quinolinyl, 2-quinolinyl, 4-hydroxyphenyl, 5-(2,3-dihydro)- benzofuranyl, 2-methoxyphenyl, 2-furanyl, 4-trifluoromethylphenyl, 2-[5-(3- trifluoromethylphenyl)]-furanyl, or l-(5-hydroxymethyl)-furanyl;, then R1, R2, R3 and R4 are not all hydrogen; and iii.) when n = 0, R1=R2=R4=H, and R3=OH, then X is not carboxy, phenyl, 2-pyridinyl, or 2-naphtalenyl; and
iv.) when n = 0, R1=R2=R3=H, and R4=Me then X is not phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methoxyphenyl, 4-methoxyphenyl, or 4-methylthiophenyl; and
v.) when n = 0, R1=R3=R4=H, and R2=Me then X is not phenyl, 2-chlorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2- methoxyphenyl, 3,4,5-trimethoxyphenyl, 2-pyridinyl, 4-pyridinyl, or 2-quinolinyl; and
vi.) when n = 0, R1=R3=R4=H, and R2=F or when n = 0, R1=R2=R4=H, and R3=F then X is not carboxy, or ethyloxycarbonyl; and
vii.) when n = 0, R1=R2=R3=H, and R4=Cl then X is not phenyl; and
viii.) when n = 0, R1=R3=R4=H, and R2=Cl then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2-pyridinyl, 4-pyridinyl, or 2-quinolinyl; and
ix.) when n = 0, R1=R3=R4=H, and R2=Br then X is not phenyl, 3-hydroxyphenyl, 4-methylphenyl, 2-pyridinyl, or 5- benzo[l,3]dioxolyl; and
x.) when n = 0, Ri=R2=R4=H, and R3=Me or when n = 0, R2= R3=H and R1 =R4=Me, then X is not phenyl, or 4-hydroxyphenyl; and
xi.) when n = 0, R2= R4=H and Ri =R3=Me, then X is not phenyl; and xii.) when n = 0, R1= R4=H and R2 =C1 and R3=Me, then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4- pyridinyl. or 2- quinolinyl; and
xiii.) when n = 0, R1= R4=H and R2 = R3=Me5 then X is not phenyl, or 4-methoxyphenyl; and
xiv.) when n = 0, R1= R3=H and R2= R4=Cl, then X is not phenyl; and
xv.) when n = 0, R1= R2=H and R3 = OH and R4=Me, then X is not phenyl, 4-methoxyphenyl, 3-hydoxyphenyl, or 5-benzo[l,3]dioxolyl; and
xvi.) when n = 1 and X is carboxy or ethyloxycarbonyl then R15R2, R3 and R4 are not all hydrogen; and
xvii.) when n = 1 and R1= R3= R4=H and R2 =Br, then X is not phenyl.
For the compounds of Formula I5 it is further provided that,
(i) when n = 0, R1=R3=R4=H, and R2=Br then X is not 4-hydroxyρhenyl or 3,4-methylenedioxyphenyl; and
(ii) when n = 0, R1=R2=R4=H, and R3=Cl then X is not phenyl.
A further particular class of compounds are those of Formula I wherein n = O5 X is carboxy, acetyl, alkylcarbonyl, arylcarbonyl, C1-Cg alkyl substituted with one to six hydroxy groups, alkyloxycarbonyl, N- alkylcarbamoyl, formyl, or -C(=N-R5)R6 and at least one of the R1, R2, R3 and R4 are each independently, chloro, bromo, C].-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-Q-Q-alkyl, C1-C4-alkoxy, trifluoromethoxy, Ci-C4-alkanoyl, amino, amino-Ci-C4- alkyl, N-(C1-C4-alkyl)amino, N,N-di(C1-C4-alkyl)amino, mercapto, Q-Gj-alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C1-C4-ElI-CyISuIfInO5 carboxy, Q-Q-alkoxycarbonyl, cyano, or nitro; most preferably R1, R2, R3 and R4 are each independently C1-C4-alkyl, chloro, bromo.
A still further particular class of compounds are those of Formula I wherein n = O, X is arylcarbonyl, C1-C6 alkyl substituted with one to six hydroxy groups, Ν-alkylcarbamoyl, or -C(=Ν-R5)R6 and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, C1-C4-alkyl, hydroxy, C2-C4-alkenyl, C2-C4-alkynyl, halo-Q-Q-alkyl, Q-Gj-alkoxy, trifluoromethoxy, C1-C4-BIlCaQOyI, amino, amino-Ci-C4-alkyl, jV-(C1-C4-alkyl)amino, N1N- di(C1-C4-alkyl)amino, mercapto, CrC4-alkylthio, sulfo, C1-C4-alkylsulfo, sulfino, C1-C4- alkylsulfϊno, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; most preferably R1, R2, R3 and R4 are each independently C1-C4-alkyl, fluoro, chloro, bromo or hydroxy.
Another particular class of compounds are those of Formula I wherein n = O, X is 2- IH- imidazolyl, 6-(2,3-dihydro)benzo[l,4]dioxinyl, 3-bromo-4-fluorophenyl, 3-bromo-4- methoxyphenyl, 3-ethoxyρhenyl, 3-phenoxyphenyl, 4-phenoxyphenyl, 4-benzyloxy-3- methoxyphenyl, 2-(4-bromo)thiophenyl, 4-isopropoxyphenyl, 3-quinolinyl, 4-quinolinyl, 5- (2,3-dihydro)benzofuranyl, 2-furanyl, 4-trifluoromethylphenyl, 2-[5-(3- trifluoromethylphenyl)]furanyl or 2-(5-hydroxymethyl)furanyl and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, Q-Q-alkyl, hydroxy, C2-C4- alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, Ci-C4-alkoxy, trifluoromethoxy, C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, N,JV"-di(C1-C4-alkyl)amino, mercapto, C1- C4-alkylthio, sulfo, Ci-Q-alkylsulfo, sulfino, C!-C4-alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; most preferably R1, R2, R3 and R4 are each independently Q-Gralkyl, fluoro, chloro or bromo.
Other representative compounds include:
(a) compounds of formula I, wherein n = 0, X is phenyl , R1= R2= R4= H and R3=Cl;
(b) compounds of formula I, wherein n = 0, X is phenyl R1= R2= R3= H and R^isopropyl; 006/001259
(c) compounds of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, 4- hydroxyphenyl, 3-chloroρhenyl, 4-chlorophenyl, 4-methylthiophenyl, 2-pyridinyl, 2- quinolinyl or 5-benzo[l,3]dioxolyl; R1= R4=H and R2= R3=Me;
(d) compounds of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, A- hydroxyphenyl, 4-chlorophenyl, 4-methylthiophenyl, 2-pyridinyl, 3-pyridinyl, 4- pyridinyl, 2-quinolinyl, 4-methoxyphenyl or 5-benzo[l,3]dioxolyl; R1= R3= H and R2= R4 =Me;
(e) compounds of formula I, wherein n = 0, X is 4-hydroxyphenyl, 4-methoxyphenyl, A- chlorophenyl, 4-methylthiophenyl, 2-quinolinyl, 3-pyridinyl or 4-pyridinyl; R1= R3= R4= H and R2=Et, F or Br;
(f) compounds of formula I, wherein n = 0, X is 4-methylphenyl, 2-ρyridinyl, 3- hydroxyphenyl or 5-benzo[l,3]dioxolyl; R1= R3= R4=H and R2=Et or F;
(g) compounds of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, 3- chlorophenyl, 4-chlorophenyl, 4-methylthiophenyl or 5-benzo[l,3]dioxolyl; R1= R3= R4= H aUd R2=Cl;
(h) compounds of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, A- chlorophenyl, 4-methylthiophenyl, 2-pyridinyl, 4-pyridinyl, 2-quinolinyl or 5- benzo[l,3]dioxolyl; R1= R2= R4=H and R3=Me; (i) compounds of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, 3- chlorophenyl, 4-chlorophenyl, 4-methylthiophenyl, 2-pyridinyl or 5- benzo[l,3]dioxolyl; R1= R4=H; R2=Cl and R3=Me; (j) compounds of formula I, wherein n = 0, X is 5-benzo[l,3]dioxolyl; R1= R3= R4= H and R2=Me
(k) compounds of formula I3 wherein n = 0, X is carboxy; R1=Me; R2= R4=H and R3=OH (1) compounds of formula I, wherein n = 0, X is acetyl; R1= R3=OH and R2= R4=H
A further particular class of compounds are those of Formula II wherein X is carboxy, acetyl, alkylcarbonyl, arylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, alkyloxycarbonyl, N-alkylcarbamoyl or -C(=N-R5)R6 and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, Ci-C4-alkyl, hydroxy, C2-C4-alkenyl, C2-C4-alkynyl, halo-Ci-C-4-alkyl, C1-C4-alkoxy, trifiuoromethoxy, Ci-C-t-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, Λr,Λr-di(C1-C4-alkyl)amino, mercapto, Ci-C4- alkylthio, sulfo, Ci-Q-alkylsulfo, sulfino, C1-C4-alkylsulfϊno, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; most preferably R1, R2, R3 and R4 are each independently C1-C4^IlCyI, fluoro, chloro or bromo.
A further particular class of compounds are those of Formula II wherein X is carboxy, acetyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups and at least one of the R1, R2, R3 and R4 are each independently, C1-C4-alkyl, fluoro, chloro or bromo.
A further particular class of compounds are those of Formula III wherein D is CHCH3, CHCH2OH or carbonyl and — is a single bond; or D is CCH3 and ~ is a double bond; and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, C1- C4-alkyl, hydroxy, C2-C4-alkenyl, C2-C4-alkynyl, halo-Ci-Q-alkyl, C1-C4-alkoxy, trifluoromethoxy, Ci-C4-alkanoyL amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, NN- di(C1-C4-alkyl)amino, mercapto, Q-Q-alkylthio, sulfo, C1-C4-alkylsulfo, sulfino, C1-C4- alkylsulfmo, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; most preferably R1, R2, R3 and R4 are each independently C1-C4-alkyl, fluoro, chloro or bromo or hydroxy.
A further particular class of compounds are those of Formula III wherein D is CH or CH2; and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, C1- C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, C1-C4-alkoxy, trifluoromethoxy, CrGφ-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, NN^i(C1-C4- alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, CrC4-alkylsulfo, sulfino, C1-C4-alkylsulfϊno, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; most preferably R1, R2, R3 and R4 are each independently C1-C4-alkyl, fluoro, chloro or bromo.
In the context of the present invention the general terms used above have the following meanings:
The term "halogen" relates to a halogen atom, which may be: fluorine, chlorine, bromine or iodine.
The term "alkyl" relates to alkyl groups derived from alkanes, which may be straight, branched or cyclic or a combination of straight and cyclic chains or of branched and cyclic chains. The preferred straight or branched alkyls are e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-bvAyl. Methyl is most preferred. The preferred cyclic alkyls are e.g. cyclopentyl or cyclohexyl. Alkyl groups may be substituted with one up to five substituents including halogen (preferably fluorine or chlorine), hydroxy, alkoxy (preferably methoxy or ethoxy), acyl, acylamino cyano, amino, N-(Ci-C4)alkylamino (preferably N-methylamino or N-ethylamino), N,N-di(C1-C4-alkyl)amino (preferably dimethylamino or diethylamino), aryl (preferably phenyl) or heteroaryl, thiocarbonylamino, acyloxy, amino, amidino, alkyl amidino, thioamidino, aminoacyl, aminocarbonylarnino, aminothiocarbonylamino, aminocarbonyloxy, aryl, heteroaryl, aryloxy, aryloxyaryl, nitro, carboxyl, carboxylalkyl, carboxyl-substituted alkyl, carboxyl-cycloalkyl, carboxyl-substituted cycloalkyl, carboxylaryl, carboxyl-substituted aryl, carboxylheteroaryl, carboxyl-substituted heteroaryl, carboxylheterocyclic, carboxyl-substituted heterocyclic, cycloalkyl, cycloalkoxy, heteroaryloxy, heterocyclyloxy, and oxycarbonylamino. Such substituted alkyl groups are within the present definition of "alkyl."
The term "C1-C4-alkyl" represents an alkyl group with 1 to 4 carbon atoms. Similarly, the term "Q-Cr-alkyl" represents an alkyl group with 1 to 7 carbon atoms. Similar terminology is used herein to represent the number of carbon atoms within a specified group. The present definition of alkyl carries over to other groups having an alkyl moiety such as alkoxy.
"Alkenyl" means a linear or branched monovalent hydrocarbon radical of two to ten, preferably two to six, carbon atoms which has at least one carbon-carbon double bond. Alkenyl groups may be substituted with the same groups as alkyl and such optionally substituted alkenyl groups are encompassed within the term "alkenyl." Ethenyl, propenyl, butenyl and cyclohexenyl are preferred.
"Alkynyl" means a linear or branched monovalent hydrocarbon radical, having a straight-chain or a branched-chain of two to ten, preferably two to six, carbon atoms and containing at least one and preferably no more than three carbon-carbon triple bonds. Alkynyl groups can be substituted with the same groups as alkyl, and the substituted groups are within the present definition of alkynyl. Ethynyl, propynyl and butynyl groups are preferred.
"Cycloalkyl" means a cyclic group having 3-8 carbon atoms having a single ring optionally fused to an aryl or heteroaryl group. The cycloalkyl groups can be substituted as specified for "aryl" below, and the substituted cycloalkyl groups are within the present definition of "cycloalkyl". Preferred cycloalkyls are cyclopentyl and cyclohexyl. "Aryl" means an unsaturated aromatic carbocyclic group having 6-14 carbon atoms having a single ring such as phenyl or multiple fused rings such as naphthyl. Aryl may optionally be further rased to an aliphatic or aryl group or can be substituted with one or more substituents such as halogen (fluorine, chlorine and/or bromine), hydroxy, Ci-C7 alkyl, Ci-C7 alkoxy or aryloxy, Ci-C7 alkylthio or arylthio, alkylsulfonyl, cyano or primary or nonprimary amino.
"Heteroaryl" means a monocyclic or a bicyclic aromatic hydrocarbon ring having from 2 to 10 carbon atoms and from 1 to 4 heteroatoms, such as O, S or N. The heteroaryl ring may optionally be fused to another heteroaryl, aryl or aliphatic cyclic group. Examples of this type are furan, thiophene, pyrrole, imidazole, indole, pyridine, oxazole, thiazole, pyrrole, pyrazole, tetrazole, pyrimidine, pyrazine and triazine, with furan, pyrrole, pyridine and indole being preferred. The term includes groups that are substituted with the same substituents as specified for aryl above.
"Heterocyclic" means a saturated or unsaturated group having a single or multiple rings and from 1 to 10 carbon atoms and from 1-4 heteroatoms selected from nitrogen, sulphur or oxygen, wherein in a fused ring system the other ring or rings can be aryl or heteroaryl. Heterocyclic groups can be substituted as specified for alkyl groups and the thus substituted heterocyclic groups are within the present definition.
The term "alkoxy" relates to straight or branched chains containing an alkoxy group. Examples of such groups are methoxy, propoxy, proρ-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy.
The term "alkanoyl" group relates to straight chains containing an acyl group such as formyl, acetyl or propanoyl.
The term "aroyl" group relates to aromatic acyl groups such as benzoyl.
Compounds of Formulae I and III possess at least one acidic hydroxy group on a coumarin nucleus, as well as the compounds of formula II wherein X denotes a carboxy group. Thus, these compounds may form corresponding salts with pharmaceutically acceptable bases. The present invention encompasses such salts. Examples of salts formed on a hydroxy substituent are e.g. aluminum salts, corresponding salts of alkali metals such as sodium or potassium, salts of alkaline earth metals such as calcium or magnesium, pharmaceutically acceptable salts of transient metals such as zinc and copper, salts with ammonia or salts with lower organic amines such as cyclic amines, mono-, di- or W
trisubstituted lower alkylamines, lower hydroxyalkylamines such as lower mono-, di- or trihydroxyalkylamines, lower (hydroxyalkyl)alkylamines or lower polyhydroxyalkylainines and salts with amino acids, e.g., methylglutamine, alanine or serine. Suitable pharmaceutically acceptable cyclic amines include, e.g., morpholine, thiomorpholine, piperidine or pyrrolidine. Suitable lower monoalkylamines include, e.g., ethylamine and tert- butylamine, suitable dialkylamines include, e.g., diethylamine and diisopropylamine and suitable lower trialkylamines include, e.g., trimethylamine and triethylamine. Corresponding lower hydroxyalkylamines include, e.g., mono-, di- or triethanolamine; lower (hydroxyalkyl)alkylamines include, e.g., ΛζiV-dimethylaminoethanol and N,N- diethylaminoethanol. Suitable amino acids include, e.g., lysine, arginine, methylglutamine, alanine or serine.
Any substituent having basic properties, e.g, including an amino or alkylamino group, may also form pharmaceutically suitable salts with inorganic acids (e.g. hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric or sulfuric acid) or organic acids (e.g. tartaric, acetic, methane-sulfonic, trifluoroacetic, citric, maleic, lactic, fumaric, benzoic, succinic, methanesulfonic, oxalic and p-toluenesulfonic acids). These salts may be prepared in situ during the final isolation and purification of the compounds of the present invention or separately in a reaction with a suitable inorganic or organic base in a manner known to one skilled in the art, for example in a suitable solvent or solvent mixture, e.g., in ethers (diethylether) or alcohols (ethanol, n-propanol, 2-propanol or fert-butanol), or by mixing equivalent amounts of corresponding reactants and the subsequent lyophilization and purification of the reaction mixture.
The prefix "lower" designates a radical having up to and including seven and, preferably, up to and including four carbon atoms. Lower alkyl is, for example, ^-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl or n-heptyl, preferably ethyl or methyl.
In view of the close connection between free forms and salt forms of the compounds of the present invention it should be understood that in the present invention the free forms of the compounds of the present invention and their pharmaceutically acceptable salts are identical forms and in the corresponding context it is suitable to consider the free forms of the compounds of the present invention and their corresponding pharmaceutically acceptable salts as synonymous. The present invention also encompasses prodrugs of compounds of Formulae I, II and III, i.e. compounds which release an active drug according to Formulae I, II or III in vivo when administered to a mammalian subject. Prodrugs of a compound of Formulae I, II and III are prepared by modifying functional groups present in the compound of Formulae I, II and III in such a way that the modifications may be cleaved in vivo to release the parent compound. Prodrugs include compounds of Formulae I, II and III wherein a hydroxy, amino, or carboxy group of a compound of Formulae I, II and III is bonded to any group that may be cleaved in vivo to regenerate the free hydroxy, amino or carboxy group, respectively. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives) of compounds of Formulae I, II and III or any other derivative which upon being brought to the physiological pH or through enzyme action is converted to the active parent drug.
The present invention also relates to solvates (preferably hydrates) that can be formed by the compounds of Formulae I, II and HI or their salts. The present invention also relates to clathrates that can be formed by the compounds of Formulae I, II and III or their salts.
The compounds represented by Formulae I, II and III, and their salts may exist in more than one physical form (e.g. in different crystal forms) and the present invention relates to all physical forms (e.g. to all crystal forms) of the compounds represented by Formulae I, II and III, and to their mixtures.
The compounds of Formulae I, II and III may exist in numerous forms of structural isomers that may be formed as a result of tautomerism, and may exist in different ratios at equilibrium. Due to dynamic equilibrium such isomers (tautomers) are rapidly interconvertible from one isomeric form to another. The most common isomerism is keto- enol tautomerism, but equilibrium between open chain and cyclic forms is also known. It is to be understood that whenever in the present invention reference is made to the compounds of Formulae I, II and III it is intended to include tautomeric forms thereof, keto-enol tautomeric, open chain-cyclic, isolated as separate isomers or existing in any other mixture of different ratios at equilibrium. The isomeric forms predominant for a particular compound of Formulae I, II and III are dependent on the nature of the substituent, whether the compound exists in the free form or in the form of any of its salts, type of the salt, solvent in which the compound is dissolved, as well as pH value of the solution. Compounds of the present invention may further exist as different geometric isomers or as different stereoisomers. Isomers that differ only with regard to the arrangement of the atoms in the space around the asymmetric (stereogenic, chiral) center are called "stereoisomers". Stereoisomers that are not mirror images of each other are called diastereomers, while stereoisomers that have a mirror-image relationship, i.e. that are mirror images of each other are called enantiomers. Each stereoisomer may be characterized by determining the absolute configuration of the stereogenic center by the use of Cahn-Ingold- Prelog priority rules and hence characterized as R- or ^-isomer. Another way of identification of stereoisomers is the measurement of the rotation of the plane of polarized light that passes through the molecule, and designating chiral molecules to be right-rotating (+) or left-rotating (-) isomers. Chiral molecules may exist in a form of single enantiomer or in a mixture of enantiomers. A mixture consisting of equal parts (+) and (-) enantiomers of a chiral substance is called a racemic mixture. The present invention relates to each stereoisomer that may be shown by Formulae I, II and III either isolated as separate enantiomers, diastereomers or existing in racemic or any other mixture thereof. Methods for determination of stereochemical configuration, resolution and separation of stereoisomers are well known in the literature. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereomeric salts which may be separated, for example, by crystallization; formation of diastereomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. The diastereomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above.
The present invention also encompasses stereoisomers of the syn-anti type, and mixtures thereof encountered when an oxime or similar group is present. The group of highest Cahn- Ingold-Prelog priority attached to one of the terminal doubly bonded atoms of the oxime, is compared with the hydroxy group of the oxime. The stereoisomer is designated as Z {zusammen = together) or Syn if the oxime hydroxyl lies on the same side of a reference plane passing through the C=N double bond as the group of highest priority; the other stereoisomer is designated as E (entgegen = opposite) oxAnti. A further aspect of the present invention involves to the processes for the preparation of the compounds of Formulae I, II and III, and salts thereof and/or, optionally, converting the resulting free compounds represented by Formulae I, II and IH, having salt-forming properties into corresponding salts, and/or, optionally, converting the resulting salts into free compounds or into other salts.
The present invention also relates to reactive intermediates obtained during the preparation of the compounds of the present invention and of their pharmaceutically acceptable salts. Such intermediates can be isolated and defined or used without isolation in the next step of chemical synthesis.
It will be appreciated by those skilled in the art that it may be desirable to use protected derivatives of intermediates used in the preparation of the compounds of Formulae I, II and III. Protection and deprotection of functional groups maybe performed by methods known in the art. Hydroxy or amino groups may be protected with any hydroxy or amino protecting group, for example, as described in Green, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis: John Wiley and Sons, New York, 1999. Selection of protective groups, processes for their addition and removal are common and well known to those skilled in the art. The amino protecting groups may be removed by conventional techniques. For example, acyl groups, such as alkanoyl, alkoxycarbonyl and aroyl groups, may be removed by solvolysis, e.g., by hydrolysis under acidic or basic conditions. Arylmethoxycarbonyl groups (e.g., benzyloxycarbonyl) may be cleaved by hydrogenolysis in the presence of a catalyst such as palladium-on-charcoal.
Synthetic Procedures:
Compounds within Formulae I, II and III can be prepared by following the methods described herein.
Compounds of Formula I wherein A represents a CH-X group, wherein X represents
CH2OH carboxy, acetyl, alkylcarbonyl, -CH2OH, or an — CH-OH group and n = O, as well as compounds of Formula I wherein A represents a carbonyl group and n = 1, may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of Formula IV:
Figure imgf000024_0001
(IV) with a corresponding aliphatic aldehyde such as glyoxylic acid, pyruvic aldehyde, glycolaldehyde or glyceraldehyde. Preferably the reaction is carried out in an aqueous medium such as water or aqueous buffer, or aqueous-organic medium inert to the utilized chemical reagents. Suitable organic solvents include, but are not limited to. tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone, methanol, ethanol, 2- propanol and tert-butaxiol. Preferable organic solvents include, but are not limited to, acetonitrile, methanol, ethanol and 2-ρropanol. When buffered aqueous or aqueous-organic medium is used, reaction may be performed in a pH range from 2 to 12, preferably in a pH range from 6 to 9. Commercially available aqueous aldehyde solution may be employed in the reaction, which may be used in substantial excess in respect to hydroxycoumarin, preferably in the ratio 2:1. Reaction may be carried out at a temperature in the range of 0 0C to the boiling point of the solvent employed.
Compounds of Formula I wherein A represents a CH-X group, wherein X represents arylcarbonyl group and n = 0, may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of Formula IV:
Figure imgf000024_0002
with an aldehyde prepared in situ by oxidation of corresponding α-acyl halide in the presence of DMSO at a temperature in the range of 0 0C to 120 0C, preferably at 80 0C (See, e.g., Trkovnik, M. et al. Actα Phαrm. Jugosl. 1982, 32, 21-27).
Compounds of Formula I wherein A represents a CH-X group, wherein X denotes CH2OH and n = 0, may optionally be prepared from corresponding intramolecular hemiacetals of Formula III wherein D represents CHOH and ~ denotes a single bond (See, e.g., WO 2005/010006) or aldehydes of Formula I wherein A represents a CH-X group, wherein X denotes a formyl group and n = 0 (See, e.g., WO 03/029237). Compounds mentioned in this section can be prepared using standard reducing reagents known to those skilled in the art, for example complex metal hydrides such as sodium cyanoborohydride.
Compounds of Formula I wherein A represents a CH-X group, wherein X represents a
CH3 — CH-OH group and n = 0, may optionally be prepared from corresponding ketones of
Formula I wherein A represents CH-X, wherein X represents an acetyl group and n = 0. Compounds mentioned in this section can be prepared using ' standard reducing reagents known to those skilled in the art, for example complex metal hydrides such as sodium cyanoborohydride.
Compounds of Formula I wherein A represents a CH-X group, wherein X denotes OH and n = 1, may optionally be prepared from corresponding ketones of Formula I wherein A represents a carbonyl group and n = 1. Compounds mentioned in this section can be prepared using standard reducing reagents known to those skilled in the art, for example complex metal hydrides such as sodium cyanoborohydride.
Compounds of Formula I wherein A represents CH2 and n = 1, may be prepared by a process which comprises the reduction of the compound of Formula I wherein A represents a carbonyl group and n = 1, by procedures known to those skilled in the art, for example by catalytic hydrogenation.
Compounds of Formula I wherein A represents a CH-X group, wherein X represents an alkyloxycarbonyl group and n = 0, may be prepared by a process which comprises condensation of the appropriate carboxylic acid or lactone with corresponding alcohol with or without the presence of dehydrating agent or acidic catalyst such as sulfuric acid (See, e.g., Fucik, K. et al. Bull. Soc. Chim. Fr. 1949, 16, 99-103; ibid., 1949, 16, 609-610).
Compounds of Formula I wherein A represents a CH-X group, wherein X denotes an N-alkylcarbamoyl group and n = 0, may be prepared by a process which comprises condensation of the appropriate carboxylic acid or lactone with corresponding primary amine using standard amide coupling procedures well known to those skilled in the art (See, e.g., Romo, D. et al. J Am. Chem. Soc. 1998, 120, 12237-12254). Compounds of Formula I wherein A represents a CH-X group, wherein X represents a -C(=N-R.5)R6 group, n = 0, may be prepared by a process which comprises condensation of the corresponding intramolecular hemiacetal of Formula III wherein D represents CHOH and ~ denotes a single bond {See, e.g., WO 2005/010006), or aldehyde of Formula I wherein A represents a CH-X group, wherein X denotes a formyl group and n = 0 (See, e.g., WO 03/029237), or ketone of Formula I wherein A represents a CH-X group, wherein X denotes an acetyl or alkylcarbonyl group and n = 0, respectively, with hydroxylamine, O- alkylhydroxylarnine (e.g. O-methylhydroxylamine), hydrazine, alkylhydrazine (e.g. methylhydrazine), aryl amine (e.g. aniline), and arylhydrazine (e.g. phenylhydrazine), respectively, using standard procedures for the preparation of oximes, imines, and hydrazones well known to those skilled in the art (See, e.g., Hadjipavlou-Litina, D. J. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 611-614).
Compounds of Formula I wherein A represents a C=N-R5 group, n = 1, may be prepared by a process which comprises condensation of the corresponding ketone of Formula I wherein A represents a carbonyl group and n = 1, with hydroxylamine, O- alkylhydroxylamine (e.g. O-methylhydroxylamine), hydrazine, alkylhydrazine (e.g. methylhydrazine), aryl amine (e.g. aniline), and arylhydrazine (e.g. phenylhydrazine), respectively, using standard procedures for the preparation of oximes, imines, and hydrazones well known to those skilled in the art (See, e.g., Hadjipavlou-Litina, D. J. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 611-614).
Compounds of Formula I wherein A represents a CH-X group, wherein X is aryl or heteroaryl and n=0 may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin with aryl or heteroaryl aldehyde using procedures known to those skilled in the art (See, e.g., Zhao, H. et al. J. Med. Chem. 1997, 40, 242-249; Sullivan, W. R. et. al. J. Am. Chem. Soc. 1943, 65, 2288-2291).
Compounds of Formula II may be prepared from the corresponding compounds of Formula I wherein n = 0, by the process of intarmolecular removal of water in which pyran ring is formed using various dehydrating agents such as thionyl chloride, acetic anhydride, acetic anhydride-acetic acid or acetic anhydride-pyridine mixtures (See, e.g., Huebner, C. F. et al. J. Am. Chem. Soc. 1943, 65, 2292-2296; Fucik, K. et al. Collect. Czech: Chem. Commun. 1951, 16, 304-318; ibid., 319-326), following the usual procedures for protection of sensitive functional groups where appropriate. The reaction may be carried out at a temperature in the range of about 0 0C to the boiling point of the employed solvent. In some cases it would be desirable to remove one or more acetyl groups after dehydration process by procedures well known to those skilled in the art, for example by acidic or alkaline hydrolysis.
Compounds of Formula II wherein X represents a formyl group, may optionally be prepared from corresponding intramolecular hemiacetals of Formula III wherein D represents CHOH and — denotes a single bond (See, e.g., WO 2005/010006), by the process described in the immediately preceding section.
CH3 Compounds of Formula II wherein X represents a — CH-OH group, may be prepared from corresponding ketones of Formula II wherein X represents an acetyl group. Compounds mentioned in this section can be prepared using standard reducing reagents known to those skilled in the art, for example complex metal hydrides such as sodium cyanoborohydride.
Compounds of Formula III wherein D represents carbonyl group may be prepared from the compounds of Formula I wherein A represents CH-X, wherein X is a carboxy group and n = 0, by a process which comprises a formation of lactone ring by procedures known to those skilled in the art (See, e.g., Fucik, K. et al. Bull. Soc. CHm. Fr. 1949, 16, 609-610). Preferably the reaction is carried out in a dehydrating agent, for example thionyl chloride, alkyl monocarboxylic acid such as acetic acid, acetic anhydride-acetic acid or thionyl chloride-acetic acid mixtures. Reactions may be carried out at a temperature in the range of about 0 0C to the about boiling point of the employed solvent.
Compounds of Formula III wherein D represents CCH3 and ~ represents a double bond may be prepared from the compounds of Formula I wherein A represents a CH-X group, wherein X is a carboxy group and n = 0, by a process which comprises a formation of a furan ring (See, e.g., Fucik, K. et al. Collect. Czech. Chem. Commun. 1951, 16, 296-303; ibid., 304- 318). Preferably the reaction is carried out in acetic anhydride or in acetic acid in the presence of dehydrating agent such as sulfuric acid. In some cases it would be desirable to remove one or more acetyl groups after dehydration process by procedures well known to those skilled in the art, for example by acidic or alkaline hydrolysis. Alternatively, the above- mentioned compounds may be prepared from the compounds of Formula I wherein A represents CH-X, wherein X is an acetyl group and n = 0, in a dehydrating agent, for example thionyl chloride {See, e.g., Fucik, K. et al. Collect. Czech. Chem. Commun. 1951, 16, 319- 326) or trifluoroacetic acid.
Compounds of Formula III wherein D represents a CH2 group and ~ represents a single bond may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of formula IV with 2-chloroacetaldehyde, its acetal, glycolaldehyde or its acetal (Fucik, K. et al. Bull. Soc. Chim. Fr. 1949, 16, 626-628). Preferably the reaction is carried out in water, alkyl monocarboxylic acid such as acetic acid or trifluoroacetic acid or mixtures thereof followed by usual purification procedures well known to those skilled in the art, for example recrystallization or trituration. Alternatively, the above-mentioned compounds may be prepared from the compounds of Formula I wherein A represents CH-X group, wherein X is -CH2OH group, n = O, in a dehydrating agent such as trifluoroacetic acid.
Compounds of Formula III wherein D represents a CH group and - represents a double bond may be prepared by a process which comprises aromatization of the corresponding compound of formula III wherein D represents CH2 group and ~ represents a single bond, and which is the object of the present invention. The aromatization process may be performed by halogenation, most preferably bromination with reagent such as N- bromosuccinimide, in the presence of a radical source such as benzoyl peroxide (Furniss, B. S. et al., Eds., Vogel's Textbook of Practical Organic Chemistry: Longman, London, 1989), followed by in situ dehydrohalogenation. Preferably the reaction is carried out in an organic solvent inert to utilized chemical reagents such as tetrachloromethane. Reaction may be carried out at a temperature in the range of 0 0C to the boiling point, preferably at the boiling point of the employed solvent.
Compounds of Formula III wherein D represents CHCH2OH and — represents a single bond may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of formula IV with glyceraldehyde {See, e.g., Eckstein, M. et al. Roczniki Chem. 1964, 38, 1115-1120). Preferably the reaction is carried out in water, alkyl monocarboxylic acid such as acetic acid or trifluoroacetic acid or mixtures thereof followed by usual purification procedures well known to those skilled in the art, for example recrystallization or trituration. Alternatively, the above-mentioned compounds may be prepared from the compounds of Formula I wherein A represents a CH-X group, wherein X
CH2OH is a — CH-OH group, in an alkyl monocarboxylic acid such as acetic acid. Reaction may be carried out at a temperature in the range of O 0C to the boiling point of the employed solvent. In some cases it would be desirable to remove one or more acetyl groups after dehydration process by procedures well known to those skilled in the art, for example by hydrolysis, most preferably by addition of water without isolation of intermediates.
Compounds of Formula IH wherein D represents CHCH3 and — represents a single bond may be prepared by a process which comprises condensation of the appropriate hydroxycoumarin of formula IV with acrolein or 2-bromo-proρionaldehyde (See, e.g., Eckstein, M. et al. Acta Pol. Pharm. 1988, 45, 8-13). Preferably the reaction is carried out in ethanol followed by usual purification procedures well known to those skilled in the art, for example recrystallization or trituration. Reaction may be carried out preferably at the boiling point of the employed solvent. Alternatively, the above-mentioned compounds may be prepared from the compounds of Formula I wherein A represents CH-X group, wherein X is
CH3 — CH-OH group, n = O, in a dehydrating agent such as trifluoroacetic acid.
Some reagents used in the synthesis of compounds of the present invention are commercial products or they are products previously synthesized and described, while others are obtained according to the processes described for analogous compounds. Thus, for example, hydroxycoumarin compounds of Formula IV may be prepared from the corresponding enamines of Formula V:
Figure imgf000029_0001
in a manner understandable per se to the one skilled in preparative organic chemistry or known from the literature, e.g. by hydrolysis in a strong acidic medium such as 50% aqueous solution of sulfuric (See, e.g., Desai, N. J. et al. J. Org. Chem. 1957, 22, 388-390) or 25% aqueous solution of hydrochloric acid (See, e.g., Sonn, A. Ber. 1917, 50, 1292-1305). Enamines of Formula V may be prepared in a manner well described in the literature, e.g. by condensation of commercially available phenols with either cyanoacetic acid (See, e.g., Sonn, A. Ber. 1917, 50, 1292-1305) or with its alley! esters such as ethyl cyanoacetate (See, e.g., Desai, N. J. et al., J. Org. Chem. 1957, 22, 388-390).
Other methods for the preparation of different derivatives of hydroxycoumarin have previously been described in much detail, such as a direct method of the action of malonic acid on substituted phenols (See, e.g., Buckle, D. et al., J. Med. Chem. 1975, 18, 391-394) or more indirect methods starting from substituted o-hydroxyacetophenones (See, e.g., Boyd, J. et al., J. Chem. Soc. 1948, 174-176; Hermodson, M. et al., J. Med. Chem. 1971, 14, 167-169) or hydroxybenzoic acids (Appendino, G. et al., J. Nat. Prod. 1999, 62, 1627-1631; EP 0694257 Al).
Methods of Use
The present invention relates to the use of the compounds of Formulae I, II and III, and their pharmaceutically acceptable salts, solvates (including hydrates), clathrates, tautomers and stereoisomers in the treatment and prophylaxis of diseases, states, disorders and/or conditions which may occur as a result of disturbance of the immunological system, particularly inflammatory diseases, states, disorders and conditions, especially asthma in mammals (especially humans), in therapeutically effective amounts.
The present invention further relates to the use of the compounds of Formula VI,
Figure imgf000030_0001
as well as the products of their intramolecular cyclization having Formulas VII and VIII,
Figure imgf000030_0002
Figure imgf000031_0001
wherein:
R1, R2, R3 and R4, are each independently hydrogen, halogen,
Figure imgf000031_0002
C2-C4-alkenyl, C2- C4-alkynyl, halo-Ci-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, Ci-C4-alkanoyl, amino, amino-Ci-Q-alkyl, ^-(CrQ-alky^amino, iV,N-di(C1-C4-alkyl)amino, mercapto, C1- C4-alkylthio, sulfo, Ci-C4-alkylsulfo, sulfino, C1-C4-alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro;
A is carbonyl, CH-X or C=N-R5;
Each occurrence of n is, independently, an integer which is O or 1;
R5 is an hydroxy, alkoxy, amino, alkylamino, aryl or arylamino group;
X is hydrogen, hydroxy, carboxy, acetyl, alkylcarbonyl, arylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, N- alkylcarbamoyl, or -C(=N-R5)R6;
R6 is hydrogen or CH3;
D is CH, CH2, CCH3, CHCH3, CHCH2OH, or carbonyl; and
— is a single or a double bond; and their pharmaceutically acceptable salts, solvates (including hydrates), clathrates, tautomers and stereoisomers in the treatment and prophylaxis of diseases, states, disorders and/or conditions which may occur as a result of disturbance of the immunological system, particularly inflammatory diseases, states, disorders and conditions, especially asthma in mammals (especially humans), in therapeutically effective amounts A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, state, disorder or condition, is sufficient to effect such treatment. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the mammal to be treated.
"Treating" or "treatment" of a disease, state, disorder or condition includes:
(1) preventing or delaying the appearance of clinical symptoms of the disease, state, disorder or condition developing in a mammal that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition,
(2) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof, or
(3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
The benefit to a subject to be treated is either statistically significant or at least perceptible to the patient or to the physician.
The four classic symptoms of acute inflammation are redness, elevated temperature, swelling and pain in the affected area, and loss of function of the affected organ. Symptoms and signs of inflammation associated with specific conditions include: rheumatoid arthritis- pain, swelling, warmth and tenderness of the involved joints; generalized and morning stiffness; insulin-dependent diabetes mellitus- insulitis; this condition can lead to a variety of complications with an inflammatory component, including: retinopathy, neuropathy, nephropathy; coronary artery disease, peripheral vascular disease, and cerebrovascular disease; autoimmune thyroiditis- weakness, constipation, shortness of breath, puffiness of the face, hands and feet, peripheral edema, bradycardia; multiple sclerosis- spasticity, blurry vision, vertigo, limb weakness, paresthesias; uveoretinitis- decreased night vision, loss of peripheral vision; lupus erythematosus- joint pain, rash, photosensitivity, fever, muscle pain, puffmess of the hands and feet, abnormal urinalysis (hematuria, cylinduria, proteinuria), glomerulonephritis, cognitive dysfunction, vessel thrombosis, pericarditis; scleroderma- Raynaud's disease; swelling of the hands, arms, legs and face; skin thickening; pain, swelling and stiffness of the fingers and knees, gastrointestinal dysfunction, restrictive lung disease; pericarditis,; renal failure; other arthritic conditions having an inflammatory component such as rheumatoid spondylitis, osteoarthritis, septic arthritis and polyarthritis- fever, pain, swelling, tenderness; other inflammatory brain disorders, such as meningitis, Alzheimer's disease, AIDS dementia encephalitis- photophobia, cognitive dysfunction, memory loss; other inflammatory eye inflammations, such as retinitis- decreased visual acuity; inflammatory skin disorders, such as , eczema, other dermatites (e.g., atopic, contact), psoriasis, burns induced by UV radiation (sun rays and similar UV sources)- erythema, pain, scaling, swelling, tenderness; inflammatory bowel disease, such as Crohn's disease, ulcerative colitis- pain, diarrhea, constipation, rectal bleeding, fever, arthritis; asthma- shortness of breath, wheezing; other allergy disorders, such as allergic rhinitis- sneezing, itching, runny nose conditions associated with acute trauma such as cerebral injury following stroke- sensory loss, motor loss, cognitive loss; heart tissue injury due to myocardial ischemia- pain, shortness of breath; lung injury such as that which occurs in adult respiratory distress syndrome- shortness of breath, hyperventilation, decreased oxygenation, pulmonary infiltrates; inflammation accompanying infection, such as sepsis, septic shock, toxic shock syndrome- fever, respiratory failure, tachycardia, hypotension, leukocytosis; other inflammatory conditions associated with particular organs or tissues, such as nephritis (e.g., glomerulonephritis)-oliguria, abnormal urinalysis; inflamed appendix- fever, pain, tenderness, leukocytosis; go ut- pain, tenderness, swelling and erythema of the involved joint, elevated serum and/or urinary uric acid; inflamed gall bladder- abdominal pain and tenderness, fever, nausea, leukocytosis; chronic obstructive pulmonary disease- shortness of breath, wheezing; congestive heart failure- shortness of breath, rales, peripheral edema;
Type II diabetes- end organ complications including cardiovascular, ocular, renal, and peripheral vascular disease lung fibrosis- hyperventilation, shortness of breath, decreased oxygenation; vascular disease, such as atherosclerosis and restenosis- pain, loss of sensation, diminished pulses, loss of function; and alloimmunity leading to transplant rejection- pain, tenderness, fever.
Subclinical symptoms include without limitation diagnostic markers for inflammation the appearance of which may precede the manifestation of clinical symptoms. One class of subclinical symptoms is immunological symptoms including, but not limited to, the invasion or accumulation in an organ or tissue of proinflammatory lymphoid cells or the presence locally or peripherally of activated pro-inflammatory lymphoid cells recognizing a pathogen or an antigen specific to the organ or tissue. Activation of lymphoid cells can be measured by techniques known in the art. Other classes of immunological symptoms are discussed infra in connection with the Examples under the Section "Pharmacological Properties".
"Delivering" a therapeutically effective amount of an active ingredient to a particular location within a host means causing a therapeutically effective blood concentration of the active ingredient at the particular location. This can be accomplished , e.g., by local or by systemic administration of the active ingredient to the host.
The present invention also includes pharmaceutical compositions containing a therapeutically effective amount of one or more of the compounds of Formula I, II, III, VI, VII, or VIII or a pharmaceutically acceptable salt, solvate, clathrate, tautomer or stereoisomer thereof with a pharmaceutically acceptable diluent or carrier. In a preferred embodiment, the pharmaceutical compositions of the invention are formulated in such a manner to achieve an optimal bioavailability of the active compounds. As used hereinafter, the term "active compound" denotes the compounds of Formula I, II, III, VI, VII, or VIII or a pharmaceutically acceptable salt, solvate, clathrate, tautomer or stereoisomer thereof.
In therapeutic use, the active compound may be administered orally, buccally, rectally, parenterally, or topically, such as nasally or by inhalation when preferred administration is local application in the respiratory tract. Thus the therapeutic compositions of the present invention may take the form of any of the known pharmaceutical compositions for oral, rectal, parenteral or topical administration. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The compositions of the invention may contain 0.1-99% by weight of active compound. The compositions of the invention are generally prepared in unit dosage form. Preferably, the unit dosage of active ingredient is 1-500 mg. The effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, tautomer or stereoisomer thereof is from about 0.004 to about 4000 μmol/kg body weight/day; preferrably from about 0.04 to about 400 μmol/kg body weight/day; more preferrably from about 4 to about 400 μmol/kg body weight/day; most preferrably from about 12 to about 120 μmol/kg body weight/day.
The excipients used in the preparation of these compositions include, but are not limited to the excipients readily known in the pharmacist's art.
A "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use. A "pharmaceutically acceptable excipient" as used in the present application includes both one and more than one such excipient.
Compositions for oral administration are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions include, but are not limited to the excipients readily known in the pharmacist's art.
Tablets may be prepared by mixing the active compound with an inert diluent such as calcium phosphate in the presence of disintegrating agents, for example maize starch, and lubricating agents, for example magnesium stearate, and tableting the mixture by known methods. The tablets may be formulated in a manner known to those skilled in the art so as to B2006/001259
give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. The tablets and capsules may conveniently each contain 1 to 500 mg of the active compound. Other compositions for oral administration include, but are not limited to, aqueous suspensions containing the active compound in an aqueous medium in the presence of a nontoxic suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
The active compound may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example water) before ingestion. The granules may contain disintegrants (for example a pharmaceutically acceptable effervescent couple formed from an acid and a carbonate or bicarbonate salt) to facilitate dispersion in the liquid medium.
Compositions of the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
Pharmaceutical compositions may also be administered parenterally (for example subcutaneously, intramuscularly, intradermally and/or intravenously [such as by injection and/or infusion]) in the known pharmaceutical dosage forms for parenteral administration (for example sterile suspensions in aqueous and/or oily media and/or sterile solutions in suitable solvents, preferably isotonic with the blood of the intended patient). Parenteral dosage forms may be sterilized (for example by micro-filtration and/or using suitable sterilising agents [such as ethylene oxide]). Optionally one or more of the following pharmaceutically acceptable adjuvants suitable for parenteral administration may be added to parenteral dosage forms: local anaesthetics, preservatives, buffering agents and/or mixtures thereof. Parenteral dosage forms may be stored in suitable sterile sealed containers (for example ampoules and/or vials) until use. To enhance stability during storage the parenteral dosage form may be frozen after filling the container and fluid (for example water) may be removed under reduced pressure. Especially important pharmaceutical compositions are those that may be administered nasally or by inhalation in known pharmaceutical forms for such administrations (for example sprays, aerosols, nebulised solutions and/or dry powders). Metered close systems known to those skilled in the art (for example aerosols and/or inhalers) may be used. For all pharmaceutical forms intended for topical administration in respiratory tract it may be beneficial to micronizing the compounds of Formula I, II, III, VI, VII, or VIII or their salts being previously homogenized in lactose, glucose, higher fatty acids, sodium salt of dioctylsulfosuccinic acid, or most preferably in carboxymethylcellulose, in such a way that most of the particles are 5 μm in size. The compounds of the present invention in the form of particles of very small size may be obtained, for example by fluid energy milling. For the inhalation formulation the aerosol can be mixed with a propellant intended for the spraying of the active substance.
Pharmaceutical compositions may be administered to the buccal cavity (for example sub- lingually) in known pharmaceutical forms for such administration (for example slow dissolving tablets, chewing gums, gums, troches, lozenges, pastilles, gels, pastes, mouthwashes, rinses and/or powders).
Compositions for topical administration may comprise a matrix in which the pharmacologically active compound of the present invention is dispersed so that the compound is held in contact with the skin in order to administer the compound transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or wax, for example paraffin wax or beeswax, together with 'a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compound may be dispersed in a pharmaceutically acceptable ointment, cream, gel or lotion. Ointments, creams and gels may be formulated with a water base or an oil base under the addition of a suitable emulsifler or gelling agent when gel is formulated The amount of the active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
The compounds of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs W
containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as a suspension or solution in a pharmaceutically acceptable oil of the compound to be infused for example in the form of s very sparingly water-soluble derivative or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused. The support may be a single body containing the entire compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
In the compositions of the present invention the active compound may be used individually or, if desired, may be associated with other compatible pharmacologically active ingredients.
A further aspect of the present invention relates to the use of one or more' of the compounds of Formula I, II, III, VI, VII, or VIII, or pharmaceutically acceptable salts, solvates (including hydrates), clathrates, prodrugs, tautomers or stereoisomers thereof or pharmaceutical compositions containing a therapeutically effective amount thereof in the prophylaxis and therapeutic treatment of inflammatory diseases, pathological allergy disorders and/or conditions. Examples of such conditions and diseases are, without limitation, asthma; chronic obstructive pulmonary disease; bronchitis; adult respiratory distress syndrome; nasal inflammatory diseases such as allergic rhinitis, nasal polyps; mflarnmatatory skin disorders such as eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis; rheumatoid arthritis; inflammatory bowel diseases such as Crohn's disease, colitis and ulcerative colitis; further insulin-dependent diabetes, autoimmune thyroiditis, lupus erythematosus, multiple sclerosis, Raynaud's disease, and other arthritic conditions having an inflammatory component such as rheumatoid spondylitis, septic arthritis, polyarthritis, retinitis, inflammatory brain disorders such as meningitis and encephalitis; conditions associated with acute trauma such as cerebral injury, heart tissue injury and lung injury; inflammation accompanying infections such as sepsis and nephritis (e.g. glomerulonephritis) . Examples
The present invention is illustrated by means of the following Examples. The reference to these and other examples anywhere in the specification is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified form. Likewise, the invention is not limited to any particular preferred embodiments described herein. Indeed, modifications and variations of the invention may be apparent to those skilled in the art upon reading this specification, and can be made without departing from its spirit and scope. The invention is therefore to be limited only by the terms of the appended claims, along with the full scope of equivalents to which the claims are entitled.
AU references cited and discussed in this specification are incorporated herein by reference in their entirety and to the same extent as if each reference was individually incorporated by reference.
PROCESSES OFPREPARATION
The preparation processes were mostly carried at atmospheric pressure. In each example the final product was characterised by means of one or several of the following methods: high-performance liquid chromatography (HPLC) and/or high-performance liquid chromatography connected to a mass spectrometer (HPLC-MS) using ESI (electrospray ionisation) and spectroscopy of nuclear magnetic resonance (NMR). Temperatures were expressed in Celsius degrees and the reaction time in hours (h), aq. = aqueous, DMSO = dimethylsulfoxide, DMF = i\ζΛ/"-dimethylformamide, MeCN = acetonitrile, MeOH = methanol, EtOH = ethanol, BuOH = butanol, /-PrOH = 2-propanol, Me2CO = acetone, ether = diethyl ether, AcOEt = ethyl acetate, Py = pyridine, AcOH = acetic acid, AC2O = acetic anhydride, TFAA = trifluoroacetic acid, EDC = l-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride, HOBT = 1-hydroxybenzotriazole.
Examples from 1 to 14 and 290
General procedure for the preparation of compounds of Formula I wherein A represents a CH-X group, X is carboxy group and n = O To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in MeCN was added 50 wt. % aq. glyoxylic acid (4 equiv.)- The reaction mixture was heated to reflux, and stirred under reflux until completion of the reaction (0.5-6 h). After cooling to room temperature, precipitate was filtered off, washed with cold MeCN and dried.
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Examples from 15 to 26 and 291
General procedure for the preparation of compounds of Formula I wherein A represents a CH-X group, X is an acetyl group and n = O
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in EtOH was added 40 wt.% aq. pyruvic aldehyde (4 equiv.). The reaction mixture was heated to reflux, and stirred under reflux until completion of the reaction (2-32 h). Precipitation usually occurred during the reflux. In some cases, after cooling to room temperature, stirring of the reaction mixture was continued until precipitation occurred. Precipitate was filtered off, washed with cold EtOH and dried.
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Examples from 27 to 33
General procedures for the preparation of compounds of Formula I wherein A represents a CH-X group, X is -CH2OH and n = 0
Method A
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in 50 mM aq. tris(hydroxymethyl)aminomethane (Tris) buffer (pH = 8.0) was added IM aqueous solution of NaOH until pH reached 8. To the prepared solution, glycolaldehyde dimer (2 equiv.) was added. The reaction mixture was stirred at room temperature until completion of the reaction (20-60 h). The mixture was acidified with IM aq. HCl, precipitate was filtered off. Product was purified by trituration or recrystallization from MeOH or EtOH.
Method B
To a suspension of corresponding intramolecular hemiacetal (0.5 mmol) of Formula III, wherein D represents -CHOH and — denotes a single bond {See, e.g., WO 2005/010006), in tert-BuOH was added cyanoborohydride (1 mmol). The reaction mixture was heated to reflux, and stirred under reflux until completion of the reaction (2h). Solvent was then evaporated, water and saturated NH4Cl were added, followed by extraction with AcOEt. Combined organic layers were washed with brine, dried over Na2SO4, organic solvent removed under reduced pressure and the residue purified by isocratic elution with CHCl3MeOH: AcOH = 9:1:0.1 on silica column.
Method C
To a suspension of corresponding intramolecular hemiacetal (0.5 mmol) of Formula III, wherein D represents -CHOH and ~ denotes a single bond (See, e.g., WO 2005/010006), in z'-PrOH was added cyanoborohydride (1 mmol). The reaction mixture was heated to reflux, and stirred under reflux until completion of the reaction (0.5 h). A mixture of «-hexane:ether = 3:1 was added to the reaction mixture, and white precipitate thus formed was filtered off, dissolved in water, followed by addition of IM HCl. The white precipitate was filtered off, washed with water and additionally purified by trituration with MeOH.
Figure imgf000046_0001
Figure imgf000047_0001
Examples from 34 to 36
General procedure for the preparation of compounds of Formula I
CH2OH wherein A represents a CH-X group, X is a — CH-OH group and n = O
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in 50 mM aq. tris(hydroxymethyl)aminomethane (Tris) buffer (pH = 8.0) was added IM aq. NaOH until pH reached 8. To the prepared solution, D,L-glyceraldehyde dimer (2 equiv.) was added. The reaction mixture was stirred at room temperature until completion of the reaction (24-48 h). The mixture was acidified with IM aq. HCl, precipitate was filtered off. Product was purified by trituration or recrystallization from MeCN or Me2CO.
Figure imgf000047_0002
Figure imgf000048_0001
Examples from 37 to 41
General procedure for the preparation of compounds of Formula I wherein A represents a carbonyl group and n = 1
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in water was added aq. solution of D,L-glyceraldehyde dimer (0.5 equiv.). The reaction mixture was heated to reflux, and stirring under reflux was continued until completion of the reaction (5-10 h). After cooling to room temperature, precipitate was filtered off and dried. Product was purified by trituration or recrystallization from MeOH, Me2CO or CHCl3.
Figure imgf000048_0002
Figure imgf000049_0001
Examples from 42 to 54 and 292 to 294
General procedures for the preparation of compounds of Formula I wherein A represents a CH-X group, X is an alkyloxycarbonyl group and n = 0
Method A
To a suspension of corresponding carboxylic acid of Formula I, wherein A represents a CH-X group, X is a carboxy group and n = 0, in appropriate alcohol (excess), cone. H2SO4 was added. The reaction mixture was heated to reflux, and stirring under reflux was continued overnight. After cooling to room temperature, precipitate was filtered off, washed with cold MeOH and dried.
Method B To a suspension of corresponding lactone of Formula III, wherein D represents a carbonyl group, in 1,4-dioxane, appropriate alcohol (excess) was added. Reaction mixture was heated to 110 0C, resulting after a while in a clear solution, and then heating and stirring was continued until the completion of the reaction (several hours). 1,4-Dioxane was removed by evaporation under reduced pressure and then water was added, followed by extraction with AcOEt. Organic layers were washed with brine, dried over Na2SO4 and evaporated to smaller volume followed by addition of ra-hexane. The precipitate thus formed was filtered off, washed with n-hexane and dried.
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Examples from 55 to 58 and 295
General procedure for the preparation of compounds of Formula I wherein A represents a CH-X group, X is an N-alkylcarbamoyl group and n = O
To a suspension of corresponding carboxylic acid (1 equiv.) of Formula I, wherein A represents a CH-X group, X is a carboxy group and n = O, in THF (CH2Cl2 may be used instead) was added Et3N (10 equiv.), resulting in a clear solution. To this solution was added HOBT (1.4 equiv.), followed by appropriate alkyl amine (1.1 equiv.) and EDC (1.5 equiv.). After stirring overnight at room temperature, the precipitate formed was removed by filtration and filtrate was evaporated to dryness. The residue was dissolved in CH2Cl2 (AcOEt may be used instead) and washed with saturated NH4Cl, saturated NaHCO3 and brine, dried over Na2SO4, and concentrated in vacuo. Grade product was purified by chromatography on silica column eluting with CH2Cl2/Me0H/NH4Cl (97/2/0.5→95/4/0.5→91/8/1 →90/60/l).
Figure imgf000054_0001
Figure imgf000055_0001
Examples 59 and from 296 to 301
General procedure for the preparation of compounds of Formula I wherein A represents a CH-X group, X is a -C(=N-R5)R6 group and n = 0
To a suspension of corresponding intramolecular hemiacetal (1 equiv.) of Formula III, wherein D represents a CHOH group and ~ denotes a single bond (See, e.g., WO 2005/010006), in /-PrOH (optionally EtOH, MeCN or water) hydroxylamine (2 equiv.) was added (or O-alkylhydroxylamine, e.g. 0-methylhydroxylamine, hydrazine, alkylhydrazine, e.g. methylhydrazine, aryl amine, e.g. aniline, or arylhydrazine, e.g. phenylhydrazine) resulting in a clear solution. Stirring at room temperature (optionally at elevated temperature if necessary) was continued until the completion of the reaction (1 h to several hours), solvent was evaporated and to the residue AcOEt was added, organic layer was washed with saturated aq. NH4Cl, saturated aq. NaHCO3, brine and dried over anhydrous Na2SO4. Evaporation of the solvent to the smaller volume resulted in precipitation of the product, which was filtered of and dried.
Figure imgf000056_0001
Figure imgf000057_0001
Examples from 60 to 246 and from 302 to 359
General procedure for the preparation of compounds of Formula I wherein A represents a CH-X group, X is aryl or heteroaryl and n = O
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in EtOH was added solution of appropriate aldehyde (1.22 equiv.) in EtOH. The reaction mixture was heated to 55 0C, and stirring at 55 0C was continued until completion of the reaction (12-96 h). Precipitation usually occurred during the heating. In some cases, after cooling to room temperature, stirring of the reaction mixture was continued until precipitation occurred. Precipitate was filtered off, washed with cold EtOH and dried.
Figure imgf000057_0002
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
W
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
W 2
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Examples from 360 to 365
General procedure for the preparation of compounds of Formula I
CH3 wherein A represents a CH-X group, X is a — CH-OH group and n = 0
To a solution of Na(CN)BH3 (2 mmol) in MeOH (5 mL) previously acidified with IM aq. HCl corresponding compound of Formula I, wherein A represents a CH-X group, X is an acetyl group and n = 0 (1 mmol) was added. Reaction mixture was heated to reflux and stirring under reflux was continued for 0.5-6 h. If necessary, additional portion of reducing agent (1 mmol) was added into the reaction mixture, followed by 1 M aq. HCl in MeOH to maintain the reaction mixture acidic, and reflux was continued for next 0.5-6 h. After cooling to room temperature, solvent was evaporated and dry residue was dissolved in water (50 mL), followed by extraction with EtOAc (3x50 mL) with addition of saturated aq. NaCl. Organic layers were combined, solvent was evaporated and the residue was dissolved in water (30 mL), followed by acidification with 1 M aq. HCl until pH = 1 resulting in precipitation of the product, which was then filtered off and dried.
Figure imgf000110_0001
Figure imgf000111_0001
Examples from 247 to 250
General procedure for the preparation of compounds of Formula II wherein X is carboxy
To a solution of corresponding ester of Formula I, wherein A represents a CH-X group, X is an alkyloxycarbonyl group and n = O, in Py was added Ac2O. Stirring of the reaction mixture at room temperature was continued overnight, precipitate was filtered off, washed with n-hexane and dried. Corresponding ester of Formula II, wherein X is alkyloxycarbonyl group, was thus formed, which was in the next step subjected to hydrolysis of the ester group as described bellow.
To a suspension of compound of Formula II, wherein X is alkyloxycarbonyl group, in THF, IM aq. NaOH was added. Stirring was continued at room temperature overnight or until the completion of the reaction. Reaction mixture was then acidified by 2M aq. HCl, and stirring at O 0C continued for a while resulting in the formation of precipitate, which was filtered off, washed with ether and dried.
Figure imgf000112_0001
Examples from 251 to 254
General procedure for the preparation of compounds of Formula II wherein X is an alkylcarbonyl group A solution of corresponding ketone of Formula I, wherein A represents aCH-X group, X is an alkylcarbonyl group and n = 0, in Ac2O was heated to reflux, and stirred under reflux until completion of the reaction (2-10 h). After cooling to room temperature, precipitate was filtered off, washed with cold n-hexane and dried.
Figure imgf000113_0001
Figure imgf000114_0001
Examples from 255 to 258
General procedure for the preparation of compounds of Formula II wherein X is a formyl group
A solution of corresponding intramolecular hemiacetal of Formula III, wherein D represents a CHOH group and ~ denotes a single bond {See, e.g., WO 2005/010006), in Ac2O was heated to reflux, and stirring under reflux was continued until completion of the reaction (4-8 h). After cooling to room temperature, precipitate was filtered off, washed with ether and dried. Corresponding acetyl derivative of the enol form of compound of Formula II, wherein X is formyl group, was thus formed, which was in the next step subjected to hydrolysis of the acetyl group as described bellow.
To a solution of acetyl derivative of the enol form of compound of Formula II, wherein X is formyl group, in AcOH was added water in small portions until solution turned into suspension. The reaction mixture was heated to reflux, and stirring under reflux was continued until completion of the reaction (12-48 h). After cooling to room temperature, precipitate was filtered off, washed with ether and dried.
Figure imgf000115_0001
Examples from 259 to 261 and 366
General procedures for the preparation of compounds of Formula II CH2OH CH3 wherein X is -CH2OH, -CH-OH or — CH-OH group
Method A
A solution of corresponding compound of Formula I, wherein A represents CH-X
CH2OH CH3 group, X is -CH2OH, -CH-OH or — CH-OH group and n = O, in Ac2O was heated to reflux, and stirred under reflux until completion of the reaction (0.1-10 h). After cooling to room temperature, precipitate was filtered off, washed with cold 77-hexane and dried.
Method B
To a solution of corresponding compound of Formula I, wherein A represents CH-X
CH2OH CH3 group, X is -CH2OH, -CH-OH or — CH-OH group and n = O, in Py was added Ac2O. The reaction mixture was stirred at room temperature overnight or until completion of the reaction. Precipitate was filtered off, washed with n-hexane and dried.
Method C
A solution of corresponding compound of Formula I, wherein A represents CH-X
CH2OH CH3 group, X is -CH2OH, — CH-OH or — CH-OH group and n = O, in Ac2O was heated to reflux until suspension was formed, followed by addition of pyridine until formation of the solution. Stirring under reflux was continued until completion of the reaction (0.2-2 h). After cooling to room temperature, precipitate was filtered off, washed with cold n-hexane and dried.
General deacetylation procedure of acetylated derivatives of Formula II, obtained by methods A, B or C
To a suspension of corresponding acetylated derivative of Formula II in 1,4-dioxane was added IM aq. KOH. Stirring was continued at room temperature overnight or until the completion of the reaction. Reaction mixture was then acidified by 2M aq. HCl and organic solvent removed under reduced pressure, followed by addition of water. Precipitate was filtered off, triturated or recrystallized from MeOH and dried.
Figure imgf000116_0001
Figure imgf000117_0001
Examples from 262 to 272
General procedures for the preparation of compounds of Formula III wherein D represents carbonyl
Method A
A solution of corresponding compound of Formula I, wherein A represents CH-X, wherein X is a carboxy group and n = 0, in SOCl2 was heated to reflux, and stirred under reflux until completion of the reaction (0.05-1 h). After cooling to room temperature, stirring of the reaction mixture was continued, followed by addition of CH2Cl2 and/or n-hexane until precipitation occurred. Precipitate was filtered off, washed with cold n-hexane and dried.
Method B
To a suspension of corresponding compound of Formula I, wherein A represents CH-
X, wherein X is a carboxy group and n = 0, in AcOH was added SOCl2, and the reaction mixture was heated to 80 0C. Stirring at 80 °C was continued for several hours. Reaction mixture was cooled to room temperature, precipitate was filtered off, washed with AcOH, followed by n-hexane and dried.
Method C
To a suspension of corresponding compound of Formula I, wherein A represents CH-
X, wherein X is a carboxy group and n = 0, in AcOH was added Ac2O, and the reaction mixture was heated to reflux. Stirring under reflux was continued for several hours. Reaction mixture was cooled to +4 °C, precipitate was filtered off, suspended in AcOH, heated to reflux and stirring under reflux was continued for an hour. After cooling to room temperature, precipitate was filtered off, washed with ether and dried.
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Examples from 273 to 279
General procedures for the preparation of compounds of Formula III wherein D represents -CCH3 and — represents a double bond
Method A
A solution of corresponding compound of Formula I, wherein A represents CH-X group, wherein X is a carboxy group and n = O, in Ac2O was heated to reflux, and stirred under reflux until completion of the reaction (0.5-8 h). After cooling to room temperature (alternatively -18 °C) stirring of the reaction mixture was continued until precipitation occurred. Precipitate was filtered off, washed with cold n-hexane and dried. Alternatively, crude product was purified by chromatography on silica column eluting with CH2Cl2/Ac0Et (100/0→95/5→9/l→4/l-»2/l→l/l). Corresponding acetyl derivative of the compound of Formula III, wherein D represents -CCH3 and - represents a double bond, was thus formed, which was in the next step subjected to hydrolysis of the acetyl group as described bellow.
To a solution of acetyl derivative of the compound of Formula III, wherein D represents -CCH3 and ~ represents a double bond, in AcOH was added water in small portions until solution turned into suspension. The reaction mixture was heated to reflux and stirring under reflux was continued until completion of the hydrolysis (9-48 h). After cooling to room temperature, precipitate was filtered off, washed with ether and dried.
Method B
A solution of corresponding compound of Formula I, wherein A represents CH-X, wherein X is an acetyl group and n = O, in TFAA was heated to reflux, and stirred under reflux until completion of the reaction (2-6 h). After cooling to room temperature, stirring of the reaction mixture was continued, followed by addition of ether and rø-hexane until precipitation occurred. Precipitate was filtered off, washed with cold n-hexane and dried.
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Examples from 280 to 281
General procedures for the preparation of compounds of Formula III wherein D represents -CHCH2OH and ~ represents a single bond
Method A
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in water was added aq. solution of D,L-glyceraldehyde dimer (0.5 equiv.). The reaction mixture was heated to reflux, and stirring under reflux was continued until completion of the reaction (5-10 h). After isolation of the corresponding compound of Formula I, wherein A represents a carbonyl group and n = 1 (Examples 37-41), mother liquor was evaporated to dryness and the product was purified by trituration or recrystallization from MeOH or CHCl3.
Method B
A solution of corresponding compound of Formula I, wherein A represents CH-X
CH2OH group, wherein X is — CH-OH group and n = 0, in AcOH was heated to reflux and stirring under reflux was continued 4-10 h, followed by addition of water in small portions. Stirring under reflux was continued until completion of the reaction (24-48 h). After cooling to room temperature, solvent was evaporated under reduced pressure and the crude product was purified by recrystallization from MeOH.
Figure imgf000123_0002
Figure imgf000124_0001
Examples from 282 to 284 and 367 to 370
General procedures for the preparation of compounds of Formula III wherein D represents a CH2 group and ~ represents a single bond
Method A
To a suspension of corresponding 4-hydroxycoumarin (1 equiv.) in AcOH (optionally in water) was added 50 wt. % aq. chloroacetaldehyde (4 equiv.). The reaction mixture was heated to reflux, and stirred under reflux until completion of the reaction (1-6 h). After cooling to room temperature, precipitate was filtered off, washed with AcOH, followed by ether and dried. Alternatively, crude product was purified by chromatography on silica column eluting with n-hexane/AcOEt (1:1) and/or recrystallization from MeOH.
Method B
A solution of corresponding compound of Formula I, wherein A represents CH-X group, wherein X is -CH2OH and n = 0, in TFAA was heated to reflux and stirring was continued until completion of the reaction (0.5-5 h). After cooling to room temperature, stirring of the reaction mixture was continued, followed by addition of ether and n-hexane until precipitation occurred. Precipitate was filtered off, washed with cold n-hexane and dried.
Figure imgf000125_0001
Examples from 371 to 374
General procedure for the preparation of compounds of Formula III wherein D represents a CHCH3 group and ~ represents a single bond
A solution of corresponding compound of Formula I, wherein A represents CH-X group,
CH3 wherein X is — CH- OH and n = O, in TFAA was heated to reflux and stirring was continued until completion of the reaction (15 minutes to 2 h). After cooling of the reaction mixture solvent was evaporated and the residue was dissolved in MeOH with alternate addition of CHCl3 or water (up to ImL). Stirring of the solution by alternate use of magnetic stirrer and ultrasound bath resulted in precipitation of the product, this was filtered off and dried.
Figure imgf000126_0001
Figure imgf000127_0001
Example 288
General procedure for the preparation of compounds of Formula III wherein D represents a CH group and ~ represents a double bond
To a suspension of corresponding compound of Formula III, wherein D represents a CH2 group and — represents a single bond (0.5 mmol) in tetrachloromethane (10 mL) was added N-bromosuccinimide (0.55 mmol), followed by addition of catalytic amount of benzoylperoxide, and reaction mixture was refluxed for 3 h. Solvent was evaporated under reduced pressure and the remaining crude product was refluxed for 5 min in water, filtered hot and washed with hot water. The crude product was purified by recrystallization from DMF. White product thus obtained was stirred with ether at room temperature for 10 minutes and then filtered off.
Figure imgf000127_0002
PHARMACOLOGICAL PROPERTIES The compounds of Formulae I, II and III possess useful pharmacological properties proved by a number of in vitro and in vivo investigations.
Assays that can be used to determine the anti-inflammatory effects of the compounds and hense, their use for the treatment of diseases characterized by pathologic inflammation are represented by Examples 285 to 287, 289 and 375 to 377. The cytokines assayed in these examples, when expressed at elevated amounts, are markers for inflammation and, in the case of other immune events assayed such as cell proliferation, granulocyte degranulation and lung netrophilia, the behaviors of these immune cells are also markers for their activation and, therefore, inflammation. Consequently, reduction of pro-inflammatory cytokine expression or secretion and reduction in cell proliferation, mast cell degranulation or neutrophil accumulation is a measure of a compound's anti-inflammatory activity. Lung neutrophilia specifically serves as a model for COPD and lung eosinophilia as a model for asthma. Phosphodiesterases are involved in various inflammatory states such as asthma* (PDE4), COPD (PDE4) and pulmonary hypertension (PDE3). Prostaglandins and leukotrienes are also potent inflammation mediators, the former being produced in the cyclooxygenase (COX) pathway and the latter in the lipooxygenase pathway. Thromboxanes are also potent inflammation mediators produced in the COX pathway.
A compound analyzed using the biological assays as defined herein is considered to be fully "active" if inhibition is significant (i.e. 50% or higher) in at least one inhibitory function (e.g., inhibition of TNF-α or IL-6) after stimulation with at least one stimulant (e.g., OVA, PMA or LPS), as described for each particular in vitro assay, or if activity in at least one of in vivo testings (e.g. in suppression of ear oedema) is statistically significantly different in comparison to a positive control group, as calculated by the statistical methods known in the art (e.g. ANOVA).
Example 285: Inhibition of RBL-2H3 Mast Cell Degranulation
Mast cell degranulation is indicated as invoked in immediate or delayed type hypersensitivity reaction, allergy, anaphylaxis, inflammation, asthma and urticaria (hives).
RBL-2H3 cell line of rat basophilic leukaemia (ATCC) was used for the investigation of inhibition of degranulation induced by the activation of Fcε receptor type I or calcium ionophors. RBL-2H3 cell line was cultivated in DMEM medium (Invitrogen Cat. No. 31966- 021) with 10 % of phoetal calf serum (Invitrogen Corporation) at 37 °C, 5 % CO2, 90 % relative humidity. Cells were seeded in the same medium into 24- well plates, 50000 per well, and left to reach 80-90 % of confluence.
Dilutions of compounds were prepared in DMEM medium without phenol red (Invitrogen Corporation) in concentrations from 200 μM to 1 μM. The medium was removed from the cells and the diluted of compounds were added to the wells with the exception of the positive and the negative control where pure DMEM medium was added. Subsequently,
1. for the IgE-induced degranulation by Fee receptor type I, a solution of SPE-I (dinitrophenyl specific IgE) antibodies (Sigma) and dinitrophenylalbumin (Sigma), both in a final concentration of 0.5 μg/mL,
2. for Ca2Λ -induced degranulation by means of a calcium ionophore, the solution A23187 (Calbiochem) in a final concentration of 250 ng/mL, and were added to the wells.
In the case of the negative control wells, pure DMEM medium was added. The cells were incubated for one hour at 37 °C, 5 % CO2, and 90 % relative humidity. Each dilution as well as the positive and the negative controls were performed in triplicate.
The supernatant (50 μL) was transferred in duplicate to a 96-well plate. Thereto 100 μL of 50 mM sodium citrate buffer with 1 mg/mL para-nitrophenyl-N-acetyl-β-D- glucosaminide (Calbiochem) were added and it was incubated for 1 hour at 37 °C. The reaction was stopped with 100 μL of a saturated sodium carbonate solution. The absorbance was measured at 405 nm. The percentage of inhibition was expressed by the formula:
% inhibition = (l-(OD4Q5sample-OD405negative control)/(OD405positive control- OD4o5negative control)) x 100.
Ketotifen, used as a standard, significantly inhibits degranulation in concentrations from 200-50 μM.
Compounds represented by Examples 7, 12, 19, 30, 44-46, 50, 53, 55, 61, 62, 66, 69, 73, 75-83, 85, 86, 88, 89, 93, 94, 116, 143-146, 148, 150, 151, 268, 284, 348, 349-351 and 354 inhibited IgE-induced degranulation by Fcε receptor type I demonstrating significant inhibitory activity in 10 μM concentration.
Compounds represented by Examples 66, 69, 73, 75-77, 80, 82, 88, 89, 94, 96, 97, 101, 103, 105, 106, 108-111, 114, 115, 116, 131, 135, 136, 137, 144, 148, 149, 154, 156, 160, 161, 166, 167, 169-171, 174, 177, 189, 225, 226, 228, 233-235, 237, 238, 241, 243, 246, 309, 314, 315-321, 324, 326, 333,-340, 342-344, 346 and 348 inhibited Ca2+-induced degranulation by means of a calcium ionophore demonstrating significant inhibitory activity in 10 μM concentration.
Example 286a: Leukotriene B4 (LTB4) Inhibition Assay
Leukotrienes are important mediators in host defense mechanisms and in inflammatory disease states due, for example, to their effects on cell migration, muscle contraction, vascular permeability, and the release of lysozomal enzymes. Leukotriene production depends on the enzyme activity of 5-lipoxygenase. RBL-2H3 cells have a potent 5-lipoxygenase activity and thus serve as a cell model for production of leukotrienes.
Compounds were assayed for their ability to inhibit the production of leukotriene B4 in A23187 stimulated RBL-2H3 cells. RBL-2H3 cell line (ATCC 2256) is grown in DMEM medium (Invitrogen) supplemented with 10% FBS (Invitrogen) in the atmosphere of 5% CO2, 90% humidity, 37 C. Cells are trypsinazed, washed with fresh DMEM medium and adjusted to 1x105 cells per mililiter. 500 μL/well of cell suspension is transferred into 24 well plate (Falcon) and grown overnight in culturing condition described herein. 10 mM solutions of tested compounds are prepared in DMSO (Sigma), and dissolved in working concentrations in DMEM medium without phenol red (Invitrogen). Dilutions of tested compounds are placed on cells, whereas for positive and negative controls only DMEM medium without phenol red are used and left in culturing conditions for 30 minutes. A23187 (Sigma) was added into all wells except negative controls in the final concentration of 250 nM and left for 45 minutes in culturing conditions. 10 μL of cellular supernatant was used to determine leukotriene B4 levels using ELISA (R&D systems). Total concentrations of LTB4 are calculated in samples, and total inhibition was calculated using the formula:
%inhibition=(l- LTB4 sample concentration/LTB4 positive control concentration) x 100.
Compounds represented by Examples 7, 17, 18-20, 25, 28-30, 32, 33, 44-47, 49-51, 55, 61, 66, 69, 71, 73, 75-78, 80-83, 86, 88, 93, 94, 96, 97-101, 103, 105, 106, 108-112, 114-116, 123, 125-128, 130, 135-138, 143-145, 148-150, 154-157, 159-162, 164, 166-172, 174, 177- 179, 181, 186, 189, 190, 207, 210, 214, 218, 225, 226, 228-235, 237, 238, 241, 243-246, 268, 292-294, 303, 304, 309, 311, 312, 314-321, 324, 326, 332, 333, 334-340, 342-351, 359, 362- 364, 369 and 371 demonstrated significant inhibition of LTB4 production at concentrations of lOμM. Example 286b: 5-Lipoxygenase, 5-LO, Inhibition Assay
5 -lipoxygenase is involved in number of immune diseases like asthma and inflammatory bowel disease.
Inhibition of 5 -lipoxygenase, 5-LO, was determined by comparison of LTB4 inhibition (Example 286a) and inhibition of Ca -induced mast cell degranulation (Example 285) in 10 μM concentration. Compounds were considered as 5-LO inhibitors if the difference between inhibitions in these two assays was significant (50% or higher) in favor of LTB4 inhibition.
Compounds represented by Examples 17, 19, 20, 25, 29, 30, 32, 44-47, 49, 50, 55, 61, 71, 83, 86, 98, 99, 100, 112, 123, 128, 130, 143, 145, 150, 155, 157, 159, 162, 168, 179, 186, 190, 210, 230, 231, 232, 293, 303, 311, 312, 332, 345, 347, 349-351, 359, 362, 364, 369 and 371 were considered as 5-LO inhibitors according to the above mentioned criterion.
Example 287: Evaluation of the compounds of the present invention
AU compounds were dissolved in dimethyl sulfoxide (DMSO). Final concentration of the DMSO in all tests was 1% (v/v). Inhibition in all tests is considered preferred if it exceeds 50% at 10 μM concentration (or less).
Human 5-Lipoxygenase, 5-LO, assay
5-lipoxygenase is involved in number of immune diseases like asthma and inflammatory bowel disease.
Human peripheral mononuclear blood cells were isolated using Ficoll density separation. Cells were incubated in Hanks Balanced Salt Solution (HBSS) with compounds for 15 minutes at 37°C. Substrate (arachidonic acid) was added in 20 μM final concentration and cells were incubated for another 15 minutes. LTB4 as a final product of arachidonic acid metabolism was measured using competitive enzyme immunoassay {See, e.g., Safayhi, H. et al. Planta Medica 2000, 66, 110-113) and percentage of inhibition was calculated from the levels of LTB4 in cell supernatant.
Compounds represented by Examples 17, 19, 30, 50, 349 and 351 inhibited human 5-LO demonstrating significantly relevant activity in 10 μM concentration.
Human Leukotriene receptor, Cysteinyl leukotriene receptor I (CysLTl), assay CysLTl receptor is involved in immune diseases such as asthma, and has clinical significance as a point of intervention in asthma therapy. CysLTl receptor is expressed in CHO-Kl cells (Chinese hamster ovary cells Kl clone). This is a competitive radioligand binding assay where substances compete with [3H]-labeled Leukotirene D4 (LTD4). Radioactive substance is measured with scintillation counting. Percentage of inhibition is calculated from the total radioactivity of the sample.
Compounds represented by Examples 19, 30, 50, 349 and 351 exhibited significantly relevant activity in 10 μM concentration.
Human Phosphodiesterase, PDE, assays
Phosphodiesterases are involved in many cellular processes of signal transduction and have implication in cell growth and division, inflammation, pulmonary hypertension and asthma. Inhibitors of PDE4 have been developed for asthma treatment. The PDE3 inhibitor cilostazol has been approved in certain countries for treatment of arterial occlusive diseases and stroke.
PDE3 assay. Isolated human platelets are pre-incubated at 25 0C in Tris-HCl buffer containing magnesium ions for 15 minutes. 1.01 μM tritium labeled cyclic adenosine monophosphate (cAMP) is added as substrate, followed by incubation at 25 °C for 20 minutes. Percentage of inhibition is calculated by comparing the adenosine levels in supernatant which is formed from cAMP in treated versus control cells.
Compounds represented by Examples 17, 19, 30, 50 and 351 significantly inhibited human PDE3 activity in 10 μM concentration.
PDE4 assay. PDE is implicated in diseases such as chronic obstructive pulmonary disease and neutrophilia. Human monocytic leukemia cell line U937 is pre-incubated at 25 0C in Tris-HCl buffer containing magnesium ions for 15 minutes. 1.01 μM tritium labeled cyclic adenosine monophosphate (cAMP) is added as substrate, followed by incubation at 25 0C for 20 minutes. Percentage of inhibition is calculated by comparing the adenosine levels in supernatant which is formed from cAMP in treated versus control cells.
Compounds represented by Examples 17, 19, 30, 50 and 351 significantly inhibited human PDE4 activity in 10 μM concentration. Human Prostanoid receptor assay
Human prostanoid receptor is expressed in Chinese hamster ovary cell line, clone Kl (CHO-Kl). Substances and radioactive competitor (tritium labelled Prostaglandin D2 in 1.7 nM concentration) are incubated with cells in HEPES buffer for 2 hours at 25 0C in the presence of manganese ions. Level of the bound PGD2 is measured by scintillation counting, and competition is calculated from comparing the total amount of the bound PGD2 in treated versus control cells. Prostanoids are involved in many physiological and pathological processes, from inflammation to pain.
Compounds represented by Examples 19, 30, 50 and 351 exhibited significantly relevant activity in 10 μM concentration.
Human Thromboxane A2, TxΛ2, assay
TxA2 receptor is expressed in HEK-293 cell line. Compounds and radiolabeled competitor SQ-29548 are incubated for 30 minutes at 25 °C. Level of bound SQ-29548 is measured by scintillation counting, and competition is calculated from the total amount of the bound SQ-29548. TxA2 receptor is an unstable lipid mediator involved in blood clotting, and immune processes.
Compounds represented by Examples 17, 19, 30, 50 and 349 exhibited significantly relevant activity in 10 μM concentration.
Human Protein Serine/Threonine Kinase, ERKl, assay
Human ERKl is expressed in Escherichia coli and purified. Compounds are pre- incubated in MOPS/EGTA buffer with pervanadate, DTT and γ-[32P]-ATP with recombinant enzyme for 15 minutes at 37 °C. Substrate (purified myelin basic protein, MBP) is added, followed by incubation at 37 0C for 30 minutes. Enzyme activity is measured by quantitation of [32P]-MBP and inhibition is calculated from specific radioactivity. ERKl is a serine/threonine kinase activated in MAPK (mitogen activated kinase) pathway. ERKl is implicated in a high proportion of human cancers, including Hodgkin disease. ERKl is involved in processes of cell growth, division and inflammation.
Compound represented by Example 19 significantly inhibited human ERKl activity at a concentration of 10 μM. Human Protein Tyrosine Kinase, LcIc, inhibition assay
Human recombinant LcIc is expressed in insect Sf21 expression system and purified. Substances are pre-incubated for 15 minutes at 25 0C in HEPES buffer containing ATP5 pervanadate and magnesium. Substrate (poly Glu-Tyr) is added and incubated for 60 minutes at 25 °C. Activity of the enzyme is measured using phosphotyrosine (p-Tyr) specific enzyme immunoassay and inhibition is calculated from the determination of the concentration of p- Tyr. Protein tyrosine kinase, Lck, is a protein tyrosine kinase which is abundantly expressed in T-lymphocytes and is essential for T-cell receptor signal transduction and thus activation of T-lymphocytes. Lck activation stimulates recruitment and activation of ZAP-70, which is essential for T-cell activation. Inhibitors of Lck act as immunoregulatory agents in various models. Lck is implicated in T-cell leukemias and inflammation.
Compound represented by Example 19 significantly inhibited human Lck activity at a concentration of 10 μM.
Human Tachykinin NK2 receptor assay
Tachykinin NK2 receptor is expressed in Chinese hamster ovary cell line, clone Kl (CHO-Kl). Substances and radioactive competitor (tritium labelled SR-48968) are incubated with cells in HEPES/NaOH buffer for 90 minutes at 25 °C in the presence of manganese ions. Levels of the bound SR-48968 is measured by scintillation counting, and competition is calculated from the total amount of the bound SR-48968 in treated and control samples. Tachykinin receptors are involved in physiological and pathological processes of inflammation and pain. Tachykinin NK2 has been identified as a target for intervention in asthma, GI disease, irritable bowel syndrome and pancreatitis.
Compounds represented by Examples 19 and 50 exhibited significant inhibition of NK2 activity at 10 μM concentration.
Example 375: Inhibition of cytokine production
A) Inhibition of cytokine production by stimulated human white blood cells (hWBCs) in vitro Stimulated hWBCs were treated with two different concentrations of the compounds (25μM and lOμM). Three different stimuli, inducing inflammatory response through different signalling pathways, were used. Anti-inflammatory activity of the compounds was evaluated based on their ability to inhibit production of pro-inflammatory cytokines (TNF-α, IL-lβ, IL-6 and IL-8).
White blood cells were obtained from venous blood of healthy volunteers by sedimentation on 2% dextran T-500 (Amersham Biosciences) and subsequent centrifugations of leukocyte rich plasma. Cells were seeded in a 48-well plate at a concentration of 3 -5x106 cells per well and preincubated with the tested compounds for 2h at 370C. Afterwards, stimuli (Sigma) were added to the final concentration of 2μg/mL lipopolysaccharide (LPS), lμg/mL phorbol-12-myristate acetate (PMA) or 120μg/mL zymosan (ZYM). Samples were incubated overnight at 37°C. At the end of incubation supernatants were centrifuged for lOmin at 150Og and stored at -20°C until cytokine concentration determination. Cytokines were determined by sandwich ELISA, using capture and detection antibodies (R&D) according to manufacturer's recommendations.
Percentage of inhibition is calculated using formula:
% Inhibition = (1 - cytokine concentration of sample/cytokine concentration of positive control) x 100.
Compounds are considered active if the percent of inhibition is 50% or greater in concentration of 25 μM or lower.
Compounds which significantly inhibited TNF-α, IL-I β, IL-6 and/or IL-8 production stimulated by PMA, LPS and zymosan are listed in the Table below in concentrations as stated.
Figure imgf000135_0001
Figure imgf000136_0001
B) Inhibition of cytokine production by lipopolysaccharide (LPS) stimulated human peripheral blood mononuclear cells (hPBMCs) in vitro
Blood was taken from healthy volunteer donor, diluted with the same volume of saline and was separated by gradient density centrifugation on FicollPaque™ Plus on 40Og for 30 minutes. PBMCs were collected, washed in RPMI, counted and number per mL was adjusted.
Collected PBMCs were cultured into 96 well tissue culture plate, flat bottom as 35.000 cells/well/200uL in RPMI supplemented with 10 % fetal bovine serum, prior inactivated on 56°C for 30 minutes. Cells were stimulated on IL- lβ production by adding LPS (serotype 0111:B4, Sigma, cat# L-2630), at final concentration lng/mL. Unstimulated cells were cultured in medium alone. Stock solution was prepared out of testing compounds as 1OmM in DMSO. Final concentrations made in cell culture medium were tested when they had been added together with LPS. The final DMSO volume ratio in all assays did not exceed 0.1%. Negative and positive control samples were prepared in sextaplicates and samples with tested compound concentrations in triplicates. After overnight incubation in humidified atmosphere containing 5% CO2, supernatants were collected.
Harvested cell culture supernatants were quantified for IL- lβ content by enzyme linked immunosorbent assay (ELISA).
Percentage of inhibition is calculated using formula:
% Inhibition = (1 - cytokine concentration of sample/cytokine concentration of positive control) x 100. Compounds are considered active if the percent of inhibition is 50% or greater in concentration of 25 μM or lower.
Compound 244 significantly inhibited IL- lβ production in concentration of 25 μM.
C) Inhibition of cytokine production by concanavalinA (ConA) stimulated mouse splenocytes in vitro
Spleen cell suspension was obtained from BALB/c mice and lymphocytes separated by gradient density centrifugation on Histopaque 1.083 on 40Og for 30 minutes. They were washed once in medium, counted and their number adjusted as 3xl05/200μL/well in 96 flat bottomed culture plate in RPMI supplemented with 10 % fetal bovine serum. Cells were stimulated on cytokine production by adding concanavalinA (ConA) at 5μg/mL final concentration. Unstimulated cells were cultured in medium alone. Stock solution was prepared out of testing compounds as 1OmM in DMSO. Final concentrations made in cell culture medium were tested when they had been added together with ConA. After 72 hours incubation period cell culture supernatants were collected. In each sample IL-4, IL-5, IL-10 and IFNγ were detected and quantified using enzyme linked immunosorbent assay (ELISA) specific for pointed cytokines (R&D Systems).
To calculate results, standard curve was made out of measured OD values for recombinant protein in known concentrations. Cytokine content in unknown samples was calculated out of OD values extrapolated from the standard curve. Percentage of inhibition is calculated using formula:
% Inhibition = (1 - cytokine concentration of sample/cytokine concentration of positive control) x 100.
Compounds are considered active if the percent of inhibition is 50% or greater in concentration of 25 μM or lower.
Compound 244 significantly inhibited IL-4, IL-5, IL-IO, as well as IFNγ production in concentration of 25 μM.
Compound 30 significantly inhibited IL-5 and IL-IO production in concentration of 25 μM.
Compounds represented by Examples 19, 295 and 364 significantly inhibited IL-5 production in concentration of 25 μM. Example 376: Pkorbol 12-myristate 13-acetate, PMA, induced ear oedema in CDl mice
Male CDl mice (Iffa Credo, France) weighing ~35-40 g were randomly grouped (n=8 in vehicle treated test group, dexamethasone treated control group as well as in groups treated with compounds to be assayed). Test compounds, dexamethasone as well as vehicle (Trans- phase Delivery System, containing benzyl alcohol 10%, acetone 40% and isopropanol 50%) (all from Kemika, Croatia), were administered topically to the internal surface of the left ear thirty minutes prior to administration of phorbol 12-myristate 13-acetate (PMA) (Alexis biochemicals, USA). Test compounds were administered at a single dose of 250 or 100 μg/15 μL/ear and dexamethasone at a single dose of 50 μg/15 μL/ear. Thirty minutes later, 0.01 % PMA solution in acetone was applied topically to the same area of each animal in a volume of 12 μL/ear. During the treatment and challenge, animals were anaesthetized by using inhalation anaesthesia. Six hours after the challenge, animals were euthanized by asphyxiation in 100% CO2 atmosphere. For assessing the auricular oedema, 8 mm discs were cut out of left and right auricular pinna and weighed. The degree of oedema was calculated by subtracting the weight of 8 mm disc of the untreated ear from that of the treated contralateral ear.
The compound at appropriate dose is considered active if the supression of ear oedema in compound treated group is statistically significantly different in comparison to positive control group, as calculated by the statistical methods known from the art (e.g. ANOVA).
Compounds represented by Examples 19, 25, 26, 28, 29, 30, 50, 51, 54, 66, 244, 292, 295, 349, 351, 363 and 364 are considered active according to the above mentioned criterion.
Example 289: Model of ovalbumin induced pulmonary eosinophilia in mice
Male Balb/C mice with a body weight of 20-25 g are randomly divided into groups, and sensitized by an i.p. injection of ovalbumin (OVA, Sigma) on day zero and day fourteen. On the twentieth day, the mice are subjected to a challenge test by i.n. (intranasal) application of OVA (positive control or test groups) or PBS (negative control). The compounds are administered daily i.n., Lp. or per os in different doses starting 2 days before the challenge and up to the completion of the test. Compounds are administered as suspension either in PBS, methyl cellulose or carboxymethyl cellulose with addition od DMSO (up to 5% of the total volume). 48 hours after Ln. application of OVA, the animals are then anaesthetized to obtain bronchoalveolar lavage fluid (BALF), which is used to determine total protein concentration as well as concentrations of cytokines such as IL- lβ and TNF-α, absolute number of cells, and percentage of eosinophils in BALF. Bronchoalveolar lavage (BAL) is performed by infusing ImL of PBS divided into 3 separate volumes (0.4, 0.3 and 0.3ml) through trachea into the lungs. The fluid is immediately withdrawn and the cell suspension stored into previously prepared l,5mL Eppendorf tube. Bronchoalveolar lavage fluid (BALF) is then centrifuged at O5Ig for 5min (4°C). Cells are resuspended in 700μL of PBS. To prepare cytospins, 320μL of suspension is centrifuged at 250rpm for lOmin (Cytospin-3, Shandon Instruments). Cells are stained with Dif-Quik (Dade Behring) to determine percentage of eosinophils by counting of at least 100 cells. The remaining resuspended cells are used for total cell count in BALF analysis (Sysmex SF 3000). Finally, lungs are sampled and stored into 10% formalin for pathohistological evaluation of eosinophil and mononuclear infiltrate. Accumulation of eosinophils and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and in alveolar spaces is monitored.
Results can be expressed as (I) decrease of absolute cell number per mL in BALF, (II) decrease of number of eosinophils per mL in BALF, (III) reduction of relative number (percentage) of eosinophils in BALF, (IV) reduction of cytokine concentrations in BALF, as well as (V) suppression of accumulation of eosinophils and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and in alveolar spaces by pathohistological scoring of treated animals compared to positive control (OVA stimulated, but untreated animals).
The results have to be statistically significantly different when compared to positive control group, as calculated by the statistical methods known in the art (e.g. ANOVA).
Fluticasone and beclomethasone are used as standard anti-inflammatory substances, and compared for ability to inhibit eosinophilia to the negative and positive controls. Compounds represented by Examples 19, 30, 50 and 363 exhibited statistically significant reduction of percentage of eosinophils and/or their total number in BALF and/or by histological scoring.
Example 377: Model of LPS induced pulmonary neutrophilia in mice
Male Balb/cJ mice (Iffa Credo, France) weighing ~25 g are randomly grouped into a negative control group, positive control group and groups treated with compounds to be assayed). Test compounds, as well as vehicle (DMSO + 0,5% methyl-cellulose) (all from Sigma), are administered in., i.p. or per os two hours prior to administration of lipopolysaccharide (LPS) (E. coli, serotype 0111:B4, Sigma) or two hours prior and two hours after administration of LPS. Test compounds are administered at a single dose (two hours prior the challenge) or divided into two doses (two hours prior and two hours after the challenge). LPS solution in phosphate buffered saline (PBS) (Sigma) is administered intranasally in volume of 60μL at concentration of 33,33 μg/mL, to all experimental groups except the negative control group, which received the same volume (60μL) of vehicle PBS. During the challenge, animals were anaesthetized by using intraperitoneal anaesthesia. Animals are euthanized by i.p. anesthesia overdose approximately 24 hours after application of LPS to obtain bronchoalveolar lavage fluid (BALF), which is used to determine total protein concentration as well as concentrations of cytokines, such as IL- lβ and TNF-α, absolute number of cells, and percentage of neutrophils in BALF. Bronchoalveolar lavage (BAL) is performed by infusing ImL of PBS divided into 3 separate volumes (0.4, 0.3 and 0.3ml) through trachea into the lungs. The fluid is immediately withdrawn and the cell suspension stored into previously prepared l,5mL Eppendorf tube. Bronchoalveolar lavage fluid (BALF) is then centrifuged at 0,Ig for 5min (4°C). Cells are resuspended in 700μL of PBS. To prepare cytospins, 320μL of suspension is centrifuged at 250rpm for lOmin (Cytospin-3, Shandon Instruments). Cells are stained with Dif-Quik (Dade Behring) to determine percentage of neutrophils by counting of at least 200 cells. The remaining resuspended cells are used for total cell count in BALF analysis (Sysmex SF 3000).
Finally, lungs are sampled and stored into 10% formalin for pathohistological evaluation of granulocyte and mononuclear infiltrate. Accumulation of granulocytes and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and alveolar spaces is monitored.
Results can be expressed as (I) decrease of absolute cell number per mL in BALF, (II) decrease of number of neutrophils per mL in BALF, (III) reduction of relative number (percentage) of neutrophils in BALF, (IV) reduction of cytokine concentrations in BALF, as well as (V) suppression of accumulation of granulocytes and mononuclear cells in peribronchial (PB) and perivascular (PV) lung tissue areas and in alveolar spaces by pathohistological scoring of treated animals compared to positive control (LPS stimulated, but untreated animals).
The results have to be statistically significantly different when compared to positive control group, as calculated by the statistical methods known in the art (e.g. ANOVA).
Compounds represented by Examples 19, 30, 50 and 363 exhibited statistically significant reduction of percentage of neutrophils and/or their total number in BALF and/or by histological scoring.

Claims

1. A compound of Formula I
Figure imgf000142_0001
(I)
or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof
wherein:
R1, R2, R3 and R4 is each independently hydrogen, fluoro, chloro, bromo , C1-C4- alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, hydroxy, CrC4-alkoxy, trifluoromethoxy, CrC4-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, ΛζiV-di(C1-C4-alkyl)amino, mercapto, Q-Q-alkylthio, sulfo, C1-C4-alkylsulfo, sulfino, C1-C4-alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro;
A is carbonyl, CH-X or C=N-R5;
Each occurrence of n is, independently, an integer which is O or 1;
R5 is hydroxy, alkoxy, amino, alkylamino, aryl or arylamino;
X is hydroxy, carboxy, acetyl, alkylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, N-alkylcarbamoyl or - CC=N-R5)R6; and
R6 is hydrogen or CH3;
provided that i.) when A is carbonyl or C=N-R5 group then n = 1 ; and ii.) when n = 0 and X is aryl, heteroaryl, formyl, carboxy, acetyl, alkyloxycarbonyl,
CH2OH arylcarbonyl, N-alkylcarbamoyl, -CH2OH, — CH-OH group, then R1, R2, R3 and R4 are not all hydrogen; and
iii.) when n = O, R1=R2=R4=H, and R3=OH or when n = O, R2=R4=H, and R1=R3=OH or when n = 0, R1=R4=H, and R2=R3=OH or when n = 0, R1=R2=H, and R3=R4=OH , then X is not a formyl or 2-formylphenyl; and
iv.) when n = 0, R1=R2=R4=H, and R3=OH or when n = 0, R2=R4=H, and R1=R3=OH, then X is not 4-carboxyphenyl group; and
v.) when n = 0, R1=R2=R4-H, and R3=OH, then X is not carboxy, phenyl, 4-styrylphenyl, 4-(N,N-dimethylamino)phenyl, 2- pyridinyl, 3- pyridinyl, 2-naphtalenyl; and
vi.) when n = 0, R1=R2=R3=H, and R4=Me then X is not phenyl, 3-bromophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 2,4-dichlorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, A- methoxyphenyl, 4-nitrorophenyl, 4-hydroxy-3-methoxyphenyl, 4-(N5N- dimethylamino)phenyl5 4-methylthiophenyl; and
vii.) when n = 0, R1=R3=R4=H, and R2=Me then X is not phenyl, 2-chlorophenyl, 4-hidroxyphenyl, 2,4-dichlorophenyl, 3- methoxyphenyl, 4-methoxyphenyl 4-hydroxy-3-methoxyphenyl, 3-nitrorophenyl, 2- nitrorophenyl, 2-methoxyphenyl, 3,4,5-trimethoxyphenyl, 4-(N5N- dimethylamino)phenyl, 2-pyridinyl, 3- pyridinyl, 4-pyridinyl, 2-quinolinyl; and
viii.) when n = 0, R1=R3=R4=H, and R2=F or when BL = O, Ri=R2=R4=H, and R3=F then X is not carboxy, ethyloxycarbonyl,
ix.) when n = 0, R1=R2=R3=H5 and R4=Cl then X is not phenyl,
x.) when n = 0, R1=R3=R4=H, and R2=Cl then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 3-nitrophenyl, 4-hydroxy- 3-methoxyphenyl, 2-pyridinyl, 3- pyridinyl, 4-pyridinyl, 2-(6-methyl)pyridinyl, 2- quinolinyl,
xi.) when n = 0, R1=R3=R4=H, and R2=Br then X is not phenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-methylphenyl, 4- hydroxy-3-methoxyphenyl, 4-hydroxy-3-ethoxyphenyl, 2-pyridinyl, 4-(N5N- dimethylamino)phenyl, 5-benzo[l,3]dioxolyl ; and
xii.) when n = 0, R1=R2=R4=H5 and R3=Me or when n = 0, R2= R3=H and R1 =R4=Me, then X is not phenyl, 4-hydroxyphenyl, 4-nitrophenyl; and
xiii.) when n = 0, R2= R4=H and R1 =R3=Me, then X is not phenyl; and
xiv.) when n = 0, Ri= R4=H and R2 =C1 and R3=Me, then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2-(6-methyl)pyridinyl5 3- pyridinyl, 4- pyridinyl, 2-quinolinyl; and
xv.) when n = 0, Ri= R4=H and R2 = R3=Me, then X is not phenyl, 4-methoxyphenyl; and
xvi.) when n = 0, Ri= R3=H and R2= R4=Cl5 then X is not phenyl xvii.) when n = 0, R1= R2=H and R3 = OH and R4=Me5 then X is not phenyl, 4-methoxyphenyl, 2-hydroxyphenyl, 3-hydoxyphenyl, 4- hydroxy-3-methoxyphenyl, 4-hydroxy-3-ethoxyphenyl, 5-benzo[l,3]dioxolyl; and
xviii.) when n = 1 and X is carboxy, ethyloxycarbonyl then R15R2, R3 and R4 are not all hydrogen; and
xix.) when n = 1 and R1= R3= R4=H and R2 =Br, then X is not phenyl.
2. A compound of formula II
Figure imgf000145_0001
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or stereoisomer thereof
wherein:
R1, R2, R3 and R4 is each independently hydrogen, fluoro, chloro, bromo, C!-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, hydroxy, Ci-C4-alkoxy, trifluoromethoxy, C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, ΛζiV-diCCi-C-j-alkyOamino, mercapto, C1-C4-alkylthio, sulfo, C1-C4-alkylsulfo, sulfino, C1-C4-alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; X is hydroxy, carboxy, alkylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, arylcarbonyl, N-alkylcarbamoyl, or -C(=N-R5)R6;
R5 is hydroxy, alkoxy, amino, alkylamino, aryl or arylamino; and
R6 is hydrogen or CH3;
provided that
CH2OH i.) when X is aryl, heteroaryl, carboxy, acetyl, alkyloxycarbonyl, -CH2OH, — CH-OH group, then R1, R2, R3 and R4 are not all hydrogen; and
ii.) when R1= R3= R4=H and R2 = Me, then X is not 3-(4-hydroxy-6-methyl-2-oxo-2H-l-benzopyranyl).
3. A compound of Formula III
Figure imgf000146_0001
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or stereoisomer thereof
wherein
R1, R2, R3 and R4 is each independently hydrogen, fluoro, chloro, bromo, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, hydroxy, Q-Q-alkoxy, trifluoromethoxy, C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, i\ζiV-di(C1-C4-alkyl)amino, mercapto, Ci-C4-alkylthio, sulfo, Q-Gi-alkylsurfo, sulflno, Ci-Q-alkylsulfmo, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro; D is CH, CH2, CCH3, CHCH3, CHCH2OH, or carbonyl; and
— is a single or a double bond;
provided that i.) when D represents CH2, CHCH3, CHCH2OH, or carbonyl group and ~ represents a single bond, or when D represents CH or CCH3 group and ~ represents a double bond, then R1, R2, R3 and R4 are simultaneously not hydrogen atom; ii.) when R1=R2=R4=H and R3=OH, or when R2=R4=H and R1=R3=OH, or when R1=R4=H and R2=R3=OH, or when R1=R2=H, R3=R4=OH, then D is not a CH or CH2 group.
4. The compound of claim 1 wherein n = 1 and A represents carbonyl group.
5. The compound of claim 1 wherein wherein n = O, X is carboxy, acetyl, alkylcarbonyl, arylcarbonyl, C1-C6 alkyl substituted with one to six hydroxy groups, alkyloxycarbonyl, N- alkylcarbamoyl, formyl, or -C(=N-R5)R6 and at least one of the R1, R2, R3 and R4 are each independently, chloro, bromo, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, Q-Q-alkoxy, trifluoromethoxy, Ci-Q-alkanoyl, amino, amino-C1-C4-alkyl, N-(Ci-C4-alkyl)amino, ΛζiV-di(C1-C4-alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C1-C4-alkylsulfmo, carboxy, Ci-C4-alkoxycarbonyl, cyano, or nitro.
6. The compound of claim 5 wherein R1, R2, R3 and R4 are each independently C1-C4- alkyl, chloro or bromo.
7. The compound of claim 1 wherein wherein n = O, X is arylcarbonyl, C1-C6 alkyl substituted with one to six hydroxy groups, N-alkylcarbamoyl, or -C(=N-R5)R6 and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, Ci-C4-alkyl, hydroxy, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, CrQ-alkoxy, trifluoromethoxy, C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, JV-(C1- C4-alkyl)amino, ΛζiV-di(C1-C4-alkyl)amino, mercapto, Q-Q-alkylthio, sulfo, C1-C4- alkylsulfo, sulfino, CrC4-alkylsulfmo, carboxy, C1-C4-alkoxycarbonyl, cyaiio or nitro.
8. The compound of claim 7 wherein R1, R2, R3 and R4 are each independently C1-C4- alkyl, fluoro, chloro, bromo or hydroxy.
9. The compound of claim 1 wherein n = 0, X is 2-liy-imidazolyl, 6-(2,3- dihydro)benzo[l,4]dioxinyl, 3-bromo-4-fluorophenyl, 3-bromo-4-methoxyphenyl, 3- ethoxyphenyl, 3-phenoxyphenyl, 4-phenoxyphenyl, 4-benzyloxy-3-methoxyphenyl, 2-(4-bromo)thiophenyl, 4-isopropoxyphenyl, 3-quinolinyl, 4-quinolinyl, 5-(2,3- dihydro)benzofuranyl, 2-furanyl, 4-trifluoromethylphenyl, 2-[5-(3- trifluoromethylphenyl)]furanyl or 2-(5-hydroxymethyl)furanyl and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, C1-C4-alkyl, hydroxy, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, Q-Gt-alkoxy, trifluoromethoxy, C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, ΛζiV-di(C1-C4-alkyl)amino, mercapto, Ci-Gt-alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C1-C4-alkylsulfϊno, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro.
10. The compound of claim 9 wherein R1, R2, R3 and R4 are each independently C1-C4- alkyl, fluoro, chloro or bromo.
11. The compound of claim 1 which is :
(a) a compound of formula I, wherein n = 0, X is phenyl , R1= R2= R4= H and R3=Cl;
(b) a compound of formula I, wherein n = 0, X is phenyl R1= R2= R3= H and
Figure imgf000148_0001
(c) a compound of formula I, wherein n = 0, X is 4-methylρhenyl, 3-hydroxyρhenyl, 4- hydroxyphenyl, 3-chlorophenyl, 4-chlorophenyl, 4-methylthiophenyl, 2-pyridinyl, 2- quinolinyl or 5-benzo[l,3]dioxolyl; R1= R4=H and R2= R3=Me;
(d) a compound of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, 4- hydroxyphenyl, 4-chlorophenyl, 4-methylthiophenyl, 2-pyridinyl, 3-pyridinyl, 4- pyridinyl, 2-quinolinyl, 4-methoxyphenyl or 5-benzo[l,3]dioxolyl; R1= R3= H and R2= R4 =Me; (e) a compound of formula I, wherein n = O5 X is 4-hydroxyphenyl, 4-methoxyphenyl, 4- chlorophenyl, 4-methylthiophenyl, 2-quinolinyl, 3-pyridinyl or 4-pyridinyl; R1= R3= R4= H and R2=Et, F or Br;
(f) a compound of formula I, wherein n = 0, X is 4-methylphenyl, 2-pyridinyl, 3- hydroxyphenyl or 5-benzo[l,3]dioxolyl; R1= R3= R4= H and R2=Et or F;
(g) a compound of formula I5 wherein n = O5 X is 4-methylphenyl, 3-hydroxyphenyl, 3- chlorophenyl, 4-chlorophenyl5 4-methylthiophenyl or 5-benzo[l,3]dioxolyl; R1= R3= R4= H and R2=Cl;
(h) a compound of formula I, wherein n = O5 X is 4-methylphenyl, 3-hydroxyphenyl, 4- chlorophenyl, 4-methylthiophenyl, 2-pyridinyl, 4-pyridinyl, 2-quinolinyl or 5- benzo[l,3]dioxolyl; R1= R2= R4=H and R3=Me; (i) a compound of formula I, wherein n = 0, X is 4-methylphenyl, 3-hydroxyphenyl, 3- chlorophenyl, 4-chlorophenyl, 4-methylthiophenyl, 2-pyridinyl or 5- benzo[l,3]dioxolyl; R1= R4=H; R2=Cl and R3=Me; (j) a compound of formula I, wherein n = 0, X is 5-benzo[l,3]dioxolyl; R1= R3= R4= H and R2=Me; (k) a compound of formula I, wherein n = 0, X is carboxy; R1=Me; R2= R4= H and
R3=OH; or (1) a compound of formula I, wherein n = 0, X is acetyl; R1= R3=OH and R2= R4= H.
12. The compound of claim 2 wherein X is carboxy, acetyl, alkylcarbonyl, arylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, alkyloxycarbonyl, N-alkyl carbamoyl or -C(=N-R5)R6 and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, Q-Q-alkyl, hydroxy, C2-C4- alkenyl, C2-C4-alkynyl, halo-Q-Q-alkyl, Q-Q-alkoxy, trifluoromethoxy, C1-C4- alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, Λr,iV-di(C1-C4- alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C1-C4- alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro.
13. The compound of claim 12 wherein R1, R2, R3 and R4 are each independently C1-C4- alkyl, fluoro, chloro or bromo.
14. The compound of claim 2 wherein X is carboxy, acetyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups and at least one of the Ri, R2, R3 and R4 are each independently, Ci-C4-alkyl, fluoro, chloro or bromo.
15. The compound of claim 3 wherein
D is CHCH3, CHCH2OH or carbonyl and ~ is a single bond; or D is CCH3 and ~ is a double bond; and at least one of the R1, R2, R3 and R4 are each independently fluoro, chloro, bromo,
C1-C4-alkyl, hydroxy, C2-C4-alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, d-C4-alkoxy, trifiuoromethoxy, C1-C4-alkanoyl, amino, aniino-Ci-C4-alkyl, iV-(Ci-C4-alkyl)amino,
N,iV-di(Ci-C4-alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, C1-C4-alkylsulfo, sulfmo, C1-C4-alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro.
16. The compound of claim 15 wherein Ri, R2, R3 and R4 are each independently C1-C4- alkyl, fluoro, chloro or bromo or hydroxy.
17. The compound of claim 3 wherein D is CH or CH2; and at least one of the R1, R2, R3 and R4 are each independently, fluoro, chloro, bromo, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, halo-Q-Q-alkyl, Ci-C4-alkoxy, trifiuoromethoxy, C1-C4-alkanoyl, amino, amino-Ci-C4-alkyl, iV-(C1-C4-alkyl)amino, ΛζiV-di(C1-C4-alkyl)amino, mercapto, Ci-C4-alkylthio, sulfo, Ci-C4-alkylsulfo, sulfmo, Ci-C4-alkylsulfmo, carboxy, Ci-C4-alkoxycarbonyl, cyano, or nitro.
18. The compound of claim 17 wherein R1, R2, R3 and R4 are each independently Ci-C4- alkyl, fluoro, chloro or bromo.
19. A pharmaceutical composition comprising one or more compounds as set forth in Claims 1-18 and one or more pharmaceutically acceptable diluents, carriers or excipients.
20. A method for treatment of an inflammatory condition or an immune disorder associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound of Formula VI
Figure imgf000151_0001
or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof wherein:
R1, R2, R3 and R4 is each independently hydrogen, halogen, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, halo-Q-Gt-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy,
C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, i\ζ7V-di(Ci-C4- alkyl)amino, mercapto, Ci-C4-alkylthio, sulfo, Ci-C4-alkylsulfo, sulfino, C1-C4- alkylsulflno, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro;
A is carbonyl, CH-X or C=N-R5;
Each occurrence of n is, independently, an integer which is 0 or 1;
R5 is hydroxy, alkoxy, amino, alkylamino, aryl or arylamino;
X is hydrogen, hydroxy, carboxy, acetyl, alkylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, N- alkylcarbamoyl, or -C(=N-R5)R6; and
R6 is hydrogen or CH3.
21. A method for treatment of an inflammatory condition or an immune disorder associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound of Formula VII
Figure imgf000151_0002
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or stereoisomer thereof wherein:
R1, R2, R3 and R4 is each independently hydrogen, halogen, d-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, hydroxy, Ci-C4-alkoxy, trifluoromethoxy,
C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, N,N-di(Ci-C4- alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, C1-C4-alkylsulfo, sulfϊno, C1-C4- alkylsulfino, carboxy, Q-Gj-alkoxycarbonyl, cyano, or nitro;
X is hydrogen, hydroxy, carboxy, alkylcarbonyl, foπnyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, Ν-alkylcarbamoyl, or -
C(=Ν-R5)R6;
R5 is hydroxy, alkoxy, amino, alkylamino, aryl or arylamino; and
R6 is hydrogen or CH3.
22. A method for treatment of an inflammatory condition or an immune disorder associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound of Formula VIII
Figure imgf000152_0001
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or stereoisomer thereof wherein
R1, R2, R3 and R4 is each independently hydrogen, halogen, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, halo-Q-Gj-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy,
C1-C4-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, N,iV-di(C1-C4- alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, Q-Gralkylsulfo, sulfmo, C1-C4- alkylsulfmo, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro;
D is CH, CH2, CCH3, CHCH3, CHCH2OH, or carbonyl; and
~ is a single or a double bond.
23. The method according to any one of claims 20, 21 or 22 wherein the inflammatory condition or immune disorder is selected from asthma; chronic obstructive pulmonary disease; bronchitis; adult respiratory distress syndrome; nasal inflammatory diseases selected from allergic rhinitis, nasal polyps; inflammatatory skin disorders selected from eczemas, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis; rheumatoid arthritis; inflammatory bowel diseases selected from Crohn's disease, colitis and ulcerative colitis; further insulin-dependent diabetes, autoimmune diseases selected from thyroiditis, lupus erythematosus, multiple sclerosis, Raynaud's disease, and other arthritic conditions having an inflammatory component selected from rheumatoid spondylitis, septic arthritis, polyarthritis, retinitis, inflammatory brain disorders selected from meningitis and encephalitis; conditions associated with acute trauma selected from cerebral injury, heart tissue injury and lung injury; inflammation accompanying infections selected from sepsis and nephritis (e.g. glomerulonephritis).
24. The method according to claim 23, wherein inflammatory condition or immune disorder is asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis, allergic rhinitis, nasal polyps, eczemas, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis, rheumatoid arthritis, or an inflammatory bowel disease.
25. A method for inhibiting or reducing inflammation in an affected organ or tissue comprising delivering to said organ or tissue a therapeutically effective amount of the compound of Formula VI
Figure imgf000153_0001
or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof wherein:
R1, R2, R3 and R4 is each independently hydrogen, halogen, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, Ci-Q-alkanoyl, amino, amino-C1-C4-alkyl, N-(C1-C4-alkyl)amino, N,N-di(Cι-C4- alkyl)amino, mercapto, Q-Q-alkylthio, sulfo, C1-C4-RIlCyISuIfO, sulfϊno, C1-C4- alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro;
A is carbonyl, CH-X or C=N-R5;
Each occurrence of n is, independently, an integer which is 0 or 1 ;
R5 is hydroxy, alkoxy, amino, alkylamino, aryl or arylamino;
X is hydrogen, hydroxy, carboxy, acetyl, alkylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, N- alkylcarbamoyl, or ~C(=N-R5)R6; and
R6 is hydrogen or CH3.
26. A method for inhibiting or reducing inflammation in an affected organ or tissue comprising delivering to said organ or tissue a therapeutically effective amount of the compound of Formula VII
Figure imgf000154_0001
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or stereoisomer thereof wherein:
R1, R2, R3 and R4 is each independently hydrogen, halogen, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, halo-Ci-C4-alkyl, hydroxy, Q-Q-alkoxy, trifluoromethoxy,
CrC4-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, N,iV-di(C1-C4- alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, Ci-C4-alkylsulfo, sulfϊno, C1-C4- alkylsulfino, carboxy, Ci-Q-alkoxycarbonyl, cyano, or nitro;
X is hydrogen, hydroxy, carboxy, alkylcarbonyl, formyl, C1-C6 alkyl substituted with one to six hydroxy groups, aryl, heteroaryl, alkyloxycarbonyl, N-alkylcarbamoyl, or -
C(=N-R5)R6;
R5 is hydroxy, alkoxy, amino, alkylamino, aryl or arylamino; and
R6 is hydrogen or CH3.
27. A method for inhibiting or reducing inflammation in an affected organ or tissue comprising delivering to said organ or tissue a therapeutically effective amount of the compound of Formula VIII
Figure imgf000155_0001
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or stereoisomer thereof wherein
R1, R2, R3 and R4 is each independently hydrogen, halogen, C1-C4-alkyl, C2-C4- alkenyl, C2-C4-alkynyl, halo-C1-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy,
Q-Q-alkanoyl, amino, amino-C1-C4-alkyl, iV-(C1-C4-alkyl)amino, N,N-di(C1-C4- alkyl)amino, mercapto, C1-C4-alkylthio, sulfo, Q-Q-alkylsulfo, sulfino, C1-C4- alkylsulfino, carboxy, C1-C4-alkoxycarbonyl, cyano, or nitro;
D is CH, CH2, CCH3, CHCH3, CHCH2OH, or carbonyl; and
— is a single or a double bond.
28. The compound of claim 1 wherein the compound is selected from the group of compounds of Examples 1-284, 288, 290-374.
29. A compound of Formula I
Figure imgf000155_0002
(I)
or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof
wherein: R1, R2, R3 and R4 is each independently hydrogen, fluoro, chloro, bromo , C1-C3- alkyl, hydroxy, or nitro;
A is carbonyl or CH-X,
Each occurrence of n is, independently, an integer which is 0 or 1; and
X is carboxy, -C(O)O(C1-4alkyl), -CH(OH)CH2OH, -CH2OH, C(O)OCH2CH2OH, C(O)NHdecyl, C(O)NH(CH2)3OH, C(O)NHC(CH3)2CH2OH, C(O)NHC(CH2OH)3, 1- hydroxyethyl, -C(=N)-OH, imidazolyl, phenyl, 2-methoxyphenyl, 4-quinolinyl, 2- quinolinyl, 2-nitrophenyl, 3-chlorophenyl, 2,4-dimethoxyphenyl, 4-(l-butyl)- imidazolyl, naphthyl, 2-hydroxy-4-nitrophenyl, 6-(2,3-dihydrobenzodioxanyl), 2-(4- chlorophenylthio)-phenyl, 2-pyridinyl, 3-bromo-4-fluorophenyl, 3-bromo-4- methoxyphenyl, 3-chloro-4-fluorophenyl, 3-ethoxyphenyl, 3-hydroxyphenyl, 3- phenoxyphenyl, 3-methoxy-4-benzyloxyphenyl, 4-thiomethylphenyl, 2-(4- bromothiophenyl), 4-chlorophenyl, 4-cyanophenyl, 4-isopropoxyphenyl, 4- methylphenyl, 4-phenoxyphenyl, 2-(5-methyl)-furanyl, 3,4,5-triniethoxyphenyl, A- fluorophenyl, 4-pyridyl, 2-chlorophenyl, 1 -imidazolyl, 3,4-methylenedioxyphenyl, 4- methoxyphenyl, 3-quinolinyl, 2-quinolinyl, 4-hydroxyphenyl, 5-(2,3-dihydro)- benzofuranyl, 2-methoxyphenyl, 2-furanyl, 4-trifluoromethylphenyl, 2-[5-(3- trifluoromethylphenyl)]-furanyl, l-(5-hydroxymethyl)-furanyl; and
provided that i.) when A is carbonyl then n = 1 ; and ii.) when n = O and X is carboxy, -C(O)O(C1-4alkyl), -CH(OH)CH2OH, -CH2OH, C(O)OCH2CH2OH, C(O)NHdecyl, C(O)NH(CH2)3OH, C(O)NHC(CH3)2CH2OH, C(O)NHC(CH2OH)3, imidazolyl, phenyl, 2-methoxyphenyl, 4-quinolinyl, 2- quinolinyl, 2-nitrophenyl, 3-chlorophenyl, 2,4-dimethoxyphenyl, 4-(l-butyl)- imidazolyl, naphthyl, 2-hydroxy-4-nitrophenyl, 6-(2,3-dihydrobenzodioxanyl), 2-(4- chlorophenylthio)-phenyl, 2-pyridinyl, 3-bromo-4-fluorophenyl, 3-bromo-4- methoxyphenyl, 3-chloro-4-fluorophenyl, 3-ethoxyphenyl, 3-hydroxyphenyl, 3- phenoxyphenyl, 3-methoxy-4-benzyloxyphenyl, 4-thiomethylphenyl, 2-(4- bromothiophenyl), 4-chlorophenyl, 4-cyanophenyl, 4-isopropoxyphenyl, 4- methylphenyl, 4-phenoxyphenyl, 2-(5-methyl)-furanyl, 3,4,5-trimethoxyphenyl, 4- fluorophenyl, 4-pyridyl, 2-chlorophenyl, 1-imidazolyl, 3,4-methylenedioxyphenyl, 4- methoxyphenyl, 3-quinolinyl, 2-quinolinyl, 4-hydroxyphenyl, 5-(2,3-dihydro)- benzoforanyl, 2-methoxyphenyl, 2-furanyl, 4-trifluoromethylphenyl, 2-[5-(3- trifluoromethylphenyl)]-furanyl, or l-(5-hydroxymethyl)-furanyl;, then R1, R2, R3 and R4 are not all hydrogen; and
iii.) when n = 0, R1=R2=R4=H, and R3=OH, then X is not carboxy, phenyl, 2-pyridinyl, or 2-naphtalenyl; and
iv.) when n = 0, R1=R2=R3=H, and R4=Me then X is not phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methoxyphenyl, 4-methoxyphenyl, or 4-methylthiophenyl; and
v.) when n = 0, R1=R3=R4=H, and R2=Me then X is not phenyl, 2-chlorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2- methoxyphenyl, 3,4,5-trimethoxyphenyl, 2-pyridinyl, 4-pyridinyl, or 2-quinolinyl; and
vi.) when n = 0, R1=R3=R4=H, and R2=F or when n = 0, R1=R2=R4=H, and R3=F then X is not carboxy, or ethyloxycarbonyl; and
vii.) when n = 0, R1=R2=R3=H, and R4=Cl then X is not phenyl; and
viii.) when n = 0, R1=R3=R4=H, and R2=Cl then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 2-pyridinyl, 4-pyridinyl, or 2-quinolinyl; and
ix.) when n = 0, R1=R3=R4=H, and R2=Br then X is not phenyl, 3-hydroxyphenyl, 4-methylphenyl, 2-pyridinyl, or 5- benzo[l,3]dioxolyl; and
x.) when n = 0, R1=R2=R4=H, and R3=Me or when n = 0, R2= R3=H and R1 =R4=Me, then X is not phenyl, or 4-hydroxyphenyl; and
xi.) when n = 0, R2= R4=H and R1 =R3=Me, then X is not phenyl; and
xii.) when n = 0, R1= R4=H and R2 =C1 and R3=Me, then X is not phenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4- pyridinyl, or 2- quinolinyl; and
xiii.) when n = 0, R1= R4=H and R2 = R3=Me, then X is not phenyl, or 4-methoxyphenyl; and
xiv.) when n = 0, R1= R3=H and R2= R4=Cl, then X is not phenyl; and
xv.) when n = 0, R1= R2=H and R3 = OH and R4=Me, then X is not phenyl, 4-methoxyphenyl, 3-hydoxyphenyl, or 5-benzo[l,3]dioxolyl; and
xvi.) when n = 1 and X is carboxy or ethyloxycarbonyl then R15R2, R3 and R4 are not all hydrogen; and
xvii.) when n = 1 and R1= R3= R4=H and R2 =Br, then X is not phenyl.
30. The use of compound according to claims 1 to 18 and 28-29 wherein suitable pharmaceutical preparations can be administered locally, parenterally ox per os.
31. The use of compound according to claims 1 to 18 and 28-29 in the prophylaxis and treatment of inflammatory conditions and diseases, wherein suitable pharmaceutical preparations can be administered locally, parenterally ox per os.
32. A method for inhibition of at least one inflammation marker selected from the group consisting of granulocyte (e.g., mast cell) degranulation, LTB4 production, 5-lipoxygenase production, CysLTl receptor, PDE3 activity, PDE4 activity, binding to human prostanoid receptor, binding to human thromboxane receptor, protein serine/threonine kinase ERKl, activity protein tyrosine kinase LCK activity, binding to tachykinin receptor, production of a least one pro-inflammatory cytokine selected from the group consisting of TNF-α, IL-I β, IL-2, IL-5, IL-6, and IL-8, oedema, eosinophilia, interferon-γ, and neutrophilia the method comprising exposing an organ or cell tissue afflicted with inflammation to an amount of a compound according to any of claims 1 to 18, 28 and 29 effective to inhibit said inflamation marker.
33. The method of claim 32 wherein said marker is mast cell degranulation and is associated with immediate or delayed hypersensitivity, allergy, anaphylaxis, inflammation, asthma or urticaria.
34. The method of claim 32 wherein said marker is LTB-4 production and is associated with inflammation.
35. The method of claim 32 wherein said marker is 5-lipoxygenase and is associated with asthma or inflammatory bowel disease.
36. The method of claim 32 wherein said marker is CysLTl receptor and is associated with asthma.
37. The method of claim 32 wherein said marker is PDE3 and is associated with cancer, inflammation, pulmonary hypertension or stroke.
38. The method of claim 32 wherein said marker is PDE4 and is associated with chronic obstructive pulmonary disease, neutrophilia or asthma.
39. The method of claim 32 wherein said marker is binding to prostanoid receptor and is associated with inflammation or asthma.
40. The method of claim 32 wherein said marker is inhibition of ERKl kinase and is associated with cancer or inflammation.
41. The method of claim 32 wherein said marker is LCK kinase activity and is associated with diseases of T-cell activation T-cell leukemia and T-cell mediated inflammatory responses.
42. The method of claim 32 wherein said marker is binding to tachykinin NK2 receptor and is associated with asthma, gastrointestinal disease, irritable bowel syndrome or pancreatitis.
43. The method of claim 32 wherein said marker is cytokine production and is associated with inflammation.
44. The method of claim 32 wherein said marker is oedema.
45. The method of claim 32 wherein said marker is pulmonary eosinophelia in mice and is associated with asthma.
46. The method of claim 32 wherein said marker is pulmonary neutrophilia in mice and is associated with COPD.
47. The compounf of claim 1 wherein the compound is selected from the group consisting of the compounds of Examples 1-54, 59, 95, 96, 98, 99, 101, 102, 103, 105-112, 114, 115, 117, 118, 120, 120, 122-124, 126-136, 138-141, 144, 147-149, 151, 153-172, 174-177, 179- 222, 224-284, 291-342 and 356-374.
48. The compound of claim 1 , wherein it is further provided that;
(i) when n = 0, R1=R3=R4=H5 and R2=Br then X is not 4-hydroxyphenyl or 3,4-methylenedioxyphenyl; and
(ii) when n = 0, R1=R2=R4=H, and R3=Cl then X is not phenyl.
49. The compound of claim 29, wherein it is further provided that;
(i) when n = 0, R1=R3=R4=H, and R2=Br then X is not 4-hydroxyphenyl or 3,4-methylenedioxyphenyl; and
(ii) when n = 0, R1=R2=R4=H, and R3=Cl then X is not phenyl.
PCT/IB2006/001259 2005-01-14 2006-01-13 Bis-(coumarin) compounds with anti-inflammatory activity WO2006111858A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007550880A JP2008526951A (en) 2005-01-14 2006-01-13 Bis- (coumarin) compound having anti-inflammatory activity
EP06765427A EP1846387A2 (en) 2005-01-14 2006-01-13 Bis-(coumarin) compounds with anti-inflammatory activity
US11/813,885 US20080153872A1 (en) 2005-01-14 2006-01-13 Bis-(Coumarin) Compounds With Anti-Inflammatory Activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64435905P 2005-01-14 2005-01-14
US60/644,359 2005-01-14
US64779305P 2005-01-27 2005-01-27
US60/647,793 2005-01-27

Publications (2)

Publication Number Publication Date
WO2006111858A2 true WO2006111858A2 (en) 2006-10-26
WO2006111858A3 WO2006111858A3 (en) 2006-11-30

Family

ID=36675904

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2006/001422 WO2006092739A1 (en) 2005-01-14 2006-01-13 Anti-inflammatory conjugates of macrolides and coumarins
PCT/IB2006/001259 WO2006111858A2 (en) 2005-01-14 2006-01-13 Bis-(coumarin) compounds with anti-inflammatory activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001422 WO2006092739A1 (en) 2005-01-14 2006-01-13 Anti-inflammatory conjugates of macrolides and coumarins

Country Status (4)

Country Link
US (1) US20080153872A1 (en)
EP (2) EP1846387A2 (en)
JP (2) JP2008526951A (en)
WO (2) WO2006092739A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007077036A (en) * 2005-09-12 2007-03-29 Kyoto Univ New compound selectively increasing fluorescence intensity at target part and composition for image diagnosis
CN104530025A (en) * 2014-12-04 2015-04-22 中国人民解放军第四军医大学 Thenylidene bishydroxycoumarin compound and application thereof
CN104529986A (en) * 2014-12-04 2015-04-22 中国人民解放军第四军医大学 Bishydroxycoumarin compound and antibacterial application thereof
CN104910118A (en) * 2014-03-13 2015-09-16 中国科学院上海药物研究所 Bishydroxycoumarin compound, preparation method and purpose thereof
EP3120848A4 (en) * 2014-03-20 2017-03-08 Nippon Zoki Pharmaceutical Co., Ltd. Therapeutic/preventive agent containing coumarin derivative as active ingredient
CN107296824A (en) * 2017-06-30 2017-10-27 广西民族大学 Comospore trifoliate jewelvine ligroin extraction and its preparation and inflammatory applications
CN107635997A (en) * 2015-03-30 2018-01-26 伊诺瓦伊斯特兹万佳斯卡医药有限公司 Coumarin derivative is as antivirotic, and its pharmaceutical composition, preparation method and purposes

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092739A1 (en) * 2005-01-14 2006-09-08 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Anti-inflammatory conjugates of macrolides and coumarins
EP2379504A2 (en) * 2008-12-22 2011-10-26 Sloan Kettering Institute For Cancer Research Coumarin-based compounds
JP6089055B2 (en) * 2014-03-20 2017-03-01 日本臓器製薬株式会社 Pharmaceuticals containing coumarin derivatives
CN107213150B (en) * 2017-04-28 2020-05-12 中国人民解放军第四军医大学 Washing-free antibacterial gel and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010007A1 (en) * 2003-07-25 2005-02-03 Pliva- Istrazivacki Institut D.O.O. Substituted furochromenes, preparation thereof and their antiinflammatory action
WO2005010006A1 (en) * 2003-07-25 2005-02-03 Pliva-Istrazivacki Institut D.O.O. Substituted furochromene compounds of antiinflammatory action
WO2005095411A1 (en) * 2004-04-02 2005-10-13 Pliva-Istrazivacki Institut D.O.O. Furochromene derivative with anti-inflammatory activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070174A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2006092739A1 (en) * 2005-01-14 2006-09-08 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Anti-inflammatory conjugates of macrolides and coumarins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010007A1 (en) * 2003-07-25 2005-02-03 Pliva- Istrazivacki Institut D.O.O. Substituted furochromenes, preparation thereof and their antiinflammatory action
WO2005010006A1 (en) * 2003-07-25 2005-02-03 Pliva-Istrazivacki Institut D.O.O. Substituted furochromene compounds of antiinflammatory action
WO2005095411A1 (en) * 2004-04-02 2005-10-13 Pliva-Istrazivacki Institut D.O.O. Furochromene derivative with anti-inflammatory activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1980 (1980-01), CHALAIA L P: "[Immunosupressant activity of direct and indirect acting anticoagulants]" XP002304624 Database accession no. NLM7189628 & ZHURNAL MIKROBIOLOGII, EPIDEMIOLOGII, I IMMUNOBIOLOGII. JAN 1980, no. 1, January 1980 (1980-01), pages 47-54, ISSN: 0372-9311 *
MIDDLETON E ET AL: "EFFECTS OF FLAVONOIDS ON IMMUNE AND INFLAMMATORY CELL FUNCTIONS" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 43, no. 6, 1992, pages 1167-1179, XP000886668 ISSN: 0006-2952 *
See also references of EP1846387A2 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007077036A (en) * 2005-09-12 2007-03-29 Kyoto Univ New compound selectively increasing fluorescence intensity at target part and composition for image diagnosis
CN104910118A (en) * 2014-03-13 2015-09-16 中国科学院上海药物研究所 Bishydroxycoumarin compound, preparation method and purpose thereof
EP3120848A4 (en) * 2014-03-20 2017-03-08 Nippon Zoki Pharmaceutical Co., Ltd. Therapeutic/preventive agent containing coumarin derivative as active ingredient
US10004716B2 (en) 2014-03-20 2018-06-26 Nippon Zoki Pharmaceutical Co., Ltd. Therapeutic/ preventive agent containing coumarin derivative as active ingredient
CN104530025A (en) * 2014-12-04 2015-04-22 中国人民解放军第四军医大学 Thenylidene bishydroxycoumarin compound and application thereof
CN104529986A (en) * 2014-12-04 2015-04-22 中国人民解放军第四军医大学 Bishydroxycoumarin compound and antibacterial application thereof
CN104529986B (en) * 2014-12-04 2017-08-11 中国人民解放军第四军医大学 Bicoumarin compound and its antibacterial applications
CN107635997A (en) * 2015-03-30 2018-01-26 伊诺瓦伊斯特兹万佳斯卡医药有限公司 Coumarin derivative is as antivirotic, and its pharmaceutical composition, preparation method and purposes
CN107296824A (en) * 2017-06-30 2017-10-27 广西民族大学 Comospore trifoliate jewelvine ligroin extraction and its preparation and inflammatory applications

Also Published As

Publication number Publication date
EP1846387A2 (en) 2007-10-24
US20080153872A1 (en) 2008-06-26
JP2008532928A (en) 2008-08-21
JP2008526951A (en) 2008-07-24
WO2006092739A1 (en) 2006-09-08
EP1846428A1 (en) 2007-10-24
WO2006111858A3 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
EP1846387A2 (en) Bis-(coumarin) compounds with anti-inflammatory activity
US10813932B2 (en) 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
KR102057058B1 (en) 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy) napththalen-1-yl) ureas as p38 map kinase inhibitors
KR100708783B1 (en) N-Heterocyclic Derivatives as NOS Inhibitors
US4572912A (en) Thiazolidine derivatives, their preparation and compositions containing them
KR930003335B1 (en) Process for preparation of thiazolidine derivatives
RU2350610C2 (en) DERIVATIVES OF BENZO {b} {1, 4} DIOXEPIN
JP2007511538A (en) Thiazoles and oxazoles useful as modulators of ATP binding cassette transporters
JP6785217B2 (en) Use as 2-amino-benzimidazole derivatives and their 5-lipoxygenase and / or prostaglandin E synthase inhibitors
WO2006093547A2 (en) Novel lipoxygenase inhibitors
AU2006210778A2 (en) Tumor necrosis factor inhibitors
US5925656A (en) Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU4948700A (en) Hydrochloride of fused-heterocycle compound
FI93013B (en) A process for the preparation of therapeutically useful pyridopyridazinone derivatives
JP2021513530A (en) Tetrahydroisoquinoline compounds, methods of their preparation, pharmaceutical compositions containing such compounds and their use.
JPH10114766A (en) New flavone compound, its production and pharmaceutical composition comprising the same
JP2002529463A (en) Compound
KR100382964B1 (en) Novel pyrimidine derivative
JP6401249B2 (en) 2,3-butanediamide epoxide compounds and methods for their preparation and use
WO2007075145A1 (en) Benzopyranone derivatives and their use as anti-coronaviral agents
JP2009541230A (en) 4-Amino-3-arylamino-6-arylpyrazolo [3,4-d] pyrimidine derivatives, process for their preparation and use as antiviral agents
US20060148889A1 (en) Substituted furochromenes, preparation thereof and their antiinflammatory action
WO2005095411A1 (en) Furochromene derivative with anti-inflammatory activity
CN116120340B (en) Pyridooxazine compound, and preparation method, composition and application thereof
US5376680A (en) Oxime derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11813885

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007550880

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006765427

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006765427

Country of ref document: EP